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Chapter 1
General Introduction

1.1 Aim and Outline of the Thesis
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The complex regional pain syndrome is poorly elucidated. In line with this its diagnosis 
and clinical management have remained suboptimal. The multifaceted nature makes it a 
fascinating study topic for scientists with varying interests, but unraveling the etiology 
has been proven a laborious mission.
The first notification of what could have been (what is currently named) complex regional 
pain syndrome (CRPS) stems from 1634, when the surgeon Ambroise Pare described 
that King Charles IX suffered from persistent pain and contractures of his arm following 
a bloodletting procedure.1 The next remarks came from the military physician Scott 
Mitchell and date from the American Civil War: “…Long after the trace of the effect 
of a wound has gone neuralgic symptoms are apt to linger, and too many carry with 
them throughout long years this final reminder of the battle field...”.2 The first scientific 
publication on CRPS was issued in 1900 from a German surgeon named Paul Sudeck.3 
His name became tied to the syndrome for long (Sudecks’ dystrophy).
Today we know CRPS as a complication of a physical trauma, for example a fracture. 
The affected extremity is marked by a broad variety of symptoms4, including pain and 
sensory disturbances such as allodynia and hyperesthesia, swelling, changes in color, 
temperature and transpiration, trophic skin alterations, hair and nail growth changes, 
weakness, decreased motion and neuromotor disturbances. As a consequence CRPS 
patients may come to suffer from severe discomfort and invalidity. In rare cases a 
state is reached wherein amputation of the affected limb becomes inevitable. Although 
debatable, CRPS is classically divided in type I, without demonstrated nerve injury, and 
type II, with demonstrated nerve injury. 
For decades CRPS has been considered mainly as a disease of the central nervous system, 
and still autonomic (sympathetic) and sensory disturbances are assumed to underlie 
many features of the disorder.5-7 However, more recently an additional interest raised 
towards the peripheral disease mechanisms that are potentially involved in CRPS.8-10 
Most patients express signs of inflammation4,11, while there are also indications that 
local oxygen deprivation may play a role.12 Moreover, some authors have specifically 
emphasized the potential contribution of psychological factors, such as somatisation and 
anxiety.13,14 
 
The cloudy and controversial insights in CRPS etiology are also reflected in the history 
of its nomenclature. Since its first description the syndrome has been addressed in the 
Angelsaksian literature alone by already more than 70 different names, that often referred 
to presumed underlying disease causes. In 1995 the International Association for the 
Study of Pain (IASP) strived to end the taxonomic diversity by introducing the term 
“complex regional pain syndrome (CRPS)”, a name based on description rather than on 
pathophysiology.15
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Aim and Outline of the thesis 
The aim of the research described in the present thesis was to gather more insight in CRPS 
as a clinical entity and into its pathogenesis and etiology. CRPS has been extensively 
studied before and we have started by reviewing the current understandings based on 
these valuable efforts (chapter 1.2).
     In the second chapter we have attempted to achieve better insight in some general 
disease characteristics of CRPS. We studied the incidence (chapter 2.1), disease course 
(chapter 2.2), and treatment and referral patterns (chapter 2.3).  
     In the third chapter we sought for potential determinants of CRPS, with the purpose 
to identify risk factors and clues for the underlying disease mechanisms. In this view 
we studied the medical history of CRPS patients for specific pre-existing morbidities 
(chapter 3.1). Also, we investigated the association between CRPS and the use of specific 
types of medications, since some drugs might interfere with mediators in the pathogenesis 
of CRPS (chapter 3.2). Finally, as CRPS has a pronounced female predominance, we 
studied the relation between CRPS and both endogenous and exogenous exposure to 
estrogens (chapter 3.3). 
     In the fourth chapter we describe how we used an experimental approach to develop 
new ideas about potential underlying disease mechanisms of CRPS. In this, we combined 
information from abstracts in Medline by applying PathwayAssist, which is tool for 
automated information retrieval based on text mining (chapter 4.1). The evolving new 
hypothesis adressed the role of NFκB in CRPS and was explored further in an animal 
model for CRPS type I (chapter 4.2). 
     The thesis closes with a general discussion of the main findings and methodology, and 
with some suggestions for future research.
figure 1. Left hand and right foot are affected by CRPS. Pictures used with kind permission of dr. 
Roland Glinz (hand), www.schmerzzentrum.ch, and dr Schwartz (foot), www.robertgschwartz.
homestead.com
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Abstract
The mechanisms underlying complex regional pain syndrome (CRPS) have been 
increasingly studied over the past decade. Classically, this painful and disabling 
disorder was considered to emerge from pathology of the central nervous 
system. However, the involvement of additional peripheral disease mechanisms 
is likely and recently these mechanisms have also attracted scientific attention. 
The present article provides an overview of the current understandings regarding 
the pathology of the autonomic and somatic nervous system in CRPS, as well 
as the roles of neurogenic inflammation and hypoxia, and the contribution of 
psychological factors. Potential connections between the separate disease 
mechanisms are discussed. Additionally, currently known risk factors for CRPS 
will be addressed. Insight in risk factors is of relevance, since it facilitates early 
diagnosis and tailored treatment. Moreover, it may provide clues for further 
unraveling of the pathogenesis and etiology of CRPS.
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Introduction
The complex regional pain syndrome (CRPS) is a painful and disabling disorder that can 
affect one or more extremities. Usually, its onset is precipitated by a physical injury, for 
example a fracture, sprain or surgery.1,2 The spectrum of symptoms and signs is broad, 
including pain and sensory dysfunction, characteristics of inflammation, impaired motor 
function and trophic disturbances.3 Differentiated by the presence of a demonstrated nerve 
lesion, CRPS can be classified into type I and type II, of which type I, without a nerve 
lesion, is the most common.4 CRPS can impose great impact on the daily functioning and 
quality of life of the patient who suffers from it.5
     Classically, CRPS has been regarded as a disorder of the central nervous system with 
sympathetic dysfunction as its major pathogenic mechanism. Recently, the interest shifted 
towards the contribution of peripheral disease mechanisms, including inflammation and 
hypoxia. Hereby we aim to provide an overview of the current understandings on the 
pathogenic mechanisms that underlie CRPS. Additionally, risk factors and determinants 
as far as presently known, will be summarized. 
Methods
Five disease mechanisms were pre-specified as theoretic main contributors to CPRS. The 
choice of mechanisms was based on discussions with internal and external CPRS experts, 
including the investigators within TREND (Trauma RElated Neuronal Dysfunction), a 
Dutch government funded knowledge consortium that integrates research on CRPS-I 
(BSIK03016). The pre-specified mechanisms included: 1. autonomic (sympathetic) 
nervous system dysfunction; 2. somatic nervous system dysfunction; 3. inflammation; 4. 
hypoxia; and 5. psychological factors. 
     For each mechanism a separate search was conducted in Medline, using the query 
“Complex Regional Pain Syndromes”[MAJR] OR sudeck combined with one of 
the following queries: for autonomic nervous system dysfunction: “sympathetically 
maintained pain” OR adrenerg* OR “sympathetic nervous system”; for somatic nervous 
system dysfunction: sensitization OR “neuropathic pain” OR motor*; for inflammation: 
inflammation OR cytokine OR neuropeptide; for hypoxia: hypoxia OR ischaemia OR 
vascular OR microcirculation OR “free radical”; and for psychological factors: 
psychology OR psychiatry OR behavior. Case reports and non research articles were 
excluded. All recovered abstracts (419 in total) were screened manually. Full text articles 
were studied if the abstract suggested an experimental or observational study design 
focused on the etiology or pathogenesis of CRPS, a review that discussed one or more of 
the pathogenic mechanisms, or a clinical trial regarding therapy. 
     Second, with the purpose to overview known determinants and risk factors, the 
query “Complex Regional Pain Syndromes”[MAJR] OR sudeck was combined with the 
following terms: incidence, epidemiology, risk factor, genetics, infection, autoimmunity, 
and comorbidity. Case reports as well as all other types of research articles were included. 
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Again, abstracts were screened manually and full text papers were considered if the 
abstract suggested an association between CRPS and any risk factor.
     Only articles written in English or Dutch that were published in the past ten years 
(after 1998) were included. The retrieved literature was supplemented with referenced 
articles from the original yield or with manuscripts that were not indexed in Medline, but 
that were known otherwise by one of the authors.
Pathogenesis and Etiology
Autonomic nervous system
Increased sweating, trophic changes, and vasoconstriction related coldness of the affected 
limb have long been considered as a result of autonomic (sympathetic) hyperactivity. 
Additionally, in the past the phenomenon called sympathetically maintained pain (SMP) 
was considered almost synonymous for CRPS. In SMP, painful sensations are provoked 
by sympathetic outflow through sympathetic-afferent coupling, in which adrenergic 
receptors are expressed on primary afferent nerve endings.6,7 The classic treatment of 
CRPS with sympatholytic blocks was aimed to attenuate the pain and vasoconstriction 
induced by sympathetic hyperactivity. 
     However, the role of sympathetic dysfunction in CRPS has currently become somewhat 
debatable. Sweating and trophic disturbances are not the most predominant features of 
CRPS3 and can also be explained as neuropeptide effects8 (see later). Vasoconstriction 
does not always reflect sympathetic activity9 and alternative mechanisms than sympathetic 
overstimulation may account for the observed vasotonic impairments.10,11 SMP may 
result from pathological failure of spinal inhibitory mechanisms to suppress nociceptive 
input by normal, instead of increased sympathetic stimulation.12 Finally, from a clinical 
viewpoint, many CRPS patients do not benefit from sympatholytic blocks.13 
     Apart from the actual role of sympathetic dysfunction in CRPS, the mechanism behind 
it also has become subject to controversy. Increased sympathetic outflow (hyperactivity) 
is one possibility. Abnormal sensitivity of adrenergic receptors for normal sympathetic 
outflow is another.16,20,21 The first mechanism is endorsed by the observation that central 
sympathetic arousal provokes pain and abnormal vasoconstriction patterns in CRPS.14,15 
Additionally, the sympathetic skin reflexes in CRPS patients are increased.16 The 
underlying cause may be sprouting of new sympathetic nerves centrally in the dorsal horn17 
or peripherally in the upper dermis18, which can be triggered by inflammatory mediators 
or nerve injury.19 On the contrary, adrenergic receptor hypersensitivity is plausible based 
on the observed increases of pain after intradermal noradrenalin injections in CRPS 
patients, but not in controls.24 Morever, the density of α-adrenoreceptors is enlarged in 
hyperalgesic skin from CRPS affected limbs25, while the sympathetic innervation of sweat 
glands and vasculature is abnormal.26 Catecholamine levels in serum derived from the 
affected side of CRPS patients are usually decreased instead of elevated23, which argues 
in favor of a local hypersensitivity. Temporarily diminished sympathetic stimulation 
has been suggested as an underlying cause of the adrenergic receptor upregulation and 
sensitization in CRPS patients.22,23
     A generally acknowledged view today is that SMP and sympathetic dysregulation 
can be, but are not an obligatory part of CRPS.27 Sympathetic blocks remain still widely 
administered for the treatment of CRPS, with beneficial results in a subset of patients. 
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Somatic nervous system
Pain and sensory disturbances in CRPS have been attributed to pathology of the 
sensory somatic nervous system. Histopathological changes in skin innervation have 
been described, such as a substantial loss of normal C and Aδ fibers and the presence 
of fibers with aberrantly branched endings.26 Compared to controls a 29% reduction of 
axonal density was reported in CRPS affected skin.28 Because of similarities in pain 
characteristics between CRPS and other neuropathic pain disorders, analogies in the 
underlying mechanisms of neuroplasticity and sensitization are generally assumed, 
although they have never been well studied particularly in CRPS patients. 
     Spinal neuronal sensitization  can follow upon continuous nociceptive input or nerve 
injury and comprises a state of hyperexcitability and disinhibition, causing a decreased 
stimulation threshold.29 Eventually, this can cause a normally non-painful stimulus to 
become painful. Animal models have revealed several biochemical processes that underlie 
spinal sensitization with roles for post-synaptic receptors, including the N-methyl-D-
aspartate (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor, and the neurokinin-1 (NK-1) receptor.30 The actual contribution 
of these mechanisms to human CRPS is difficult to study, since it would require 
investigation of spinal cord neuronal tissue. However, the NMDA-receptor antagonist 
memantine was effective in relieving pain and motor symptoms in CRPS patients.31 
Anti-epileptics however, that increase neuronal excitation thresholds and are applied 
generally for neuropathic pains, are only moderately effective in CRPS patients, as was 
demonstrated in one randomized crossover trial with gabapentin.32
     In addition to spinal sensitization, supra-spinal alterations are also present in CRPS, 
as suggested by findings of impaired perceptual learning33 and of a relation between 
pain severity and impaired tactile discrimination.34 Brain imaging studies have indicated 
changes of cerebral blood flow, particularly in the hypothalamus.35,36 Some CRPS 
patients experience referred sensations37,38 or body perception disturbances39-41, which 
is in line with studies that demonstrate altered brain activation patterns42,43 and sensory 
mapping.44,45 
     CRPS affects not only afferent sensory systems; efferent motor pathways are also 
hampered, which leads to clinical signs of a decreased range of motion, involuntary 
movements and dystonia.46,47 Post-synaptic motor reflex inhibition was found impaired 
in CRPS patients.48 Moreover, measures of cortical reorganization of motor units 
correlated  with the extent of motor dysfunction.49,50 Experiments using transcranial 
stimulation revealed hyperexcitability of both the sensory and motor cortex.51,52 Based 
on all these findings, graded motor imaginary and mirror therapy have been proposed 
as beneficial in CRPS treatment, since this is considered to reconcile motor output and 
sensory feedback.53,54 Beneficial effects of mirror therapy have indeed been observed in 
relatively small open label studies.54-56  
Inflammation
In the early phase, CRPS affected limbs often display the classic ‘dolor, rubor, calor, 
tumor’ aspects of an inflammatory disorder. Despite the fact that this clinical presentation 
was appreciated for a long period, it was not until recently that inflammatory mediators 
actually were demonstrated as involved in CRPS. Classic inflammation is marked by 
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typical immune cells like lymphocytes, phagocytes and mast cells, which excrete classic 
pro-inflammatory cytokines. In fluid derived from artificially produced blisters on CRPS 
affected extremities, compared to unaffected sides, levels of interleukin-6 (IL-6), tumor 
necrosis factor α (TNFα), and tryptase were increased.57,58 Analysis of blister fluid with 
a multiplex array, testing for 25 different cytokines, revealed an even stronger pro-
inflammatory expression profile, with increased markers for activated monocytes and 
macrophages.59 A pro-inflammatory cytokine expression profile was also demonstrated 
in liquor60,61 (IL-1β and TNFα increased) and occasionally in venous blood62,63 (mRNA 
levels of TNFα and IL-2  increased; levels of soluble TNFα receptor increased; mRNA 
levels of anti-inflammatory cytokoines IL-4, IL6 and tissue growth factor-β decreased). 
Additionally, there is an enhanced migration of injected radiolabelled autologous 
leucocytes or non-specific immunoglobulines towards the CRPS affected location.64,65 
However, systemic parameters of inflammation that are usually applied in clinical 
settings, including white blood cell count and C-reactive protein, are normal in CRPS 
patients.66,67 
   Neurogenic inflammation is mediated by neuropeptides, which are excreted by nociceptive 
C-fibers in response to various triggers and that possess vasoactive and immunologic 
properties.8,68,69 The secretory nerve endings of these nociceptives are mainly located in 
the distal parts of extremities, the typical location for CRPS.69 However, primary afferent 
depolarisation can also induce neuropeptide release within the dorsal horn, where they 
can mediate central sensitization. Cardinal mediators in neurogenic inflammation are 
Substance P (SP) and calcitonin gene-related protein (CGRP).70 In rats SP application 
induced or increased CRPS-like symptoms71,72, while in human CRPS patients intradermal 
SP administration provoked abnormal plasma extravasation.73 Both SP and CGRP have 
been measured systemically elevated in CRPS patients.66,70,74 Bradykinin, another peptide 
involved in inflammation and peripheral nociceptor sensitization75,76, was four times 
higher in venous blood of CRPS patients compared to controls74. Neuropeptide Y (NPY) 
and perhaps angiotensin converting enzyme (ACE) have been suggested as potential 
modulators of the neuroinflammatory responses.77 The involvement of vasoactive 
intestinal protein (VIP) has also been suggested, but could not be demonstrated.78 
Compared to controls CRPS patients displayed a facilitated neuro-inflammatory response 
upon electrical C-fibre stimulation, even in the unaffected extremity, as measured by 
plasma protein extravasation and axon reflex vasodilation.79,80
     The important contribution of inflammation to CRPS is underlined by the successful 
reports from open label studies on treatment with immuno-modulating agents such as 
infliximab81,82 and thalidomide.83 Additionally, one clinical trial showed benefit from 
treatment with oral corticosteroids.84 
Hypoxia
The presence of hypoxia in CRPS is endorsed by several observations. In skin, employing 
micro-lightguide spetrophotometry has revealed decreased capillary oxygenation85, and 
dermal microdialysis has demonstrated increased lactate levels.86 In muscle, nuclear 
magnetic resonance spectroscopy revealed signs of acidosis and impaired high energy 
phosphate metabolism.87 CRPS affected limbs display histo-pathological characteristics 
consistent with oxidative stress.88 Hypoxia leads to acidosis and free radical formation, 
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which are well known triggers for primary afferents to cause severe painful sensations. In 
CRPS patients, experimentally induced tissue acidosis increased pain.89 However, blood 
oxygen was not deprived as was demonstrated with capillary blood gas analysis.90 
     Hypoxia in CRPS has been proposed to be caused by extreme vasoconstriction, 
either sympathetically thriven (see before) or resulting from a local dysbalance between 
endothelial factors.91 In the latter case, nitric oxide (NO) and endothelin (ET-1) are 
opposite mediators, whereas NO induces vasorelaxation and ET-1 vasoconstriction. In 
CRPS patients, venous ET-1 levels were found equal between the affected and unaffected 
sides10, but in blister fluid ET-1 levels were increased at the affected side, while NO 
levels were decreased.11 Since this was observed in chronic cold CRPS patients, these 
findings suggest a role of endothelial dysfunction induced hypoxia in ongoing CRPS, for 
which consequently NO donating agents have been proposed as therapeutics.92 
     In addition to sustaining chronic cold CRPS, acute hypoxic injury might also contribute 
to CRPS induction. In an animal model for CRPS, called the chronic post ischemia pain 
(CPIP) model, rats develop CRPS like symptoms, including swelling, hyperaemia and 
allodynia, after three hours of ischemia caused by tourniquet binding of the hindlimb, 
followed by rapid reperfusion.93 In the model, neuropathic pain like symptoms develop 
without microscopic demonstrable nerve damage, similar to CRPS-I in human. The 
authors have proposed triggering of afferents and initiation of inflammatory responses 
by free radicals, which are formed under oxidative stress. Although the model could 
not be fully reproduced by another research group that used an alternative method for 
ischemia induction94, the involvement of free radicals is likely in view of the positive 
outcomes of randomized clinical trials in human CRPS wherein scavengers, such as 
dimethylsufoxide95, N-acetylcysteine95 and vitamine C96, were effective in the early 
treatment.
Psychological factors
Psychological factors and behavioural aspects are thought to contribute to chronic pain 
disorders in general and to CRPS in particular.97,98 In an extreme view CRPS has been 
characterised as ‘a pseudoneurological disease, i.e. that many features of CRPS are 
manifestations of somatoform disorders, malingering, and psychiatric pathology’.99 
Although ‘this view is now generally disregarded’ 100, experts do emphasize the need for 
psychological and behavioural therapy as part of optimal treatment programs for CRPS 
patients.101 Still, the actual association between psychological factors and CRPS remains 
controversial due to the lack of methodological high quality studies. Most studies do 
not include prospectively collected data, have limited patient numbers, and lack a 
proper control group.102,103 Few of the studies that addressed psychological factors in the 
etiology of CRPS have reported increased incidences of stressful life events in relation 
to CRPS onset.104-106 More studies have addressed psychological factors and personality 
in the maintenance (instead of onset) of CRPS, whereby occasionally associations with 
anxiety, depression, somatisation, and hypochondria, were observed. However, the 
majority of studies showed no relation between psychological factors and CRPS105-107, 
not even in particular subgroups.108 
     A psycho-physiological mechanism that possibly affects chronic pain in CRPS 
patients is the mode of anger expression. Anger-out, meaning the tendency to express 
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anger overtly through verbal or physical means, was related with increasing pain in the 
affected extremity of CRPS patients but not in controls.109 Anger-out influences pain 
intensity in other chronic pain disorders, and is assumed to act through reactive muscle 
activity and by inhibition of the endogenous opioid antinociceptive systems activation. 
Another physio-psychological mechanism in CRPS may be the stress induced release of 
catecholamines, which have been observed as systemically elevated in CRPS patients.110,111 
In a vicious circle, emotional distress can sustain the pain, but be a consequence of it as 
well. Affective distress indeed has been demonstrated a predictor for the near future pain 
intensity in CRPS patients.112 
     Extreme fear for pain can lead to disuse of the affected extremity, thereby making 
a feasible contributor to the disease course of CRPS. Prolonged immobilisation can 
cause a decreased active range of motion, diminished nutritive blood flow, and trophic 
alterations.113 Graded activity physical therapy, conducted at overcoming movement 
anxiety is considered of great therapeutic value114, since it stimulates desensitization 
for mechanical allodynia and prevents against accumulation of catecholamines, 
neuropeptides and inflammatory mediators.101
Risk factors and determinants
Demographics
Population based incidence rates have been investigated in one North American2 and 
one European1 study. The US study reported an incidence rate of 5.5 per 100.000 person 
years, while the European reported 26.2. The striking difference between both studies 
most likely results from differences in case validation methodology and reflects the 
importance of uniform diagnostic assessment and nomenclature. However, despite the 
varying incidence rates, some demographic characteristics were generally similar in 
both studies. CRPS affected women predominantly with a ratio approximating 3.5. Its 
onset ranges from childhood through old age, but most cases were seen between their 
fifties and seventies. It is generally believed that CRPS occurs mainly in Caucasian and 
Japanese people.115
Injury related factors
Wrist fractures are considered the typical initiating trauma for CRPS, but the reported 
incidences after a wrist fracture vary broadly between 1 and 37%.116,117 Incidences after 
other precipitating events vary as well, for example between 0.7 and 21% after total knee 
prosthesis surgery118,119 and between 1.6 and 48.8% after a stroke.120,121 The estimated 
incidence rates appear highly dependent on the applied diagnostic criteria as well as the 
time between trauma and assessment of CRPS.119 
     Case reports describe the onset of CRPS after a wide subset of events, including 
any type of common or iatrogenic injury, cardiovascular events, cancer, infections, and 
medications.122 Spontaneous CRPS is rare1,122, but occurs. In general, fractures are the most 
common precipitating events and the upper extremity is more frequently involved than 
the lower.1,118,119 Severity of the physical injury is not related to the risk of CRPS97,123,124, 
although in two studies CRPS patients more often had an intra-articular localization of 
the fracture.125,126 Fracture repositions and external fixation are not associated with CRPS 
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occurence.123,124 During cast immobilization, increased pressure and early complaints of 
tightness are predictive factors for the onset of CRPS.125,127 
Genetics
The risk of CRPS may depend on the susceptibility for exaggeration of the underlying 
mechanisms of disease, such as inflammation and sensitization. In line with this, the 
presence of a specific genetic profile in CRPS patients has been suggested. Based on 
the biological plausibility, polymorphisms have been studied of genes that code for 
potential mediators of inflammation in CRPS, including TNFα (increased in blisters 
from CRPS patients)57,60 and angiotensin converting enzyme (ACE, modulator of SP 
and bradykinin)128,129. Primarily warm CRPS was associated with a polymorphism in one 
of the TNFα promoter genes.130  The ACE I/D polymorphism was increased in a small 
population of Japanese CRPS patients (n=14)131, but not in a larger, but still relatively small 
European study (n=60).132 Polymorphisms in the human leukocyte antigen system (HLA) 
have also been studied and loci from all three HLA classes have been reported associated 
with CRPS onset133,134, treatment resistance135 or related dystonia.136 The associations 
with the HLA-DR and HLA-DQ polymorphisms were particularly remarkable in view 
of the similar findings in patients with multiple sclerosis and narcolepsy.133-135  
Antecedent infections 
Since CRPS is suggested to be (partly) the consequence of an exaggerated inflammatory 
response, an autoimmune approach of CRPS becomes feasible. The many existing case 
reports of CRPS onset in patients with an autoimmune disease underline this idea.137-143 
Bearing in mind the mechanisms of infection induced cross reactivity against auto-antigens, 
the prevalence of antecedent viral infections in CRPS patients has been investigated. 
Two reports revealed increased seroprevalences of Parvo B19 IgG antibodies compared 
to healthy controls144,145, while one report revealed increased levels of IgG antibodies 
against herpes simplex viruses.146 Increased immunoreactivity against Campylobacter 
Jejuni was observed in CRPS patients with recent onset.147 CRPS after lyme boreliosis 
has been described148,149, as well as after spirochetal infection.150 Finally, Rubella and 
hepatitis B vaccination have been noted in case reports to precede CRPS.151,152 Recently, 
two studies have demonstrated the presence of autoantibodies against neuronal structures 
in CRPS patients147,153, but their actual contribution is not yet elucidated. 
Related disorders
The co-occurrence of CRPS with other diseases is mainly described in case reports. 
Patients with bone metabolism disorders, including osteoporosis154, osteomalacia155 
and osteogenesis imperfecta156,157 have been suggested as more susceptible for CRPS. 
However, they are prone for fractures and probably thereby for CRPS. Other case 
reports describe CRPS in patients suffering from chronic inflammatory disorders, such 
as rheumatic diseases.137-143 CRPS as paraneoplastic phenomenon has been suggested 
twice.158,159 Additionally, two publications report CRPS in a patient with amyotrophic 
lateral sclerosis160,161  and one in patients with Ehlers-Danlos syndrome.162
     A limited number of studies on CRPS related disorders have been conducted in 
relatively small study populations. One retrospective case-control study using 
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questionnaires revealed headaches to be more than twice as common in CRPS patients, 
even before the actual onset of CRPS.163 Furthermore, associations between psychiatric 
disorders and CRPS have been studied, although most of these studies are considered 
methodologically poor and address the influence on sustaining CRPS rather that the 
etiological contribution102,103. The results are contradictive, but associations between 
CRPS and depression, anxiety and somatoform disorders have occasionally been 
described.102,103,105,106,164
Discussion
Several distinct pathogenic mechanisms may contribute to the clinical syndrome that is 
currently named complex regional pain syndrome (CRPS). Alternating in time, CRPS 
has been regarded a disorder that was mainly based on a neurological, inflammatory 
or psychosomatic etiology. In the past decade significant progress has been made in 
the understanding of the separate disease mechanisms. Although sometimes speculative, 
paths for interaction between the different mechanisms can be hypothesized (figure 1): 
Hypoxia may trigger inflammatory responses.1. 93 (Interaction: hypoxia ↔ 
inflammation (classic and  neurogenic)).
Continuous nociceptive input by hypoxia2. 89,91, inflammation19,62 or sympathetic 
stimulation6,14,19,25 may lead to sensitization and alterations in cortical 
organization of sensory and motor units.165 (Interaction: hypoxia, inflammation 
and autonomic dysfunction ↔ somatic neuronal dysfunction (sensitization and 
cortical reorganization)).
Neuropeptides (SP) released in the dorsal horn may facilitate sensitization trough 3. 
interaction with NK-1 and NMDA receptors.8,70,166 (Interaction: inflammation 
(neurogenic) ↔ somatic neuronal dysfunction (sensitization)).
Sympathetic dysfunction (either central sympathetic hyperactivity or increased 4. 
peripheral adrenergic receptor hypersensitivity) may cause hypoxia due 
to impaired nutritive blood flow.8 (Interaction: autonomic dysfunction ↔ 
hypoxia).
Adrenergic receptors can be expressed on immune cells and catecholamines 5. 
can modulate cellular immunity8,111,167, while it also has been speculated that 
inflammation may change sensitivity or expression of α-adrenergic receptors on 
nociceptive fibres.168 (autonomic dysfunction ↔ inflammation (classic)).
Cytokines influence the NO/endothelin balance.6. 169 (Interaction (classic) 
inflammation ↔ hypoxia).
Psychological distress may influence sympathetic outflow and levels of 7. 
catecholamines.21,110,111 (Interaction: psychological factors ↔ autonomic 
dysfunction).
Severe chronic pain and disability may cause psychological distress. 8. (Interaction: 
somatic neuronal dysfunction (sensitization) ↔ psychological factors).
Fear of movement may result in the accumulation of inflammatory mediators 9. 
and free radicals, and prevent desensitization.101 (Interaction: psychological 
factors ↔ inflammation and hypoxia and somatic neuronal dysfunction).
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Figure 1. Interaction between the pathogenic mechanisms underlying CRPS. For explanation of 
the numbers see the discussion section on the opposite page.
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     The representation of CRPS as the sum, or even more than the sum, of several 
involved disease mechanisms makes sensible why CRPS is a disorder with varying 
clinical presentations and disease severity. However, while separate mechanisms may 
keep each other ongoing, the origin remains unclear. Are there premorbid alterations in 
the central nervous system that (genetically) predispose a person for CRPS at the moment 
of a trauma? Does the disease start with minimal peripheral nerve injury, making CRPS 
a specific kind of a neuropathic pain syndrome? Are the neuropathic pain symptoms 
secondary to ischemic injury or an exaggerated immunological response, perhaps 
subsequent to a viral infection or related to autoimmunity? Or is CRPS a somatoform 
disorder in emotionally unstable patients? Finally, is the initiating or predominant 
underlying mechanism the same for every patient, or does CRPS consist of many 
subtypes, all with different etiology and pathogenesis, but with a clinical presentation 
that much similar that they are all gathered under the same painful syndrome? 
     Apart from these questions addressing etiology, two other clinically relevant 
issues stand up. First, which patients develop CRPS? In order to answer this question 
determinants and risk factors associated with CRPS need to be assessed. Until today, 
sound epidemiological studies that compare pre-morbid characteristics in a large cohort 
of CRPS patients to a valid control group, have been performed scarcely. Of course 
such studies will encounter many challenges, for example related to the relative low 
prevalence of CRPS and its poor diagnostic definition. Nonetheless such efforts may 
provide very interesting new information that can lead to new insights in CRPS. 
     The second relevant issue addresses the lack of effectiveness of most current 
treatment strategies, despite their interference with plausible underlying disease theories. 
Considering the complex, multifactor pathogenesis of CRPS, it is understandable that not 
one single therapeutic modality is sufficient to attenuate all ongoing processes together. 
Additionally, it is well possible that not all disease mechanisms are equally prominent in 
each single patient. Finding a common factor that is relevant in all CRPS patients might 
be a challenging effort, but would be highly interesting. If a candidate could be identified, 
it would likely be a general down stream compound in a biochemical pathway. It might 
not be specific for CRPS and targeting it would interfere with important physiological 
processes and provoke unpleasant or even serious side effects. Nonetheless, if such a 
common factor should be found, the balance between therapeutic and unwanted effects 
of targeting this factor needs to be investigated. For severe CRPS patients side effects, 
safety provided, will outweigh their pain and disability. 
Conclusion
Based on the results from fundamental and clinical studies, it is reasonable to assume 
that mediators of different disease mechanisms are involved in a complex network of 
interactions, resulting in the painful and impairing disorder CRPS. Although ongoing 
fundamental research is needed to further elucidate the molecular background, from 
both a clinical and etiological perspective it is also of high importance to investigate 
determinants and risk factors for CRPS in epidemiological studies. Increased insight 
in predisposing factors may facilitate early diagnosis and improve the chance of good 
outcome, but also may provide new clues for potential underlying mechanisms. The 
elucidation of a single biochemical factor common in all potential underlying disease 
mechanisms would offer a highly interesting target for pharmacotherapy.
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Abstract
Introduction: The Complex Regional Pain Syndrome (CRPS) is a painful disorder 
that can occur in an extremity after any type of injury, or even spontaneously. 
Data on the incidence of CRPS are scarce and mostly hospital based. Therefore 
the size of the problem and its burden on health care and society are unknown. 
The objective of the present study was to estimate the incidence of CRPS in the 
general population. 
Methods: A retrospective cohort study was conducted during 1996-2005 in the 
Integrated Primary Care Information (IPCI) project, a general practice research 
database with electronic patient record data from 600,000 patients throughout 
the Netherlands. Potential CRPS cases were identified by a sensitive search 
algorithm including synonyms and abbreviations for CRPS. Subsequently, cases 
were validated by electronic record review, supplemented with original specialist 
letters and information from an enquiry of general practitioners. 
Results: The estimated overall incidence rate of CRPS was 26.2 per 100,000 
person years (95% CI: 23.0-29.7). Females were affected at least three times more 
often than males (ratio: 3.4). The highest incidence occurred in females in the 
age category of 61-70 years. The upper extremity was affected more frequently 
than the lower extremity and a fracture was the most common precipitating event 
(44%). 
Discussion: The observed incidence rate of CRPS is more as four times higher 
than the incidence rate observed in the only other population based study, 
performed in Olmsted County, USA. Postmenopausal woman appeared to be at 
the highest risk for the development of CRPS.
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Introduction
Complex Regional Pain Syndrome (CRPS), formerly known as Sudecks dystrophy or 
reflex sympathetic dystrophy, is a painful disease with clinical features that include 
pain, sensory, sudo- and vasomotor disturbances, trophic changes and impaired motor 
function.1 The disease course varies from relatively mild and self-limiting to chronic 
disease with a high impact on daily functioning and quality of life.2 Usually, symptoms 
appear in one extremity after even a relatively mild trauma, for example a fracture, 
contusion or surgery, but symptoms have also been described after varicella zoster 
infection and myocardial infarction.3 The diagnosis is based on the findings during the 
history and physical examination, for which several diagnostic criteria sets have been 
developed. The most well known are the IASP (International Association for the Study of 
Pain) criteria, that where established during a consensus meeting of experts in 1994.4 The 
pathogenesis and etiology may involve both neurological and inflammatory disorders, 
but remain to be completely unraveled.5,6
     Due to its complexity and broad spectrum of symptoms, CRPS patients are treated by 
physicians from different clinical backgrounds, including anesthesiologists, (orthopedic) 
surgeons, neurologists, rheumatologists and rehabilitation doctors. The incidence of 
CRPS has been studied retrospectively and prospectively in clinical settings after a 
certain precipitating event, most frequently after a distal radius fracture.7-11 Sandroni 
and colleagues have been the only ones so far to assess the incidence of CRPS in the 
general population (Olmsted County, USA) and they reported an incidence rate of 5.46 
per100,000 person years (PY).12 
     In our study, the objective was to assess the incidence of CRPS in the general 
population in the Netherlands. Moreover, we classified cases according to different 
diagnostic criteria and described the precipitating events of CRPS.
Methods
Setting
The Integrated Primary Care Information Project (IPCI) is a longitudinal observational 
database including electronic patient’s records of more than 600,000 patients from more 
than 150 general practitioners (GPs). The patient population is representative of the 
Dutch population regarding age and sex.13,14
     In the Dutch Health Care System, all persons need to be registered with a GP who 
acts as a gatekeeper for further medical care. The electronic records store information on 
demographics, signs and symptoms (using the International Classification for Primary 
Care (ICPC) codes (a classification system for primary care15) and narratives), diagnoses 
(using ICPC and narratives), clinical findings, specialist referrals, laboratory findings, 
hospitalizations, and drug prescriptions. Summaries of the hospital discharge letters 
and information and letters from specialists are entered in a free text format and hard 
copies of original letters can be provided upon request. To maximize completeness of 
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the data, GPs who participate in the IPCI project are not allowed to use paper-based 
records. The system complies with the European Union guidelines on the use of medical 
data for medical research and has been proven valid for (pharmaco)-epidemiological 
studies.16 The Scientific and Ethical Advisory Group of the IPCI project approved the 
study (projectnumber 04/70)
Source Population
     The source population comprised all persons of all ages, with at least 1 year of valid 
history in the IPCI database during the study period (January 1996-June 2005). This 
meant that the practice had been contributing data to the IPCI database for at least one 
year and that the patient had been registered with the GP for at least one year. This 
one year period was required to have sufficient background information on all subjects. 
Follow-up started at the beginning of the study period or on the date that one year of 
valid history was available, whichever date was latest. Follow-up was terminated when 
the person transferred out of the practice, on the date of last data supply by the GP, death, 
diagnosis of CRPS or at the end of the study period, whichever came first.
      Since additional data collection was required for validation of CRPS, the source 
population was restricted to all practices that were still active in the IPCI database in 2006 
and provided additional information. For clarification of the data collection procedures 
see also figure 1.
Diagnosed by GP
61
Possible cases
797
Source population
217,653
52 GP’s
Reconfirmed
279
Unknown
4
Search algorithm
and first manual validation
Prevalent
247
No reply
54
6 GP’s
Questionnaires
mailed to GP’s
Denied
213
Incident
238
Prevalent
41
Diagnosed by specialist
177
Validation based
on questionnaires
Incident
550
Reply
496
46 GP’s
Figure 1.The process of identification of CRPS cases in the Integrated Primary Care Information 
(IPCI) database.
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Case Definition
Potential cases of CRPS were identified in the IPCI database using an extensive string 
search including an exhaustive list of synonyms and abbreviations for CRPS (for example 
complex regional pain syndrome, Sudecks dystrophy, reflex sympathetic dystrophy, 
posttraumatic dystrophy, CRPS, RSD, PTD, etc.), plus prescriptions of dimethyl 
sulfoxide (DMSO). In the Netherlands, DMSO is exclusively prescribed for CRPS. In 
a first validation step, performed by a medical doctor with clinical experience in CRPS, 
all potential cases were manually evaluated by reading the patients records in order to 
eliminate obvious non cases and to classify possible cases as incident or prevalent. A 
possible case was defined as each patient for whom CRPS was suggested or diagnosed in 
the patient record. A possible case was considered incident when the first occurrence fell 
within the follow-up time of that person. 
     To further validate the diagnosis of CRPS in the incident possible cases, a short 
questionnaire was mailed to the GPs. The questionnaire was used to confirm whether 
the person, according to the GP’s judgment, indeed suffered from CRPS and whether 
the patient had been seen and diagnosed by a specialist. Copies of all specialist letters 
were requested. Specialist letters usually provide information about history and physical 
examination of the patient. That information was used to verify the fulfillment of 
diagnostic criteria for CRPS according to the IASP criteria4, the Bruehl criteria17,18, and 
the Veldman criteria9 (see the legend of table 1b for a description of the criteria sets).  The 
choice for these sets of criteria was based on international acceptance of the IASP criteria, 
high specificity of the Bruehl criteria, and national acceptance of the Veldman criteria. 
These criteria sets differ from each other in the types and the number of symptoms and 
signs that have to be present in order to establish the diagnosis CRPS. The IASP criteria 
are regarded as very sensitive, whereas the Bruehl criteria have lower sensitivity, but 
are highly specific. The Veldman criteria are the only ones that theoretically allow a 
diagnosis of CRPS in the absence of pain. 
     The fulfillment of the diagnosis according to the different criteria sets was judged 
independently by two physicians who are familiar with CRPS. In case of discrepancies 
between their judgments, consensus was reached by discussion. Where pain and an 
increase of the symptoms after use of the affected limb (an obligatory feature according 
to the Veldman criteria) were not mentioned in the letters, it was reasonable to assume 
that they were present in most of the cases. Therefore, the criteria were first applied both 
in a strict sense, and subsequently without taking into account the presence of pain and 
increase after use of the affected limb. Information on precipitating events and referrals 
were derived from the electronic medical records and the specialist letters.
Analysis
The incidence rate of CRPS was calculated by dividing the number of incident cases 
(as established by reconfirmation of the diagnosis) (numerator), by the total number 
of accrued person years in the population (denominator). Incidence rates (IR) were 
calculated per calendar year, sex, and age category. Calculations were stratified for CRPS 
following a fracture and CRPS following other precipitating events. 95% Confidence 
intervals were constructed around the rates based on the Poisson distribution.
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     In addition to the incidence rate based on the reconfirmed diagnoses, we also calculated 
an incidence rate based on cases that fulfilled the IASP criteria. However, the IASP 
criteria could only be applied in a subset of the specialist diagnosed cases (for whom 
specialist letters with diagnostic information were available). Therefore, the percentage 
of fulfillment was extrapolated only within the specialist diagnosed case group. Cases 
that were diagnosed by the GP alone were excluded from this analysis. 
     In order to be able to compare our results with the incidence found by Sandroni and 
colleagues, we calculated standardized morbidity ratios (SMR), using the method of 
indirect standardization on age and gender, as described by Rothman.19
     Standard descriptive statistics were used to compare categorical variables (Chi-
square test, univariate logistic regression), or means (Student’s t-test). Kappa statistics 
were calculated to judge interrater agreement for the diagnostic criteria. The Statistical 
Package for Social Sciences (SPSS) 12.0 for Windows was used for all statistical tests. 
 
Results
In the initial source population of 217,653 persons registered with at least one year of 
valid history at one of the 52 active practices in the IPCI database, 238 incident cases 
of CRPS could be identified after finalization of the validation process (figure 1). The 
response rate for the short questionnaires amongst GP’s was 88%. Only the populations 
from the practices that responded were included in the source population for calculations 
of the IR. This source population comprised 190,902 persons from 46 practices, and 
concerned the mentioned 238 cases. 
     For 95 (54%) of the 177 cases that were diagnosed by a specialist, letters with information 
on anamnesis and physical examination were available. Structured extraction of data 
(table 1a) allowed for classification of the cases according to different CRPS criteria 
sets (table 1b). 86% of these specialist diagnosed cases fulfilled the strictly applied IASP 
criteria for CRPS. If pain and an increase in pain after use of the body part were assumed 
to be present (even if not mentioned in the letter), 93% of the cases fulfilled the IASP 
criteria, 47% the Bruehl criteria and 58% the Veldman criteria (table 1b). The interrater 
agreement varied between the different criteria sets, with the lowest κ = 0.43 (moderate) 
for the IASP criteria with pain assumed to be present, and the highest κ = 0.78 (good) for 
the Veldman criteria.  In the available specialist letters the presence or absence of vaso- 
and sudomotor and motor-trophic signs and symptoms were reported more frequently 
than the presence or absence of sensory and neurological signs and symptoms. 
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     Characteristics of the cases are displayed in table 2. The mean age at CRPS diagnosis 
was 52.7 ± 2.20 (range: 7-90) years in the total group. The mean age for males was 
51.1 ± 4.2 years and for females 53.0 ± 2.6 years. The age at diagnosis did not differ 
between males and females (p = 0.404). The most common precipitating event for CRPS 
was a fracture, followed by a contusion/sprain. In more than ten percent of the cases 
no precipitating event was reported or could be identified in the medical record. Upper 
extremities were more often affected than lower extremities (59.2% versus 39.1%, p 
<0.001), whereas the right side and left side of the body were affected with the same 
frequency (p=0.464). Patients who were diagnosed only by GPs were significantly 
older than patients who were also referred to and diagnosed by a specialist (p=0.039). 
Anesthesiologists were the most frequently involved specialists and usually one type of 
specialist was seen by the patient.
Table 1b. Fullfillment of the GP confirmed CRPS patients according to the different diagnostic 
criteria sets.
N=95 Strict If presence of pain is assumed
If increase of pain after 
use of affected body 
part is assumed  
Interobserver
agreement
n % n % n % κ
IASPA 82 86.3% 88 92.6%  n.a.      n.a. 0.43 - 0.66 (moderate - good)
BruehlB 41 43.2% 45 47.4% n.a.      n.a. 0.66 - 0.69 (good)
VeldmanC 17 17.8% 17 17.8% 55    57.9% 0.63 - 0.78 (good)
A. IASP citeria: 1.  Develops after an initiating noxious event (type I) or after a nerve injury (type II)
       2. Spontaneous pain or allodynia/hyperalgesia that is not limited to the territory of a single    
           peripheral nerve and is disproportionate to the inciting event.  
       3. There is or has been evidence of edema, skin blood flow abnormality, or abnormal 
            sudomotor activity in the region of the pain since the inciting event.
       4. This diagnosis is excluded by the existence of conditions that would otherwise account for the 
           degree of pain and dysfunction
B. Bruehl criteria: 1. Continuing pain which is disproportionate to any inciting event.
          2. Must report at least one symptom (history) in each of the following categories. Must 
              display at least one sign (physical examination) in two or more of the following categories. 
                  Sensory: hyperesthesia, hyperalgesia (to pinprick) and/or allodynia (to light touch)
                   Vasomotor: temperature asymmetry and/or skin color changes and/or skin color asymmetry
                  Sudomotor/edema: edema and/or sweating changes and/or sweating asymmetry
              Motor/trophic: decreased range of motion and/or motor dysfunction (weakness, tremor, 
                                     dystonia) and/or trophic changes (hair, nail, skin).
C. Veldman criteria: 1. 4 or 5 of:   Unexplained diffuse pain; Difference in skin color relative to other limb;               
                   Diffuse edema; Difference in skin temperature relative to other limb;
                 Limited active range of motion
              2. Occurrence or increase of above signs and symptoms after use.
              3. Above signs are present in an area larger than the area of primary injury or operation 
                  and including the area distal to the primary injury.
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Table 2. Characteristics of CRPS patients.
Characteristics Total, N=238 By GP only, N=61 By specialist, N=177 p-value
        
  n % n       % n       %       
                        
mean age at onset (std) 52.7 (17.31)     56.6 (19.63)     51.3 (16.27) 0.039*
Female 184 77.3% 52 85.2% 132 74.6% 0.086
CRPS II 7  2.9% 1 1.6% 6 3.4% 0.485
            
Precipitating event         
None 25 10.8%        8 13.1%             17 9.6%   0.941
Fracture 105 44.1% 28 45.9% 77 43.5% 0.790
Sprain 42 17.6% 13 21.3% 29 16.4% 0.953
Elective surgery 29 12.2% 5 8.2% 24 13.6% 0.617
                     CTS 8 3.4% 1 1.6% 7 4.0% 0.441
                     Dupytren 6 2.5% 1 1.6% 5 2.8% 0.577
Tendon injury 13 5.5% 2 3.3% 11 6.2% 0.484
Others 21 8.8% 4 6.6% 17 9.6% 0.575
unknown 3 1.3% 1 1.6% 2 1.1%
    
Localization at diagnosis
Right side of the body 114 47.9% 31 50.8% 83 46.8% 0.279
Left side of the body 115 48.3% 26 42.6% 89 50.2% 0.154
Unknown 9 3.8% 4 6.6% 5 2.9%      
Upper extremity 141 59.2% 40 65.6% 101 57.1% 0.243
Lower extremity 93 39.1% 19 32.2% 74 41.8% 0.141
Unknown 4 1.7% 2 3.2% 2 1.1%       
    
Type of specialist to whom patient is referred (more than one possible)
Anesthesiologist         87 49.7%        
Rehabilitation doctor         52 29.4%        
Orthopedic Surgeon         49 27.7%   
Surgeon         45 25.4%   
Neurologist         19 10.7%   
Rheumatologist         8 4.5%   
Plastic Surgeon         5 2.8%   
Other         6 3.4%   
    
No. of specialists seen  
1         105 59.3%   
2         54 30.5%   
3         14 7.9%   
4         4 2.3%   
                
  
* significance at p<0.05, X2 test, given for differences in characteristics between patients 
diagnosed by the GP alone and patients additionally confirmed by a specialist.
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     The incidence rate of CRPS in the Netherlands was 26.2 per 100,000 (PY) (95% 
CI: 23.0-29.7) (table 3). The standardized morbidity ratio (SMR) was calculated as 
4.2, meaning that, after standardization for age and gender to the source population of 
Sandroni and colleagues, we found a 4.2 times higher incidence rate than described 
in their study. If only specialist confirmed cases were considered, the incidence rate 
was 19.5 per 100,000 PY (95%CI: 16.8-22.5). The incidence rate based on specialist 
diagnosed cases that fulfilled the IASP criteria was 16.8 per 100,000 PY (95%CI: 14.7-
19.2). The SMR compared to the results of Sandroni was 2.7.
     Gender-specific incidence rates, based on the reconfirmed diagnoses, for females 
and males were 40.4 (95% CI: 34.8-46.5) and 11.9 (95% CI: 9.0-15.4) per 100,000 
PY, respectively. The incidence of CRPS was more than threefold higher in females 
than in males (RR: 3.4, 95%CI: 2.9-3.9). The incidence rate of CRPS did not change 
significantly over time between 1996 and 2005 (figure 2). The confidence intervals 
in 1996 and 2005 were relatively wide due to the low number of person years by left 
censoring in 1996 (early stage of the IPCI database) and a high degree of right censoring 
in 2005 (data available only until June). The incidence varied profoundly with age, the 
highest incidence rate was observed in the group 61-70 years of age (figure 3). The age 
and sex distribution pattern was similar in a subgroup including only the cases with 
another precipitating event than a fracture.
Discussion
In this study, we demonstrated that the population-based incidence of CRPS in the 
Netherlands is 26.2 per 100,000 PY, with a peak incidence at 61-70 years of age. Fracture 
was the most common precipitating event accounting for 44% of the CRPS cases. The 
upper extremities were more often affected than the lower extremities with no preference 
for either left or right side. A wide variety of specialists was involved in the diagnosis and 
treatment of CRPS patients. 
     The incidence rate in this study is more than four times higher than the population-
based incidence rate that was reported by Sandroni and colleagues in Olmsted County12. 
The difference sustained even after standardization (IR: 22.8 per 100,000 PY) and when 
we included only specialist-diagnosed cases in our calculations (IR: 19.0 per 100,000 
PY). Possibly, differences in population characteristics such as ethnicity, socio-economic 
factors and incidence of fractures can explain the observed difference. More likely, 
however, it is secondary to the difference in case definitions and validation. The study 
of Sandroni and colleagues used the IASP criteria, which were applied retrospectively 
to information from electronical medical records. We also used a retrospective approach 
and used both electronical medical records as well as information from GP questionnaires 
and specialist letters for the diagnosis. In contrast to Sandroni we did not require that all 
cases should fulfill diagnostic criteria; we retained all cases on the basis of a reconfirmed 
diagnosis of CRPS by the GP or specialist. 
     Criteria sets were also applied on a subset for which detailed diagnostic data were 
available, but were used merely to see differences in criteria sets. However, an incidence 
rate based on the strictly applied IASP criteria (IR: 16.8 per 100,000 PY), as done in 
the Sandroni study, was calculated and was still almost three times higher in our study 
51
The Incidence of Complex Regional Pain Syndrome     2.1
20
120
100
80
60
40
140
<10 10-19 20-29 30-39 40-49 50-59 60-69 70-79 >80
0
IR
 p
er
 1
00
,0
00
 P
Y
women total
women, specialist diagnosed only
men total
men, specialist diagnosed only
IR
 p
er
 1
00
,0
00
 P
Y
10
20
30
40
50
60
70
80
0
1997 1998 1999 2000 2001 2002 2003 2004 2005
IR
 p
er
 1
00
,0
00
 P
Y
IR
 p
er
 1
00
,0
00
 P
Y
Figure 2. Incidence rates (with 95% confidence lines) of CRPS in the Netherlands per calender 
year.
Figure 3. Incidence rates of CRPS in the Netherlands per age catgory, stratified by gender and 
confirmation level (diagnosed by GP alone or additionally confirmed by a specialist). 
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as the incidence rate found in Olmsted County (SMR=2.7). Remarkable is, that in our 
subset of specialist diagnosed cases 86% fulfilled the IASP criteria, compared to 19% 
of the cases in the Sandroni study. The supposedly high rate of incorrectness of the 
CRPS diagnosis (81%) in the Sandroni study has been questioned by others before20, 
and suggests that the retrospective application of the IASP criteria to information on 
electronic charts might have been overly strict. The IASP criteria are considered highly 
sensitive and incidence rates based on this should be comparable with incidence rates 
based on specialist’s diagnoses.
     The highest incidence rate in our study was observed in the age group of 61-70 years 
and the mean age at diagnosis was 52.7 years. This age peak is higher than is generally 
expected and observed in some non-population based investigations9. However, other 
clinical studies show high average ages of the included CRPS patients, in line with our 
observation.7,10,11 It could be suggested that the increasing incidence of CRPS with age is 
due to a higher occurrence of fractures at older age. However, the same age distribution 
pattern was observed in the group of patients with another precipitating event than a 
fracture. From our findings, it can be concluded that the majority of the CRPS cases in 
females occur in the post-menopausal stage of life. This was noted before by Zollinger et 
al.10 The age and sex distribution pattern suggests that hormonal etiological factors may 
be involved in the pathogenesis of CRPS. 
     Noteworthy is that less than half of the CRPS cases have a fracture as precipitating 
event, similar to the observations of Sandroni and colleagues. Fracture is often regarded 
as the primary precipitating event and the incidence of CRPS after a fracture has been 
studied prospectively.8,9 Hence, other precipitating events, such as surgery and tendon 
rupture may be worthwhile including in prospective research.  Additional findings of 
interest were the fact that patients who were diagnosed only by the GP without referral 
to a specialist, tended to be older. 
     Limitations in our study are related to the absence of a gold standard for the diagnosis 
of CRPS. As observed in the specialist letters, physicians focused on vaso- and sudomotor 
and motor/trophic signs, whereas the presence or absence of sensory and neurological 
symptoms was not frequently reported. Van de Beek and colleagues have stated that 
general dissatisfaction with the available criteria has resulted in the use of personally 
favoured criteria.21 As a consequence of this, descriptions of the patients differ and lack 
detail, which has complicated uniform classification of the cases in our study. However, 
if detailed information for the application of diagnostic criteria would have been 
available as in a prospective study, the choice for one specific criteria set for validation 
of the diagnosis above the others would also have been disputable, since none of them 
is definitely superior.21 For this reason we decided that the most reliable incidence rate 
calculations would be based on reconfirmed clinical diagnoses. However, the problems 
regarding case definition that were encountered during our study emphasize again the 
need for validated and well documented diagnostic criteria, that can be applied more in 
primary and secondary care and in prospective and retrospective studies. 
     Despite the above described, we do not believe that the inability to uniformly 
classify all patients has resulted in an overestimation of the incidence rate. We sought 
reconfirmation of all cases and allowed GPs to reconsider whether an initial diagnosis 
actually was correct. In addition, almost three quarters of the patients were referred to a 
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medical specialist who reconfirmed the diagnosis as well, after exclusion of alternative 
diagnoses. The actual incidence rates varied with the choice to base the validation of 
the CRPS diagnosis on GP or specialist confirmed cases. However, the pattern of the 
incidence rate (sex and age distribution) was similar for both groups. On the contrary, 
we consider it more likely that our incidence rates are an underestimation of the reality. 
Although we have used a sensitive search algorithm for identification of the CRPS 
cases, we might have missed cases that had symptoms but were not diagnosed as such 
in the medical record because of unfamiliarity of the GP with the syndrome and its 
nomenclature. Mainly the relative mild and self limiting cases of CRPS might not always 
have been recorded as such in the medical journal and were therefore not included in our 
calculations. 
     In conclusion, we estimated an incidence of CRPS in the general population of the 
Netherlands of 26.2 per 100,000 PY, which is much higher than previously described. 
Postmenopausal women appeared to be at an increased risk for the development of the 
disease. Uniform use of more generally accepted diagnostic criteria would improve the 
quality of epidemiological and clinical studies concerning CRPS in the future.
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Abstract
Introduction: The outcome of complex regional pain syndrome (CRPS) is 
relatively unknown. High disease resolution rates have been reported, but also 
long-lasting impairments in many patients. The present study aims to assess 
CRPS outcome in a population based cohort of CRPS patients. 
Methods: CRPS patients were retrospectively identified (1996-2005) in a Dutch 
GP database, the Integrated Primary Care Information project, and included if 
at onset (i.e. in the past) they had complied with IASP diagnostic criteria. The 
disease status at minimal two years since onset was assessed during visits using 
questionnaires, interviews and physical examination. Symptoms (subjective) 
and signs (objective) were compared to reference patients with an identical past 
injury but without CRPS. Actual fulfillment of the IASP criteria, treatment status, 
self-reported recovery, and working status were recorded. Moreover, to identify 
potential prognostic factors, baseline patient characteristics were compared 
across subgroups according to CRPS outcome. These subgroups were derived 
by cluster analysis on actual symptoms and signs.
Results: Hundred-and-two CRPS patients were assessed at on average 5.8 years 
(range 2.1-10.8) since onset. CRPS patients displayed still higher symptom 
and sign prevalences in all categories (sensory, vasomotor, sudomotor, motor/
trophic) than references. Sixteen percent (95%CI: 9-22) reported the CRPS as 
still progressive, while 31% (95%CI: 19-43) was incapable to work. Patients 
in the poorest outcome cluster had more often their upper extremity affected, 
another event than a fracture, and cold CRPS.
Discussion: Severe CRPS outcome is rare, but a majority of patients has persistent 
impairments at two or more years since onset. 
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Introduction
Complex Regional Pain Syndrome is a painful complication of a fracture, surgery 
or other type of injury. The diagnosis is mainly based on the presence of symptoms 
(subjective) and signs (objective). Several sets of diagnostic criteria have been proposed, 
of which the criteria from the International Association for the Study of Pain (IASP) are 
the most widely accepted for clinical use.1,2 The criteria proposed by Harden and Bruehl 
are considered the most specific and have been recommended for research purposes.2,3
     Insight into the disease course and outcome of CRPS is limited. Various studies 
have been performed, often in small or selected populations and without a reference 
group. Regarding the course of CRPS, Bonica et al. classically described the disease as 
one with sequential stages, wherein the initial sensory disturbances diminish over time 
and the motor/trophic abnormalities increase.4 Bruehl et al. tried to actually demonstrate 
these stages in a group of CRPS patients by conducting a cluster analysis based on 
clinical features (symptoms and signs). However, the three distinct clusters that were 
formed were not associated with CRPS duration and therefore the results argued against 
sequential staging of CRPS.5 
     Regarding the outcome of CRPS, contradicting reports have been published. For 
example Sandroni et al. performed a population based study and mentioned complete 
symptom resolution in 74% of the patients within one year after CRPS onset6, based on 
medical chart review. On the contrary, also after one year or more, Veldman et al. and 
Galer et al. objectively assessed persistent disturbances in most of their patients.7,8 In 
addition both Geertzen et al. and Vaneker et al. reported impairments and disability in 
patients whom they assessed at three to nine years since CRPS onset.9,10 The variability in 
results may reflect either the assessment methods (chart review versus actual assessments) 
or the setting (population based versus hospital based). Prognostic factors for a good or 
poor outcome of CRPS are not known, although coldness of the affected limb has been 
associated with longer disease duration11 and worse functional outcome.12 
     The aim of the present study was to get more insight into the general disease outcome of 
CRPS, using a population-based retrospective comparative cohort study. CRPS patients 
and reference (no CRPS) patients had experienced a similar past physical trauma at least 
two years prior to the assessment date. 
Methods
Setting
All patients were selected from the Integrated Primary Care Information (IPCI) project, 
a longitudinal General Practitioners (GP) database maintained by the Department of 
Medical Informatics of the Erasmus Medical Center in Rotterdam. Presently, the database 
stores the electronic patient records of more than 800,000 patients. The population in 
the database reflects the general population of the Netherlands regarding age and sex 
distribution. Details of the project have been described elsewhere.13 In the Dutch health 
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care system all persons have to be registered with one GP, who acts as a gatekeeper and 
receiver for secondary care. GPs who participate in the IPCI project are not allowed to 
use paper-based patient records, in order to maximize completeness of the electronic data. 
The IPCI project complies with the European Union guidelines on the use of medical 
data for medical research and has been proven valid for (pharmaco-epidemiological) 
research.14 The study has been approved by the Scientific and Ethical Advisory Group 
of the Project (project number 04/70) and by the Medical Ethical Board of the Erasmus 
Medical Center (Protocol number 2006-099).
Source population
The source population was restricted to all practices that were still active in the IPCI 
database in 2006 and were able to provide additional information upon request. From 
these, all persons in database follow-up between January 1996 and June 2005 were 
included. To be able to characterize patients, a minimum of one year of valid history 
was required for each person before follow up was started, which meant that the GP 
practice had been participating in IPCI for at least one year and that the patient had been 
registered with that GP for at least one year. 
CRPS cohort 
Identification of possible CRPS cases was performed using a sensitive string search 
algorithm in the IPCI database, followed by a first validation step in which GPs were 
asked to reconfirm the CRPS diagnosis in a short questionnaire. The index date was 
chosen as the date of the precipitating injury, or in cases with spontaneous CRPS at the 
date of first symptoms in the GP records. This part of the case identification procedure is 
explained in detail in our study on the incidence of CRPS in the Netherlands.15 
     The confirmed cases were invited via the GP to participate in the present study. In 
the invitation letter we clearly explained that the time load of participation would be 
less than three hours in total, visits could occur either at the GP or at home, and that 
early morning/late evening visits were possible to avoid interference with daily (work) 
activities. Additionally we stressed that participation was relevant regardless if the CRPS 
was still active or not. 
     Patients who provided informed consent were visited once by the primary investigator 
(MM), who is a physician with clinical experience in diagnosing CRPS, together with 
a research assistant (MHB). Due to the retrospective nature of the study these visits 
occurred at a minimum of two years after CRPS onset (date of precipitating injury) for all 
subjects. Prior to the visit participants received a questionnaire about their CRPS related 
complaints, precipitating injury, disease course, referrals, therapy, impairments, and 
ability to work. These questionnaires were completed by the patients in advance, and were 
discussed briefly during the visit in order to avoid incompleteness or misinterpretations. 
Subsequently, during the visit a history focused on CRPS related symptoms was taken, 
as well as physical examination of the affected and contralateral unaffected limb. 
Symptoms (subjective) and signs (objective) relevant for the diagnosis of CRPS were 
collected in a standard assessment form, as is used within TREND (Trauma Related 
Neuronal Dysfunction), the Dutch scientific knowledge consortium in which the study 
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was embedded.16 Time since injury was categorized as 2-5 years; 5-7.5 years or >7.5 
years.
     Based on self-reported predominant temperature characteristics of the affected limb(s) 
patients were classified as warm or cold CRPS. Patients were included in the study if at 
the moment of CRPS onset (i.e. in the past, not per definition by the time of visit) they 
had fulfilled the IASP criteria for CRPS, based on the combined information from the 
visits (symptoms and signs history), the GP records and specialist letters.
Reference cohort
Reference patients were randomly selected from the IPCI database and matched to the 
CRPS patients on age, gender, calendar time (two year band) and specific type of injury 
that precipitated CRPS (fracture, surgery, soft tissue injury, etc.). This meant that each 
CRPS case patient was compared to a reference patient with an identical injury at a 
similar location (upper or lower extremity). If the case had no specific injury preceding 
CRPS onset, the reference patient was allowed to be free of injury either. For each 
CRPS patient two reference patients were asked to participate. If both refused, up to 
six additional persons were invited. Reference patients who provided informed consent 
received a questionnaire similar to the one for CRPS patients, without the parts specifically 
addressing CRPS. Reference patients were visited, during which a history taking and 
physical exam was performed of the past injured extremity, as well as the contralateral 
extremity, using the same standardized assessment form as for CRPS patients. Time 
since injury was categorized as 2-5 years; 5-7.5 years or >7.5 years.
Outcome parameters
In this descriptive study we used three different ways to investigate the long-term 
outcome of CRPS. First, we compared the actual prevalence rates of specific symptoms 
(subjective) and signs (objective) as assessed during the visit between CRPS patients and 
the reference group. 
     Second, within the group of CRPS patients alone we categorized patients according 
to the following classifications of disease outcome: 1. fulfillment of IASP criteria; 2. 
continuing CRPS treatment  3. self-reported recovery (completely recovered, stabilized or 
progressive disease); 4. employment status (completely resumed former work activities, 
working with adaptations or complete incapability to work). 
     Third, within the group of CRPS patients, we also defined subgroups according to 
CRPS outcome status by using a cluster analysis method. Patients were grouped in one 
cluster if they resembled  each other with respect to long-term persisting symptoms and 
signs. We compared baseline patient characteristics between these subgroups (clusters) 
with the purpose to identify prognostic factors of CRPS outcome. 
Statistics
Standard descriptive statistics were used to compare means (one way analysis of variances 
(ANOVA)) and frequencies (Pearson chi square) across subgroups. The symptom and 
sign prevalence rates at the moment of visit were compared between CRPS cases and 
reference patients using a McNemar test for matched observations. 
     To better identify subgroups of CRPS outcome, a K-means cluster analysis was 
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performed in a similar manner as done before by Bruehl et al.5 The K-means cluster 
analysis is a non-hierarchical clustering method to derive homogeneous subgroups of 
patients based on selected characteristics, for which we choose the symptoms and signs of 
CRPS at the moment of visit. First, for each patient we defined the number of features that 
was still present at the moment of visit within the following classes of signs/symptoms: 
sensory, vasomotor, sudomotor/edema and motor/trophic17 (appendix 1). A total of eight 
scores were derived per patient. Since the maximum number of features differs across 
the categories we converted the raw scores into standardized scores (Z-scores) using the 
formula (X-μ)/σ, wherein X is the raw score, μ is the mean of the population, and σ is the 
standard deviation. Finally, the individual patient Z-scores were imported as dependent 
variables in the K-means cluster analysis. We pre-specified to search for three clusters 
in order to investigate the intuitive existence of complete, partially and non-recovered 
patient subgroups. Additionally, this would make the results comparable to those of 
Bruehl and colleagues.5
As potential prognostic factors for CRPS outcome (categorized in the cluster analysis) 
we considered: age, gender, precipitating injury (fracture or other), affected extremity 
(upper or lower), and (self reported) cold/warm CRPS. Migraine, osteoporosis, menstrual 
cycle related disorders, neuropathies, and hypersensitivity related disorders (especially 
asthma) were also evaluated, since they were associated with the onset of CRPS in a 
previous study.18 Psychological factors were considered as they have often been discussed 
as involved in CRPS onset and disease course.19,20 Information on medical history was 
obtained by systematic review of the complete electronic medical records prior to the 
index date.
     All computerized analyses, including the K-means cluster analysis, were conducted 
using SPSS, version 12.0. Two-tailed significance was established at p<0.05. 
Results
Study population
The source population comprised of 204,281 persons from 48 GPs. In this population 
259 patients with physician confirmed CRPS were identified, 216 (83%) of them could 
be contacted for study participation, while the remaining 43 patients were untraceable 
due to re-identification problems (n=25), transferring out (n=16) or death (n=2). Of the 
216 contacted patients, 134 (62.0%) provided informed consent and completed study 
assessments. No significant differences in age, gender distribution, CRPS duration, 
and prevalence of concurrent diseases were observed between participants and non-
participants. In participants, the lower extremity was affected more frequently compared 
to non-participants (45% versus 34%; p=0.04), and participants less often lived in a socio 
economically deprived area (1% versus 6%; p=0.03).
     With the additional information obtained during the visits, eight (6.0%) CRPS patients 
turned out to be prevalent (onset of CRPS prior to start of the follow-up time) and were 
excluded. In hindsight, 24 (19%) patients had never fulfilled the IASP criteria, despite 
their previously physician confirmed diagnosis. Reasons for not fulfilling the criteria 
were presence of a possible alternative diagnosis (n=18), absence of pain (n=2), and 
absence of vasomotor or sudomotor disturbances (n=4). In total 102 CRPS patients 
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remained for inclusion in the cohort.  The mean follow-up time since CRPS onset (initial 
injury) was 5.8 years (median 5.7, range 2.1-10.8). Mean age at CRPS onset was 51 
years (range 12-86) and 79% was female. Fracture was the precipitating event in 54%, 
surgery in 12%, and soft tissue injury in 27% of the CRPS cases. In 3% CRPS had 
developed spontaneously. 
     For the 102 included case patients 263 reference patients, matched on age, gender, 
calendar time, and precipitating injury, were invited to the study. Of these 75 (29%) gave 
consent for participation, yielding 75 matched case-reference pairs (CRPS patients for 
whom no matched reference patient participated were excluded from the case-reference 
comparisons). The mean follow-up time since the precipitating injury in the references 
was 5.4 years (median 5.4, range 2.1-10.7). Participating and non-participating reference 
patients were similar regarding age, gender and medical conditions, but participants lived 
less often in a socio economically deprived area (1% versus 4%; non-significant). 
Symptoms and signs prevalence rates in CRPS and reference patients
At the moment of visit CRPS patients still had considerably more symptoms (subjective) 
and signs (objective) than reference patients who had an identical past injury at a similar 
point in time (table 1). Differences in prevalences were most pronounced for sensory and 
motor/trophic signs. 
CRPS outcomes
Within the group of CRPS patients, there was no association between symptom/sign 
prevalences and the duration of CRPS (figure 1). 
     At the moment of visit 64% (95%CI: 55-73) of the CRPS patients still fulfilled the 
IASP criteria for CRPS diagnosis (figure 2). According to the self reports 30% (95%CI: 
21-39) considered themselves recovered, 54% (95%CI: 44-64) were stable, and 16% 
(95%CI: 9-22) still suffered from severe progressive disease. Only 27% (95%CI: 18-
36) of patients were still actively treated (pharmacological, invasive treatment or 
physiotherapy). Among the 54 patients who were employed before CRPS onset, 41% 
(95%CI: 28-54) had resumed their former job completely, 28% (95%CI: 16-40) had 
resumed their work with adjustments (altered function or decrease in working hours per 
week), and 31% (95%CI: 19-43) had become completely unable to work. 
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Figure 1. Prevalences of sign/symptom categories in CRPS patients after different time windows 
since CRPS onset. 2-5 years: n = 37; 5-7.5 years: n=44; > 7.5 years n=21.
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Figure 2. The circle diagrams display the percentage of CRPS patients per outcome status by 
several parameters (ongoing fulfillment of IASP criteria, ongoing treatment, self reported outcome, 
working status). The bar diagrams display symptom/sign category prevalences (signs and symp-
toms taken together) per outcome parameter subgroup. Mean durations since CRPS onset: 5.8 
years (range: 2.1-10.8). 
67
Disease Outcome of Complex Regional Pain Syndrome     2.2
Subgroups according to cluster analysis
The K-means cluster analysis on symptoms and signs managed to produce three CRPS 
patient clusters that were significantly different from each other with regard to almost 
all symptom and sign categories (table 2). The clusters could be ranked according to 
disease ‘severity’, whereby patients in the most severe cluster (cluster 3) also had the 
worst outcome status if the other outcome measures  (IASP criteria, ongoing treatment, 
self reported outcome status, working status) were compared (table 2). In the poorest 
outcome cluster all symptoms and signs prevalences were more pronounced than in the 
other two clusters, except for sudomotor symptoms and signs, which were strongest in 
Table 2. Subgroups derived from K-means cluster analyses on signs and symptoms.
Cluster 1
‘best outcome’
Cluster 2
‘moderate 
outcome’
Cluster 3
‘poor outcome’
Number of patients 63 25 14
Symptoms (subjective) Mean number (SD) Mean number (SD) Mean number (SD)
Sensory (n=1) 0.21 (0.41) 0.48 (0.51) 0.86 (0.36)
Vascular (n=2) 0.29 (0.46) 1.44 (0.58) 2.00 (0.0)
Sudomotor (n=2) 0.21 (0.48) 1.24 (0.44) 1.00 (0.68)
Motor/trophic (n=3) 1.03 (0.93) 2.20 (0.87) 2.70 (0.61)
Signs (objective) Mean number (SD) Mean number (SD) Mean number (SD)
Sensory (n=2) 0.22 (0.46) 0.60 (0.71) 1.43 (0.65)
Vascular (n=2) 0.16 (0.37) 0.84 (0.47) 1.93 (0.27)
Sudomotor (n=2) 0.03 (0.18) 0.84 (0.37) 0.21 (0.43)
Motor/trophic (n=3) 0.68 (0.88) 1.56 (1.56) 2.36 (0.74)
Recovery
Ongoing CRPS  (IASP criteria)
no fulfillment at moment of visit
fulfillment at moment of visit
Still receiving therapy
no
yes
Self reported recovery
recovered
stabilized
progressive
Working activity
former work resumed
working with adaptations
stopped working
All three of the clusters were significantly different for all sign/symptom categories (one way 
ANOVA, p<0.05), except sudomotor and mototrophic signs between cluster 2 and 3; and 
sudomotor symptoms between cluster 1 and 3. Patients in cluster 3 had the highest number of 
signs and symptoms in all categories (except sudomotor). For each of the clusters the distribution 
of outcome according to other parameters of recovery is displayed in circle diagrams. For all four 
parameters the patients in cluster 3 had the poorest outcome.
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cluster 2 (moderate outcome). Remarkably there was no difference in time since CRPS 
onset between any of the clusters. 
     Age at onset was lowest in the patients from the poor outcome cluster (45.8 years 
compared to 51.3 and 54.1 for cluster 2 and 1 respectively), but the difference was not 
significant (p=0.279) (table 3). Patients in the worst outcome cluster more often had the 
upper extremity affected (p=0.017), less often had a fracture as precipitating injury (0.004), 
and more often had cold CRPS (p=0.000). Medical history prior to CRPS onset was not 
significantly different between any of the patients clusters, although hypersensitivity 
related disorders appeared more common in patients with poor outcome (43%), than in 
patients with a moderate outcome (36%) or best outcome (24%; p=0.260). 
Characteristics
Clusters according to CRPS ‘outcome’
Best, N=63 Moderate, N=25 Poor, N=14 p-value
n % n % n %
Mean disease duration (sd)    5.7 (2.2)    6.2 (2.2)    5.2 (1.7) 0.363
Patient characteristics
Mean age at onset (sd)    51.3 (15.6)    54.1 (14.3)    45.8 (17.3) 0.279
Female 47 75% 23 92% 11 79% 0.190
Fracture as initiating event 33 52% 19 76% 3 21% 0.004*†
Upper extremity affected 27 43% 8 32% 11 79% 0.017*†
Cold CRPS 19 30% 10 40% 13 93% 0.000*
History prior to CRPS
Migraine 6 10% 1 4% 2 14% 0.527
Osteoporosis 6 10% 2 8% 1 7% 0.947
Menstrual cycle related dis. 6 10% 3 12% 1 7% 0.881
Neuropathic pain 7 11% 2 8% 1 7% 0.850
Psychiatric disorders 19 30% 7 28% 2 14% 0.482
Hypersensitivity related dis. 15 24% 9 36% 6 43% 0.260
   Asthma 4 6% 4 16% 2 14% 0.324
* Significant at p<0.05, X2 test comparing differences between the three clusters.
† There was no difference between the proportion of fractures as initiating event between the upper 
and lower extremity (48% and 45% respectively). 
Table 2. Patient characteristics per cluster derived from K-means cluster analyses on signs and 
symptoms.
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Discussion
This study has several important findings. First, at an average of 5.8 years after the 
initiating injury (range 2.1-10.8), CRPS patients still had significantly higher symptom 
and sign prevalence rates than reference patients with the same precipitating injury. 
Second, within CRPS patients symptom and sign prevalence rates did not decrease 
significantly upon longer time since disease onset, and 64% still fulfilled IASP criteria 
at an average of 5.8 years after the initial injury. Third, the impact of the disease on the 
ability to work was high: 31% had become permanently incapable to work, while another 
28% had to make working adjustments. Fourth, CRPS outcome was worse in patients 
with involvement of the upper extremity, another precipitating injury than a fracture, and 
cold CRPS. 
     To our knowledge, this is the first study that addresses disease status in a population-
based cohort of CRPS patients with prolonged disease duration (on average 5.8 years). Our 
symptom and sign resolution rates are much lower than those in a previous population-
based study by Sandroni et al., who reported complete resolution within one year in 74% 
of the patients.6 The discrepancy might be explained by the methodology of assessment. 
Sandroni et al. obtained information on the presence of remaining symptoms/signs from 
the electronic medical charts while our study involved actual history taking and physical 
examination. On the other hand, Zyluk et al. also used actual assessments and revealed 
good resolution of some symptoms, such a pain and swelling. However, that study also 
revealed a high prevalence of remaining functional impairments.21
     The study by Sandroni et al. reported that permanent job restrictions related to CRPS 
occurred in only 11% of the cases6 while in our population almost half of the patients had 
a permanent complete or partial job restriction (31% complete inability to work and 28% 
working with adaptations). Part of this discrepancy may be explained by the difference in 
social system between the Netherlands and the United States. In the Netherlands people 
who are unfit for work get financial compensation by the government, while in the US this 
is less common. One previous hospital based study revealed permanent job restrictions 
in as much as 90% of the patients22, however, this might just reflect the severity of CRPS 
patients selected in hospitals rather than from the general population.
     Similar to the findings by Bruehl et al., we observed one patient cluster as clearly 
poorer than the other two, reflected in a higher frequency of almost all symptoms and 
signs. In contrast to Bruehl, however, in our study the remaining two clusters also differed 
from each other with regard to all four sign and symptom categories. Disease duration 
did not differ across the patient clusters which was in line with the findings of Bruehl 
et al. Cold CRPS has been suggested to be associated with poor outcome before11,12 but 
to our knowledge the association between poor outcome and affected upper extremity 
has never been previously described. The observation that poor outcome patients had 
their CRPS more often after an ‘atypical’ injury (opposite to fracture, which is usually 
considered a ‘typical’ injury for CRPS), might suggest that easy triggering of CRPS 
coincides with a less favorable disease course. 
     Some limitations of our study should be addressed, which are related to selection, 
information bias and confounding as in any observational study. First, only 65% of the 
invited CRPS patients participated in the study. Despite our efforts to reduce time burden 
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for patients (and reference patients), some selection may have occurred. Patients with full 
recovery may have been less motivated to participate than those with serious impairments. 
However, there were no age, gender and disease duration differences between participants 
and non participants, suggesting that selection was confined. A second limitation is that 
medical history and physical examination during the visits were performed by one single 
investigator, allowing the occurrence of systematic error. However, standard forms were 
used as provided by TREND consortium, which reduced the possibility of deviations in 
history taking and examination. Finally, the patient cluster with worst outcome CRPS 
included only 14 patients. This hampered the ability to conduct multivariate modeling 
for assessment of prognostic factors for poor outcome. Repeated cluster analyses and 
cluster comparison in a much larger patient cohort is highly recommendable.
     A strong feature of our study is the population based setting, providing results 
representative of the general CRPS patient and not only for (tertiary care) hospital 
referred patients, who usually suffer more serious disease. Secondly, signs and symptoms 
were obtained directly from the patients rather than medical charts. Finally, we compared 
symptom and sign resolution to reference patients with an identical injury as the CRPS 
patients, showing that the ongoing symptoms and signs are not attributable to the initial 
injury itself.  
     In conclusion, severe disease outcome in CRPS is relative rare but incomplete 
resolution of all signs and symptoms is common and only one third of the patients 
reaches full recovery according to self-reports. The present findings confirm the existing, 
but also questioned, ideas that CRPS should be considered a serious condition with a 
high probability of remaining impairments. 
Appendix 1. CRPS diagnostic criteria by Bruehl and Harden (1999).
1. Continuing pain which is disproportionate to any inciting event.
2. Must report at least one symptom (history) in each of the following categories:
    Sensory: hyperesthesia
    Vasomotor: temperature asymmetry and/or skin color changes and/or skin color asymmetry
    Sudomotor/edema: edema and/or sweating changes and/or sweating asymmetry
    Motor/trophic: decreased range of motion and/or motor dysfunction (weakness, tremor, 
                             dystonia) and/or trophic changes (hair, nail, skin)
3. Must display at least one sign (physical examination) in two or more of the following    
    categories:
    Sensory: hyperalgesia (to pinprick) and/or allodynia (to light touch)
    Vasomotor: temperature asymmetry and/or skin color changes and/or skin color asymmetry
    Sudomotor/edema: edema and/or sweating changes and/or sweating asymmetry
    Motor/trophic: decreased range of motion and/or motor dysfunction (weakness, tremor, 
                             dystonia) and/or trophic changes (hair, nail, skin)
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Abstract
Introduction: CRPS patients are seen and treated by a variety of physicians. The 
present study aims to describe referral and treatment patterns for CRPS patients 
in the Netherlands.
Methods: CRPS patients were selected from 1996 until 2005 in the Integrated 
Primary Care Information project, a Dutch general practice (GP) database storing 
electronic medical files. Identified patients were invited for study participation, 
involving diagnosis verification (International Association for the Study of Pain 
criteria) and assessment of referrals and treatment through information retrieved 
from GP journals, patients’ questionnaires, pharmacy dispensing lists, and 
specialist letters if available. 
Results: One-hundred-and-two patients were included in the descriptions. Sixty-
one percent had presented first at the GP, while 80% subsequently consulted one 
or more medical specialists, most frequently an anesthetist (55% of the cases) or 
rehabilitation doctor (41%). Over 90% of the patients received pharmacotherapy, 
89% received non invasive therapy (i.e. physiotherapy), and 18% was treated with 
nerve blocks. Analgesics and free radical scavengers were administered in the 
early phase of CRPS, while vasodilating drugs and coanalgesics (antidepressants 
and anti-epileptics) were administered later on. Pharmacotherapy was usually 
initiated by a medical specialist. 
Discussion: Although the Dutch treatment guidelines recommend free radical 
scavenger prescription (plus physiotherapy) as initial treatment step for CRPS, 
only half of the cases received a scavenger within the first three months after 
disease onset. Since two thirds of the CRPS patients present first at the GP, GPs 
should be encouraged to initiate treatment, while waiting for the results from 
further specialist consultation.
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Introduction
The Complex Regional Pain Syndrome (CRPS) is a painful complication of an injury in 
the extremities, for example a fracture, which coincides with vasomotor, sudomotor and 
motor/trophic disturbances.1 The diagnosis is based on clinical criteria as established by 
the International Association for the Study of Pain (IASP).2 The average age of onset lies 
between the fifth and sixth decade and women are affected more often than men.3,4 The 
disease course is unpredictable, but in some cases ongoing discomfort and functional 
impairment can affect the quality of life and daily activities permanently.5  
     Treatment for CRPS aims at interference with the several presumed underlying 
mechanisms of disease, including autonomic (sympathetic) dysregulation6, (neurogenic) 
inflammation7,8, ischemic injury9, impaired sensor/motor processing10-12, and psychological 
factors.13 In the past, sympathetic blocks have been administered with the purpose to 
relieve vasoconstriction and sympathetically maintained pain.14 Vasodilating drugs 
have also been suggested as useful for the improvement of nutritive peripheral blood 
flow.15,16 More recently, free radical scavengers have been demonstrated efficacious in 
prevention and treatment of CRPS17-19, which is attributed to their attenuation of free 
radical induced (neurogenic) inflammation.20 Corticosteroids have been recommended 
because of their general anti-inflammatory properties21, as well as bisphosphonates that 
also reduce accelerated bone remodeling in CRPS22. Pain relief is to be obtained by 
analgesics and anti-neuropathics. The last mentioned group includes antidepressants16 
and anti-epileptics23 that are commonly applied in the treatment of neuropathic pain. 
Transcutaneous electronic neurostimulation (TENS) is a non pharmacological method 
to treat neuropathic pain non invasively.24 In order to restore motor function and also 
to diminish pain, physiotherapy is strongly recommended.25 Muscle relaxants, such 
as benzodiazepines and baclofen, can be prescribed in patients having dystonia.26 
Psychological/behavioral therapy is usually advised for chronic CRPS patients in order 
to improve coping skills and pain management.27
     Beneficial effects have only been demonstrated convincingly in randomised clinical 
trials for bisphosphonates28-30,  free radical scavengers17-19, and corticosteroids.21,31 The 
evidence for other treatments is scarce, being mostly derived from open label studies 
or studies without a control group.16,22,32,33 Based on the available evidence, a treatment 
guideline for CRPS was released in the Netherlands in 2006. It recommends free radical 
scavengers combined with analgesics and physiotherapy as the first treatment step for all 
patients.34 Dependent on the disease course subsequent treatment steps are advised, for 
example anti-neuropathics for further pain relief or vasodilating drugs for cold CRPS. 
     Limited insight exists as to how CRPS patients were actually treated and referred to 
other disciplines in the Netherlands before issuing of the guideline. This information 
is useful as a baseline for interpreting the effect of guideline implementation later on. 
Therefore, we conducted a study to describe treatment (pharmacological and other) and 
referral patterns in a population based selection of CPRS patients during a study period 
(1996-2005) prior to issuing of the Dutch evidence based treatment guidelines (2006).
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Methods
Setting
The Integrated Primary Care Information Project (IPCI) is a longitudinal observational 
database maintained by the Medical Informatics department of the Erasmus University 
Medical Center in Rotterdam, The Netherlands. Currently, the database stores electronic 
records of more than one million patients of more than 150 general practitioners 
(GPs). The patient population is representative of the Dutch population regarding age 
and sex distribution.35,36 The electronic records comprise anonymous information on 
demographics, signs and symptoms (using the International Classification for Primary 
Care (ICPC) codes37 and narratives), diagnoses (using ICPC codes and narratives), 
clinical findings, specialist referrals, laboratory findings, hospitalizations, and drug 
prescriptions. Summaries of the hospital discharge letters and information and letters 
from specialists are entered in a free text format and hard copies of original letters can be 
provided upon request. Since in the Dutch health care system the GP acts as a gatekeeper 
to and from secondary care, the GP is assumed to possess complete medical information 
regarding the patients.38 To maximize completeness of the data, GPs who participate in 
the IPCI project are not allowed to use paper-based records. The system complies with 
the European Union guidelines on the use of medical data for medical research and has 
been proven valid for (pharmaco)-epidemiological studies.39 The Scientific and Ethical 
Advisory Group of the IPCI project approved the study (project number 04/70), as well 
as the Medical Ethical Board of the Erasmus Medical Center (protocol number 2006-
099). 
Source population
The source population comprised all persons with at least 1 year of valid history within 
the IPCI database during the study period (January 1996-June 2005). Follow-up in the 
database started on the date that one year of valid history was available and ended upon 
transferring out of the practice, the date of last data supply by the GP, death, diagnosis 
of CRPS or at the end of the study period, whichever came first. Since additional data 
collection was required for validation of the CRPS diagnosis, the source population was 
restricted to all practices that were still active in the IPCI database in 2006 and were able 
to provide additional information.
Selection of CRPS patients
Potential incident CRPS cases were identified in the electronic medical records using a 
sensitive string search algorithm including Dutch synonyms, abbreviations and obvious 
spelling errors for CRPS. After manual evaluation of the records, GPs were asked to 
reconfirm or reject the diagnosis in a short questionnaire. The process of case validation 
until this point has been described in detail in our study on the incidence of CRPS in the 
Netherlands.40
     In a second validation step, all identified and GP reconfirmed patients were invited 
to participate in our study on CRPS per letter through the GP. If informed consent was 
obtained, patients were visited once by the primary investigator (MM) together with 
a research assistant (MHB). Prior to this visit, all patients received a questionnaire 
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addressing CRPS related complaints and impairments, disease course, treatment, 
general health, quality of life and daily function. Patients completed the questionnaires 
by themselves and during the visit they were briefly discussed with the investigator to 
ascertain completeness. In addition, patients underwent a physical examination of the 
affected and contralateral extremity. Patients were included in the present descriptive 
study if the visit assessments demonstrated that they (had) fulfilled (in the past) the 
diagnostic criteria for CRPS as established by the International Association for the 
Study of Pain (IASP). Since the exact starting date of CRPS complaints and symptoms 
is difficult to establish in retrospect, the date of CRPS onset was defined as the date of 
the precipitating injury. In absence of a precipitating injury the index date was set as the 
date of first symptoms. Based on their own reports patients were classified as initially 
warm or cold type CRPS.
Referrals
Referrals were studied during the entire disease course. Information on this was derived 
manually from electronic medical records in the IPCI database, patient reports (in 
questionnaires) and specialist letters. Referral patterns included the first type of physician 
that was visited for CRPS, the physician who diagnosed the CRPS and all types of 
physicians that were consulted for the CRPS during the entire disease course. 
Treatment
Treatment patterns were studied during the first two years after the index date (precipitating 
injury). Information on prescriptions for oral and topical drugs indicated for CRPS was 
retrieved from the IPCI database and from pharmacy dispensing data that were obtained 
retrospectively from the pharmacies of the patients. Information on intravenous drugs, for 
example mannitol (a free radical scavenger), could not be retrieved from these sources, 
since they are usually administered during hospital admissions. The IPCI database 
included all prescriptions by the GP, displaying brand name, starting date, quantity, 
strength, indication, prescribed daily dose and the Anatomical Therapeutical Chemical 
(ATC) classification code.41 Pharmacy dispensing data comprised drugs prescribed by 
both GPs and medical specialists and usually displayed brand name, starting date, stop 
date, quantity, strength, prescribed daily dose, and type of prescribing physician. 
     The following oral and topical drugs were considered as study drugs if newly prescribed 
(i.e. not prescribed in the year prior to CRPS) within two years after CRPS onset: 1. free 
radical scavengers (topical and systemic), including dimethylsulfoxide cream (50%), 
N-acetylcysteine and vitamin C; 2. systemic vasodilating drugs, including ketanserin, 
verapamil and nifedipine; 3. analgesics, including paracetamol, NSAIDS and opiates; 4. 
coanalgesics, including tricyclic antidepressants and some anti-epileptics (gabapentin, 
carbamazepine, pregabalin and duloxetin); 5. various other drugs, including  capsaicin 
cream, carnitene, corticosteroids (oral), baclofen (oral), and benzodiazepines. Legend 
durations for each drug were calculated as the total number of units supplied divided by 
the number of units taken per day. 
     Information on intravenous medication, additional treatments (for example 
physiotherapy), and invasive therapies (for example nerve blocks) was obtained from 
electronic medical records in the IPCI database, patient reports (in questionnaires) and 
specialist letters altogether.
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Data analysis
The percentages of users of oral and topical CRPS medication were calculated and 
graphed over time as three months moving averages, meaning that the percentage for 
each time point is the average of the previous, present and next time month. The median 
(inter quartile range, IQR) duration of use was calculated as the total number of using 
days for a specific drug class in the two year follow-up period. Time to treatment (from 
the index date) was estimated per drug class using Kaplan Meier survival analysis and 
compared between patients who presented first at GP and patients who presented first at 
a medical specialist, using a log-rank test. In patients receiving a specific class of drugs 
the median (IQR) time to treatment for that class was calculated (in days). Treatment 
patterns were stratified for warm and cold CRPS. All statistics were performed using the 
Statistical Package for Social Sciences (SPSS) version 12.0 for Windows. Significance 
was established at a p-value <0.05.
 
Source population
n=204,281
Identified and GP reconfirmed
n=259
Invited for study participation
n=216
deanonymization problems: n=25
transfer out of patient: n=16
death of patient: n=2
Participated
n=134
Confirmed by investigator
(IASP) criteria
n=102
prevalent: n=8
alternative diagnosis=18
no IASP criteria: n=6
no informed consent: n=82
Description of referral patterns
and therapy other than
oral/topical pharmacoptherapy
Description of oral/topical
pharmacotherapy
complete dispensing records
n=73
no or incomplete dispensing records: n=29
Figure 1. Selection of the study population.
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Results
After identification and initial GP reconfirmation, 259 CRPS patients were selected from 
a source population of 204,281 persons in the IPCI database. Of these 216 (83%) were 
invited for further study participation, whereas the remaining could not be contacted 
due to de-anonymization problems (n=25), transferring out of the patient (n=16), or 
death (n=2). Out of 216 contacted patients, 134 (62%) provided informed consent and 
were visited in order to fulfill study assessments. Hundred and two (75%) of the visited 
patients complied or had ever complied with the IASP criteria and were incident during 
the study period. Among the 32 excluded patients eight appeared prevalent (CRPS onset 
before study period), 18 had a likely alternative diagnosis for their complaints earlier 
attributed to CRPS, and six never displayed the signs required to fulfill the IASP criteria 
(figure 1).
     The mean age at CRPS onset was 51 years (range 12-86), whereas 81 patients (79%) 
were female. Fracture was the precipitating event in 55 cases (54%), while only 3 (3%) 
had CRPS without a known precipitating event. The average duration since CRPS onset 
was 5.8 years (median 5.7; range: 2.1-10.8).
     Physicians who were consulted by the CRPS patients are displayed in table 1. On 
average a patient consulted 2.4 different specialties of physicians. The referrals by the 
first visited physician, the diagnosing physician and by any consulted physician are 
depicted in figure 2A-C. Especially patients with CRPS following a soft tissue injury 
presented at the GP first instead of a medical specialist (75% versus 25% respectively, 
p=0.033), while patients with CRPS after surgery usually first presented at the medical 
specialist (17% versus 83%, p=0.002). Cases precipitated by a fracture presented 
themselves at GP and specialist equally often (46% versus 55%, p=0.228). In total 61% 
of the CPRS patients visited the GP before consulting a medical specialist. In 63% of 
these cases the GP already suspected or made the CRPS diagnosis. Eventually, more than 
80% of the patients visited a medical specialist at some point during their disease course. 
The anesthetist was the most commonly involved medical specialist, visited by 55% of 
the CRPS patients, while rehabilitation doctors were the second most common (41%). 
Medical specialists referred CRPS patients to an anesthetist or rehabilitation doctor in 
more than half of the cases, while GPs had the tendency to refer more to (orthopedic) 
surgeons. The most common referral pattern was from GP to (orthopedic) surgeon to 
anesthetist or rehabilitation doctor. In most cases (over 80%) the CRPS diagnosis had 
been made before consultation of the anesthetist or rehabilitation doctor.
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N=102 First 
physician
Diagnosing 
physician
Anytime 
consulted
Mean order of 
consultation
Type of physician
n % n % n %
GP 62 61% 39 38% 62 61% 1.0
Surgeon 23 23% 21 21% 35 34% 1.4
Orthopedic surgeon 14 14% 23 23% 38 37% 1.8
Anesthetist 0 0% 12 12% 56 55% 2.4
Rehabilitation doctor 0 0% 2 2% 41 40% 2.9
Neurologist 3 3% 4 4% 15 15% 2.5
Rheumatologist 0 0% 1 1% 5 5% 2.6
Dermatologist 0 0% 0 0 1 1% 2.0
First physician: physician who was first visited for CRPS symptoms; Diagnosing physician: 
physician who made the CRPS diagnosis; Anytime consulted: any physician consulted for CRPS 
during complete disease course. Mean order of consultation: the lower this number, the earlier 
this type of physician is consulted by a patient. For example the GP is usually consulted first and 
therefore has a mean order of consultation of 1.0.
Table 1. Physicians consulted by CRPS patients.
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Figure 2. A. Referrals by the first physicians visited by CRPS patients. B. Referrals by the physi-
cian who diagnosed CRPS. C. Referrals by any physician consulted on CRPS. GP = general prac-
titioner; SURG = surgeon; ORTH = orthopedic surgeon; ANES = anesthetist/pain physician; REHA 
= rehabilitation physician; N/R/D = neurologist/rheumatologist/dermatologist   
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     Pharmacy dispensing records that covered complete follow-up time from the index 
date until the moment of visit were only available for 73 (72%) patients. For other 
patients the pharmacy data did not cover the onset of CRPS since it was too long ago. 
These patients were excluded from the analyses regarding oral or topical administered 
pharmacotherapy. Ninety percent of the GP prescriptions recorded in the IPCI database 
had also been dispensed.  
     The use of oral or topical pharmacotherapy in the first two years after onset of CRPS is 
demonstrated in table 2 and in figure 3A-B. Analgesics and free radical scavengers were 
mainly used in the early phase of CRPS, while the use of calcium antagonists and co-
analgesics increased during later phases. Free radical scavengers (in 79% of the patients) 
and analgesics (77%) were the most frequently prescribed drugs (table 2). Both drugs were 
prescribed more in patients with cold type CRPS compared to warm type CRPS (both 
87% versus 67% respectively; p-value 0.050). Most of the CRPS specific medications 
were started by a medical specialist, rather than by the GP (table 2). However, for none 
of the drug classes the time to treatment was significantly different between patients who 
had visited the GP first or who had visited a medical specialist first (log rank test). Fifty-
two percent of the patients received a scavenger within the first three months after the 
initial injury. Anti-neuropathics and vasodilating drugs were used for longer periods than 
analgesics, scavengers and various other drugs (table 2). 
Table 2. Oral and topical medication dispensed for CRPS treatment.
N=73 Users No. of  drugs 
within class 
Duration (days)
of drug use 
Time (days) to 
treatment 
(receivers only)
GP first 
Pre-
scriber 
Specialist
first pre-
scriber 
Drug classes
% Mean (range) Median (IQR) Median (IQR) % %
Scavengers 79% 1.6 (1-3) 122 (67-255) 71 (42-108) 29% 71%
 DMSO cream 68%
 N-acetylcysteine 40%
 Vitamin C 19%
Vasodilators 30% 1.1 (1-2) 328 (93-1257) 126 (62-198) 27% 73%
 Verapamil 12%
 Nifedipine 19%
 Ketanserin 1%
Analgesics 77% 1.5 (1-3) 123 (40-364) 62 (6-186) 52% 48%
 Paracetamol 22%
 NSAIDs 77%
 Opiates 21%
Anti-neuropatics 23% 1.4 (1-3) 232 (93-890) 203 (57-399) 35% 65%
 TCAs 19%
 Anti-epileptics 12%
Other agents 11% 1.6 (1-2) 80   (24-268) 176 (143-470) 50% 50%
 Steroids 4%
 Carnitene 3%
 Baclofen 3%
 Benzodiazepines 1%
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Figure 3. A. Absolute percentage of patients using medication during the first two years after  
CRPS onset (initial injury). B. Cumulative percentage of patients having received medication within 
the first two years after CRPS onset.
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     Apart from the drugs included in the four pre-specified classes, a wide variety of 
other drugs was also reported to have been prescribed for CRPS treatment, including 
allopurinol, hydrokinine, clonidine, levopromazine, ephedrine, venlafaxine, amantadine, 
and various types of vitamins (apart from vitamin C) and food supplements. Seven percent 
of the CRPS patients received no kind of oral or topical pharmacotherapy whatsoever.
     The percentages of CRPS patients receiving other treatments than oral or topical 
pharmacotherapy is displayed in table 3. Non invasive treatments (for example physical 
therapy) were prescribed to more than 90% of the patients, while invasive nerve blocks 
were administered only to 18%. 
Table 3. Treatment for CRPS other than oral/topical pharmacotherapy.
N=102 Receiving therapy Beneficial according to patients
Type of therapy
n % % of patients receiving therapy
Non invasive (total) 91 89%
Physiotherapy 89 87% 76%
Ergonomic therapy 19 19% 68%
Psychological therapy 10 10% 43%
TENS 21 21% 53%
Nerve blocks (total) 18 18%
Sympathetic block 11 11% 33%
Loco regional  pain block 7 7% 25%
Regional intravenous block 1 1 % 100%
Non oral pharmacotherapy (total) 46 45%
Intravenous mannitol 37 36% 58%
Intravenous other drugs 10 10% 80%
Iontoforesis 15 15% 57%
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Discussion
In the presented study, we describe referral and treatment patterns in 102 CRPS patients 
selected from a GP database in the Netherlands in a study period from 1996 until 2005, 
which is before the issuing of the Dutch evidence based treatment guideline for CRPS in 
2006. The majority of the patients first presented with CRPS at the GP, before consulting 
a medical specialist, especially cases following a soft tissue injury or fracture. Free 
radical scavengers were the most frequently administered drugs, prescribed in 79% of 
the patients. However, only in half of the patients scavenger treatment was commenced 
within the first three months after the initiating injury.
     High quality trials showing effectiveness of CRPS treatment have hardly been 
performed.32,42 The observation that free radical scavengers are prescribed in a majority 
of the CRPS patients is in line with available evidence in the literature. Scavengers have 
been demonstrated beneficial in randomized trials17,18 and the high prescription frequency 
in practice suggests good clinical experience with these drugs as well. On the contrary, 
corticosteroids have also been demonstrated as beneficial in randomized trials21,31, but are 
rarely prescribed in practice, probably out of caution for the notorious adverse effects on 
energy metabolism and the immune system. 
     Anti-neuropathics were used by less than a quarter of the patients, despite the proven 
effectiveness (in particular gabapentin) in one randomized trial.23 The evidence for oral 
vasodilating drugs is limited (no randomized trials), but oral vasodilating drugs were 
prescribed in almost one third of the patients and the use was quite prolonged. Common 
analgesics were prescribed widely in our study population, despite a complete lack of 
evidence in the literature for benefit from these drugs in CRPS. However, the prescription 
of an analgesic is likely a natural response to a patient who presents with pain in an early 
phase of CRPS. Remarkable are the reports of intravenous mannitol administration in 
one third of the patients, in the absence of trials that have proven its benefit.43 Since 
hospital admission is usually needed, mannitol is an expensive treatment option, with a 
risk for renal failure in patients with pre-existent renal dysfunction.44 
     Most CRPS patients presented at the GP first, but GPs prescribe predominantely 
analgesics. Due to the relatively low incidence of CRPS40, GPs may be relatively 
unfamiliar with the disease spectrum and treatment opportunities. However, early 
commencement of therapy may be of relevance since this may prevent potential long 
term damage by the ongoing underlying disease processes. The Dutch evidence based 
treatment guideline for CRPS, which came out in 2006, presents a schematic display of 
suggested therapeutic strategies, which starts with free radical scavenger prescription 
combined with analgesics and physiotherapy.34 Although before guideline appearance a 
majority of patients was already treated with a scavenger at some point in time, a treatment 
delay of more than three months was observed in half of the cases. Realizing this, CRPS 
treatment can be improved by earlier commencement of therapy. Especially GPs should 
be informed and encouraged to do this, as they are usually the first physician to whom 
CRPS patients present and they often suspect the diagnosis already. The straightforward 
general first treatment step from the guideline can easily be initiated by the GP (or any 
other physician who is confronted with the first presentation of CRPS), while waiting for 
further evaluation by a consulted CRPS specialist.
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     Some limitations bound to this descriptive study need to be addressed. First, the number 
of patients for whom sufficiently complete information could be collected was low, 
especially regarding dispensing patterns of oral and topical pharmacotherapy. Therefore, 
we were not able to compare treatment strategies across subtypes of patients and types 
of medical specialist. Additionally, while we had detailed time information for oral and 
topical pharmacotherapy from pharmacy delivery lists, this was lacking for other types 
of treatment, for which the information had to be obtained by questionnaires. Therefore, 
prescription patterns and delays of such treatments, for example physiotherapy, could not 
be described and we had to restrict to simple summarization of treatment percentages. 
Finally, the results are reflecting the Dutch situation and may not be generalizable 
to other geographic areas. Although no reports exist that argue in favor of or against 
international variability, we have the impression that free radical scavengers may be 
prescribed particularly in the Netherlands, since most of the trials regarding these drugs 
have a Dutch origin. 
     A strong feature of our study is the fact that it was performed in a population based 
setting, preventing selection of a subset of patients with high disease severity. We believe 
that by using pharmacy dispensing lists we had accurate information on prescribed oral 
and topical pharmacotherapy in CPRS patients, considering a retrieval rate of 90% of the 
prescriptions from the GP database in the pharmacy lists. For all other data we also used 
several sources of information, including GP journals, specialist letters if available, and 
patient reports. 
     In conclusion, we observed that GPs are frequently the first physicians with whom 
CRPS patients present, but that therapy is often initiated by a medical specialist upon 
referral. Therefore, especially GPs should be encouraged to initiate CRPS treatment 
according to the first steps of the guidelines. Early commencement of CRPS treatment 
may eventually improve CRPS disease course and outcome, an assumption which may 
be investigated if the period past guideline implementation is sufficiently long. 
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Abstract
Introduction: Knowledge concerning the medical history prior to the onset 
of complex regional pain syndrome (CRPS) might provide insight into its risk 
factors and potential underlying disease mechanisms. 
Methods: To evaluate prior to CRPS medical conditions, a case-control study 
was conducted in the Integrated Primary Care Information (IPCI) project, a 
general practice (GP) database in the Netherlands. CRPS patients were identified 
from the records and validated through examination by the investigator (IASP 
criteria) or through specialist confirmation. Cases were matched to controls on 
age, gender and injury type. All diagnoses prior to the index date were assessed 
by manual review of the medical records. Some pre-specified medical conditions 
were studied for their association with CRPS, whereas all other diagnoses, 
grouped by pathogenesis, were tested in a hypothesis generating approach. 
Results: Of the identified 259 CRPS patients, 186 cases (697 controls) were 
included, based on validation by the investigator during a visit (102 of 134 visited 
patients) or on specialist confirmation (84 of 125 unvisited patients). A medical 
history of migraine (OR: 2.43, 95%CI: 1.18-5.02) and osteoporosis (OR: 2.44, 
95% CI: 1.17-5.14) was associated with CRPS. In recent history (one year before 
CRPS), cases had more menstrual cycle related problems (OR: 2.60, 95% CI: 
1.16-5.83) and neuropathies (OR: 5.7; 95% CI: 1.8-18.7). In a sensitivity analysis, 
including only visited cases, asthma (OR: 3.0; 95%CI: 1.3-6.9) and CRPS were 
related. Psychological factors were not associated with CRPS onset. 
Discussion: Because of the hypothesis-generating character of this study, 
findings should be confirmed by other studies.
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Introduction
The complex regional pain syndrome (CRPS) can be a painful disorder affecting one or 
more extremities. It usually occurs following a physical injury, for example a fracture 
or surgery, but spontaneous onset may occur as well.1 The diagnosis is based on its 
clinical presentation, whereby the diagnostic criteria as developed by the International 
Association for the Study of Pain (IASP) are the most widely accepted.2 Apart from pain 
and sensory disturbances, these criteria demand the presence of edema, skin blood flow 
abnormalities or abnormal sudomotor activity. Functionality of the affected limb is often 
impaired1,3 and ongoing pain and dysfunction can leave patients severely disabled.4 The 
peak incidence of CRPS lies between 50 and 70 years of age and women are affected 
more frequently than men.5,6     
     In the past decade, insights into the mechanisms underlying CRPS have gradually 
increased. The role of inflammation is endorsed by the demonstration of inflammatory 
mediators in serum7, blister fluid8, and spinal fluid9 from CRPS patients. Additionally, 
abnormal vasoconstriction patterns, either sympathetic nerve system driven10 or 
due to local factors11, can result in blood flow disturbances. These peripheral disease 
mechanisms may precede and sustain the sensitization12 and altered sensory processing at 
spinal and supraspinal levels13,14, that lead to pain of neuropathic nature. Sympathetically 
maintained pain, probably caused by sympathetic-afferent coupling.15  occurs in a subset 
of patients.2   
     To date it is unknown whether other diseases that also involve inflammation, impaired 
(micro-) circulation, or neuropathic pain lead to an increased risk of CRPS. However, 
studies on the potential co-occurrence of these disorders with CRPS can be informative, 
since they might give clues to potential shared pathogenic or etiologic factors, as well as 
reveal risk factors for CRPS. The aim of the present investigation was to identify whether 
and which medical conditions or categories of medical conditions are associated with the 
occurrence of CRPS.
Methods
Setting
A retrospective case-control design was used to compare disease history prior to the 
onset of CRPS between patients and controls from the general population. The study 
was nested in the Integrated Primary Care Information (IPCI) database, which is a 
general practice (GP) database of longitudinal electronic medical records of around 
800,000 patients.16, 17 The project was initiated in 1992 and new practices have started 
to contribute data ever since. The IPCI population is considered representative of the 
general population in the Netherlands regarding age and gender distribution. The Dutch 
Health Care System requires all persons to be registered with one GP (even if they are 
healthy), who acts as a gatekeeper for further medical care and who receives and files 
all health care information. Therefore, the electronic records contain virtually complete 
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medical information concerning each patient.18 To optimize completeness of the data, 
GPs participating in the IPCI project do not keep additional paper records (except for 
specialist and discharge letters). The present study has been approved by the Scientific 
and Ethical Advisory Group of the Project and by the Medical Ethical Board of the 
Erasmus Medical Center (protocol number 2006-099). 
Source population
The dynamic source population comprised all persons of all ages with at least 1 year of 
valid history in the IPCI database during the study period (January 1996 - June 2005). 
Observation time in the database started on the date that one year of valid history was 
available and ended upon transferring out of the practice, the date of last data supply by 
the GP, death, diagnosis of CRPS or at the end of the study period, whichever came first. 
Since additional data collection was required for validation of the CRPS diagnosis, the 
source population was restricted to all practices that were still active in the IPCI database 
in 2006 and were able to provide additional information.
Cases
Details on the case identification procedure in the IPCI database have been described 
in our incidence study on CRPS in the Netherlands.5 Briefly, potential incident CRPS 
cases were identified using a search algorithm including synonyms and abbreviations 
for CRPS in codes and narratives. Subsequently, GPs were asked to reconfirm or reject 
the CRPS diagnosis in a short questionnaire. Information regarding the precipitating 
injury for the CRPS was extracted from the GP journals and from specialist letters when 
provided by the GP. Injury categories included fracture, soft tissue injury, surgery, tendon 
injury and various other types of injuries (including nerve injury). 
     For this specific study, all previously identified and GP reconfirmed cases were contacted 
to ask them to participate in a nationwide study on CRPS. Patients who provided written 
informed consent were visited by the primary investigator of this study (MM), a physician 
with clinical experience in diagnosing CRPS. A physical examination was performed of 
the affected and contralateral extremity, and self-administered questionnaires were used 
to gain information on present and past symptoms of CRPS. Patients were included into 
the main analyses of this study if during the visit the CRPS diagnosis was verified by the 
investigator using the IASP criteria.2 Additionally, cases were included who could not be 
visited, but of whom the CRPS diagnosis had been confirmed by a medical specialist (in 
a letter to the GP). The index date was chosen as the date of the precipitating injury, or 
the date of first symptoms in cases with spontaneous CRPS. Since some previous studies 
have revealed different results in ‘warm’ and ‘cold’ type CRPS patients19-21, suggesting 
these to be distinct subtypes, cases were divided into subgroups based on their own 
reports of predominant temperature characteristics (visited patients only). 
Controls
First, for each CRPS case all other persons in the IPCI database with similar age (year 
of birth) and gender were selected as potential controls. Subsequently, from these, up to 
four controls per case were chosen who had experienced an injury identical to the injury 
that precipitated the CRPS in the case (within a two year band of calendar time). This 
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meant that cases with CRPS after a fracture were matched to up to four controls with 
a fracture, cases with a surgery to controls with a surgery, cases with a nerve injury to 
controls with a nerve injury, etc. Similar to cases, the index date in controls was defined 
as the date of the injury. When CRPS had occurred in a case without precipitating injury, 
controls were not required to have an injury either and the index date was chosen as the 
date of first symptoms in the case.
Medical history
The medical history until the index date was extracted from the electronic medical 
records during the observation time in the database. While being blinded to the case or 
control status of the patient, the entire medical record was evaluated and all GP contacts 
were classified into episodes of medical problems. 
     The association between CRPS and medical conditions prior to CRPS onset was 
studied in three different ways. First, in a hypothesis generating approach, all medical 
conditions were categorized based on pathogenesis and each category was examined for 
its association with CRPS. The chosen pathogenic categories were mutually exclusive 
and included the following (see also supplemental appendix): anatomic, trauma-induced, 
degenerative, hormonal, metabolic, neoplasm, infections, inflammation, psychological, 
no disease and miscellaneous. Sometimes, a patient had contacted the GP for complaints 
or symptoms for which no explanatory cause had been provided. These episodes were 
categorized as ‘unexplained complaints’ (including subjective complaints such as nausea) 
or ‘unexplained symptoms’ (including objective symptoms such as vomiting). The main 
pathogenic categories were divided further into mutually exclusive subcategories (see 
also supplemental appendix 1). Initiating injuries for CRPS (fracture, sprain, nerve injury, 
etc.) were matching factors and were excluded from this categorization. The assignment 
of the medical conditions to a specific disease category was performed independently by 
two physicians (MM, JSHAK) and kappa statistics were calculated to assess interrater 
agreement. 
     Second, and apart from our hypothesis-generating approach, we tested a priori 
hypotheses about associations between CRPS and a few medical conditions that had 
occasionally had been suggested associated with CRPS (in one or more previously 
published studies). These conditions included headaches22, osteoporosis23, psychological 
factors24,25 and fibromyalgia.26
     Third, we explored the association between CRPS and groups of medical conditions 
that might hypothetically be related to CRPS, based on similarities in the assumed 
underlying disease mechanisms. These groups of medical conditions involved 
hypersensitivity/exaggerated inflammation related disorders (asthma, autoimmune 
disorders, allergies), disorders caused by impaired circulation (cardiovascular diseases, 
raynaud’s syndrome, chilblains, etc.), and preexisting disorders marked by sensory 
disturbances (neuropathies).
Data Analysis
Standard comparative statistics were used to compare frequencies (Chi-square test), or 
means (Student’s t-test and Mann Whitney-U test). Associations between prior to CRPS 
medical history and CRPS were investigated by conditional logistic regression, adjusted 
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for observation time in the database. Medical history was studied in two exposure 
windows: 1) the complete database history of patients, and 2) the one year before 
the index date. Subgroup analyses were performed for ‘warm’ and ‘cold type’ CRPS. 
Sensitivity analyses were performed to inspect misclassification of outcome (CRPS) 
and determinants (diagnoses prior to CRPS). Misclassification of CRPS was limited 
in sensitivity analyses including only cases that could be visited and verified by the 
investigator (IASP criteria). Misclassification of diagnoses prior to CRPS was inspected 
by considering a diagnosis valid only when specific treatment was given (for example 
inhalator medication for asthma, anti-migraine drugs for migraine, etc.).  Finally, in order 
to evaluate presence of Berkson’s bias (patients who visit the physician more often may 
also be diagnosed with diseases earlier), we adjusted for the number of GP contacts. 
SPSS 12.0 was used for all statistical tests. Significance was established at p<0.05.
Results
In the source population, comprising 204,281 persons, 259 CRPS patients were identified 
and reconfirmed by the GP. Some of these cases were untraceable for further contact due 
to retirement of the GP or software changes at the practice (n=25 patients), patients having 
left the practice (n=16) or death of patients (n=2). In total 216 (83.4%) cases could be 
contacted for study participation. Of these, 134 (62.0%) provided informed consent and 
completed study assessments. No significant differences in age, gender distribution and 
disease prevalences were observed between participants and non-participants.
     During the study visit, eight (6.0%) cases turned out to be prevalent (the patient 
already had CRPS at the start of observation time in the database) and were therefore 
excluded from the final study population. Hundred-and-two (82.3%) of the remaining 
126 incident CRPS cases had fulfilled the IASP criteria according to the investigator. 
Reasons for not fulfilling the IASP criteria were the presence of a possible alternative 
diagnosis (n=18), the absence of pain (n=2), and the absence of vasomotor or sudomotor 
disturbances (n=4). Verification of the CRPS diagnosis using the additional information 
obtained during visits yielded a false positive rate of 19% for all patients who were 
initially reconfirmed by the GP and 13% for the patients with an additional medical 
specialist diagnosis. 
     A total of 186 CRPS cases were finally included in the main analyses (102 cases 
validated during a visit plus 84 unvisited cases with a specialist confirmed diagnosis). A 
total of 697 controls matched to a case on age, gender and type of injury were selected 
from the source population in the database. The mean age at onset in the study population 
was 51 years and 77% was female. A fracture was the most common precipitating injury 
in 91 (49%) of the cases, while for 15 (8%) no precipitating event could be extracted 
from the records (similar percentages for the matched controls). Other initiating events 
included soft tissue injury (20%), surgeries (11%), tendon injuries (6%), and various 
others (6%). The summed observation time until the index date was 529 years for cases 
(mean: 2.8; range: 0.9-8) and 1,994 years for controls (mean: 2.9; range: 1-10). The mean 
number of GP contacts and medical episodes per year did not differ significantly between 
cases (contacts: 4.3; episodes: 3.8) and controls (contacts: 3.8; episodes: 3.3; p=0.107 
and p=0.093 respectively). However, cases had more medication prescriptions per year 
than controls (8.9 versus 6.4 respectively; p=0.009). 
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     The interrater agreement for categorization of disease episodes into pathogenic groups 
varied per group, but was very good (kappa > 0.80) for all groups except for metabolic 
disorders and miscellaneous disorders, for which the interrater agreement was good 
(kappa > 0.60).  
     Results of the analysis that comprised all medical conditions prior to CRPS are 
demonstrated in table 1. The odds ratio’s (OR) are displayed for all main pathogenic 
categories and for subgroups only if significant. The association between menstrual cycle 
related disorders and CRPS (OR: 2.60, 95%CI: 1.16-5.83) in the year before the index 
date was the only new observation, that was not hypothesized a priori. In the one year 
window also the main groups of trauma induced conditions (excluding known initiating 
events for CRPS), infections and the number of unexplained complaints were associated 
with CRPS, but none of its subgroups were significant.
     From the medical conditions that have occasionally been associated with CRPS 
before, migraine (OR: 2.43, 95%CI: 1.18-5.02) and osteoporosis (OR: 2.44, 95%CI: 
1.17-5.14) were significantly associated in our study (table 2). No association was 
observed between psychological factors and CRPS (OR: 1.17, 95%CI: 0.83-1.67). The 
prevalence of fibromyalgia was too low to perform any meaningful analyses.
     From the categories of diseases that were hypothesized to be related with CRPS based 
on presumed pathogenic similarities, asthma (OR: 3.0; 95%CI: 1.3-6.9) was associated 
with CRPS, but only in the sensitivity analysis including visited cases that fulfilled the 
IASP criteria (table 3). Preexisting neuropathies (OR: 5.7; 95%CI: 1.8-18.7) were also 
more frequent in CRPS patients in the one year window.
     In the subgroup with self reported ‘warm’ CRPS (cases=48, matched controls=182), 
all previously mentioned associations decreased and became non significant. In the 
subgroup with self reported ‘cold’ CRPS (cases=42, matched controls=156) associations 
increased for asthma (OR: 10.6, 95%CI: 2.1-53.5), migraine (OR: 4.6, 95%CI: 1.1-20.5), 
and for osteoporosis (OR: 5.8, 95%CI: 1.0-34.8), but not so much for menstrual cycle 
related morbidity (OR: 2.8, 95%CI: 1.0-8.0). However, power in these analyses was 
minimal due to low numbers.
     If specific disorders in the medical history were considered only when treatment 
was given (for example treated asthma or migraine, osteoporosis) an increasing OR was 
observed for migraine, menstrual cycle related disorders, and neuropathies; an unchanged 
OR for osteoporosis; and a lower OR for asthma (table 4). Adjustment for the contact 
frequency at the GP did not affect the OR substantially (table 4).
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Discussion
In this study, we systematically investigated associations between medical history and 
CRPS occurrence with the purpose to find potential risk factors and leads towards 
disease mechanisms underlying CRPS. While the study confirmed previously reported 
associations between CRPS and osteoporosis and headaches22,23, the increased prior to 
CRPS presences of asthma and menstrual cycle related disorders were new. In addition, 
we did not find evidence that psychological factors were related to CRPS. Although 
a few have reported otherwise24,25, this is in line with the conclusions of several other 
studies on psychological factors and CRPS.27-29 Subgroup analyses in ‘warm’ and ‘cold 
type’ CRPS patients revealed that the observed high OR for migraine, osteoporosis, and 
asthma were mainly attributable to ‘cold type’ CRPS. 
     CRPS shares pathogenic mediators with both migraine and asthma. First, neurogenic 
inflammation, marked by neuropeptides such as gene related peptide (CGRP) and 
Substance P (SP), is likely to play a role in all three disorders.30-33 Asthma patients show 
hyper-responsiveness to SP34, while migraine and other headache patients have increased 
serum levels of both SP and CGRP.35,36  In CRPS patients CGRP was systemically 
elevated and SP release was facilitated.37,38 Second, in both asthma39 and migraine40 mast 
cells are involved, while tryptase (a product released by mast cells) is elevated in blister 
fluids41 of CRPS patients. Finally, another common mediator in asthma and migraine 
is the nuclear factor kappa B42,43, a transcription factor involved in inflammation and 
apoptosis, that was recently hypothesized to be of importance in CRPS based on the 
results of automated information retrieval from Medline.44
     The strong association between CRPS and osteoporosis and menstrual cycle related 
disorders needs further exploration. Interestingly, osteoporosis has been considered 
as a consequence of CRPS rather than as a risk factor. Although one could argue that 
osteoporosis predisposes to fractures and thereby to CRPS, this can not explain the 
observations of the present study, since controls were matched to cases on injury type 
(for example fracture). Inflammatory mediators in CRPS, such as IL-1 and TNFα, have 
also been suggested to be increased in post-menopausal osteoporosis, but a definite role 
was never established.45,46 Remarkably, bisphosphonates, frequently used in the treatment 
of osteoporosis, have been proven effective in CRPS treatment.47 Sex hormones, such as 
estrogens, are of interest with regard to CRPS, due to its high incidence in women and at 
postmenopausal age. The observations in the present study warrant further investigation 
regarding hormonal factors in CRPS.
     The increased presence of preexisting neuropathies (that included mainly radicular 
syndromes and polyneuropathies) in the year before CRPS suggests that existing 
sensitization predisposes to new sensitization. It is unlikely that the reported neuropathies 
were early unrecognized symptoms of CRPS, since they were reported prior to the CRPS 
precipitating injury. However, since the actual numbers are very small the results should 
be interpreted with caution.
     In the past, it has been suggested that CRPS is a (partially) psychosomatic disorder 
and associations with several psychological factors have occasionally been described.48,49 
However, methodology of these studies was considered as poor.24,25 and results were not 
confirmed in several other studies.27-29 In the present study, where psychological factors 
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were registered in the records prospectively by the GP before the onset of CRPS, no 
association was observed between any type of psychological factors and CRPS. Also, in 
contrast to previous suggestions50, there was no strong indication for a general tendency 
of somatisation in CRPS patients. We found no significant increase in prior to CRPS 
GP contact frequency in cases compared to controls, although our study may have 
lacked power to demonstrate minor differences. Such an eventual small increase can be 
explained as a consequence of more pre-existing somatic illness. A marginal, however 
significant, increase in unexplained complaints was observed in CRPS patients in the last 
year before the index date alone, but this was not strengthened in a sensitivity analysis. 
     Being observational, this study should be interpreted in the light of its limitations. 
Major threats to the validity of this study are selection bias and misclassification of the 
outcome (CRPS) or determinants (prior to CRPS medical conditions). 
     Selection of the study population was limited by still including part of cases that could 
not be visited (refusers and untraceable patients), namely the specialist diagnosed cases. 
Additionally, no significant differences in age and gender distribution or prevalences of 
medical conditions were observed between participants and non-participants.
     Misclassification of the outcome (CRPS) was reduced due to an extensive case 
validation procedure and by performing sensitivity analyses including only cases that 
could be verified by the investigator during a visit. Despite this, some misclassification 
may have remained since ascertainment of CRPS had to be done retrospectively, 
combining patient-reported symptoms and disease course with GP reconfirmation and 
specialist letters if available. However, at the time of acute CRPS, the diagnosis was 
always assessed clinically by a physician based on symptoms and signs at that moment, 
and only cases that had been reconfirmed afterwards by the GP were included. The 
additional validation step that implied visiting the cases that were identified during the 
previous described CRPS incidence study5, yielded a false positive CRPS diagnosis 
for 19% of the cases and a 6% misclassification of the date of onset. This suggests 
an overestimation of the incidence rate calculated using the reported methods in that 
study (validation by GP reconfirmation only). A revised incidence calculation after the 
additional validation step (in which we were rather strict in excluding cases in order 
prevent misclassification) would roughly provide an estimate of 20 incident cases per 
100,000 person years (instead of the previously reported 26). This incidence rate is still 
much higher than previously mentioned.6 
     Misclassification of the determinants (medical conditions prior to CRPS) may have 
occurred. The dynamic character of the IPCI database has lead to variation in length 
of observation time within the study population, being shorter in patients who entered 
the database early during the study period or who got CRPS soon after the start of their 
observation period in the database. To deal with this, a minimum observation time of 
one year before CRPS onset was required for each patient, while also in the analyses we 
adjusted for observation time, thereby preventing against confounding by the length of 
the observation period. Diagnoses could have been missed if they occurred before start of 
observation in the database, although we suspect that serious ongoing medical conditions 
will have been noted again during the actual observation period. Moreover, diagnoses 
mentioned in the journal may be false positive since for efficiency reasons in general 
practice they are not always validated with complementary research. However, any 
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misclassification resulting was likely indifferent between cases and controls and would 
therefore only have leaded to an underestimation of associations. The actual observed 
associations increased in sensitivity analyses, wherein the diagnoses (determinants) were 
strengthened by requiring specific treatment. 
     The fact that all medical conditions have been assessed and registered in patients before 
the onset of CRPS, meaning that both doctor and patient did not know that the patient 
was susceptible to CRPS, is a strong feature of the study. Recall bias and differential 
information bias are therefore not an issue. A second advantage is the availability of 
a relatively large population based control group that was matched to the cases on the 
same type of injury preceding CRPS (additional to age and gender). As CRPS generally 
occurs after an injury, matching on this risk factor is important if additional risk factors 
are sought. For 8% of the CRPS patients no precipitating injury could be extracted from 
the journal, which is in line with previously reported percentages of spontaneous CRPS.1 
Finally, due to the gatekeeper role of the GP in the Netherlands, it was possible to study 
the medical history of the patient from the electronic medical records, which is likely to 
be more accurate than a self report by the patient.
     In conclusion, a medical history of asthma, migraine, osteoporosis and a recent history 
of menstrual cycle related problems and preexisting neuropathies were associated with 
CRPS. Since the etiologies of some of these diseases are better understood they may give 
leads to potential disease mechanisms underlying CRPS. The association with asthma and 
migraine favors the existing ideas of neurogenic inflammation involvement in CRPS.
Supplementary data associated with this article can be found in the online version at 
doi:10.1016/529 j.pain.2008.07.002.
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Abstract
Introduction: Antihypertensive drugs interact with mediators that are also 
involved in the complex regional pain syndrome (CRPS), such a neuropeptides, 
adrenergic receptors and vascular tone modulators. Therefore we aimed to study 
the association between the use of antihypertensive drugs and CRPS onset.
Methods: A population based case-control study was conducted in the Integrated 
Primary Care Information (IPCI) database in the Netherlands. Cases were identified 
from electronic records (1996-2005) and included if they were confirmed during 
an expert visit (using IASP criteria), or if they had been diagnosed by a medical 
specialist. Up to four controls per cases were selected, matched on gender, age, 
calendar time and injury. Exposure to angiotensin converting enzyme (ACE) 
inhibitors, angiotensin II receptor antagonists, β-blockers, calcium channel 
blockers, and diuretics was assessed from the automated prescription records. 
Data were analyzed using multivariable conditional logistic regression.
Results: A total of 186 cases were matched to 697 controls, (102 confirmed 
during an expert visit plus 84 with a specialist diagnosis). Current use of ACE 
inhibitors was associated with an increased risk of CRPS (ORadjusted: 2.7, 95%CI: 
1.1-6.8). The association was stronger if ACE inhibitors were used for a longer 
time period (ORadjusted: 3.0, 95%CI: 1.1-8.1) and in higher dosages (ORadjusted: 
4.3, 95%CI: 1.4-13.7). None of the other antihypertensive drug classes was 
significantly associated with CRPS.
Discussion: ACE inhibitors use was associated with CRPS onset. We hypothesize 
that ACE inhibitors influence the neuro-inflammatory mechanisms underlying 
CRPS by their interaction with the catabolism of substance P and bradykinin.
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Introduction
The complex regional pain syndrome (CRPS) can occur in one or more extremities as 
painful complication from a fracture, surgery or any other type of physical injury.1 Its 
incidence in the Netherlands is estimated at 26 per 100,000 person years, while women 
are affected 3.4 times more frequently than men.2 In the absence of a sensitive and specific 
biomarker the diagnosis is based on clinical criteria as established by the International 
Association for the Study of Pain (IASP).3 The mechanisms underlying CRPS have been 
studied increasingly over the past decade and parts of the pathogenesis become slowly 
unraveled. Both inflammatory and neurogenic (autonomic and somatic) disturbances 
contribute to CRPS and are represented in the clinical presentation. Most patients display 
classic inflammatory signs like pain, swelling, redness, and warmth in the initial phase 
of the disease.1 Autonomic disturbances, neuropathic pain, and motor impairment may 
follow, causing ongoing discomfort and functional disability.4   
     Mediators of inflammation in CRPS include classic pro-inflammatory cytokines 
such as IL-1β, IL-6 and TNFα, which are elevated in blister fluid and spinal liquor of 
CRPS patients.5-7 Additionally, neuropeptides such as calcitonin gene related protein 
(CGRP) and substance P (SP) play a role in CRPS8,9, contributing to vasodilatation, long 
lasting erythema and plasma protein extravasation.10-13 Substance P also stimulates other 
immunological responses14 and, when released by terminal nerve endings in the dorsal 
horn, it mediates central sensitization.15 Moreover, bradykinin, which is involved in 
acute and chronic inflammatory responses16 and in peripheral nociceptor sensitization17 
is systematically elevated in CRPS patients.9 
     In addition to inflammatory markers CRPS patients also have elevated systemic 
levels of catecholamines18 whereas local levels are decreased.19  Catecholamines are 
considered to be mediators in sympathetic hyperactivity, to which many signs of CRPS 
have been attributed. Under certain circumstances, catecholamines can also induce 
proinflammatory responses, mediated through the interaction with α-receptors expressed 
on immune cells.20,21 
     Some of the above mentioned inflammatory mediators that are elevated in CRPS 
patients also play a role in the mechanism of action of antihypertensive drugs. In particular 
ACE inhibitors are of interest, as they might block the ACE dependent degradation of 
substance P and bradykinin.22,23 Therefore ACE inhibitors could be hypothesized to 
increase the risk of CRPS onset. On the other hand, β-blockers attenuate the effects that 
are mediated by catecholamines, and therefore may decrease the symptoms of CRPS. 
Calcium channel blockers cause vasodilatation, thereby improving peripheral blood 
circulation and counteracting potential CRPS symptoms. Based on these mechanisms 
of action, we hypothesized that antihypertensive drugs could influence the occurrence of 
CRPS. This study aims therefore to investigate whether antihypertensive drugs, and in 
particular ACE inhibitors, are associated with the risk of developing CRPS. 
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Methods
Design and setting
A retrospective case-control design was used, comparing antihypertensive drug use 
in CRPS patients to that in controls selected from the same general population. The 
study was nested in the Integrated Primary Care Information (IPCI) database, which is a 
longitudinal general practice (GP) database that currently contains the electronic records 
of more than 800,000 persons in the Netherlands. The IPCI population reflects the age 
and gender distribution of the general Dutch population. In the Dutch Health Care System 
all persons are registered with one GP independent of their health status. The GP acts 
as a gatekeeper for further medical care and as a central receiver of information about 
secondary care. Therefore, the electronic records can be assumed to contain complete 
medical information of each patient.24 GPs participating in the IPCI project do not 
keep additional paper records, except for specialist and discharge letters. Details on the 
database have been described previously.25 
     The IPCI project complies with the European Union guidelines on the use of medical 
data for medical research and has been proven valid for (pharmaco-)epidemiological 
research.26 The present study has been approved by the Scientific and Ethical Advisory 
Group of IPCI and by the Medical Ethical Board of the Erasmus Medical Center (protocol 
number 2006-099).
Source population
The source population comprised all persons with at least 1 year of valid history in the 
IPCI database during the study period (January 1996-June 2005) to ensure sufficient 
baseline information on all subjects. This meant that the practice had been contributing 
data to the IPCI database for at least one year and that the patient had been registered 
with the GP for at least one year. Follow-up started on the first of January 1996 or on the 
date that one year of valid history was available, whichever date was latest. Follow-up 
was ended upon transferring out of the practice, the date of last data supply by the GP, 
death, diagnosis of CRPS or at the end of the study period, whichever came first. The 
source population was restricted to all practices that were still active in the IPCI database 
in 2006. 
Cases
Potential incident CRPS cases were identified in the database using a sensitive string 
search algorithm. Subsequently, short questionnaires were mailed to the GPs, in which 
they were asked to reconfirm whether the person indeed had suffered from CRPS and to 
provide copies of all available specialist letters. A more detailed description of the case 
identification and validation process up to this point has been described in our study on 
the incidence of CRPS in the Netherlands.2 
In a subsequent step all confirmed cases were invited to our study. Cases who consented 
to participate in our study were visited by the primary investigator, a physician with 
clinical experience in diagnosing CRPS (MM). Preceding this visit, patients received an 
extensive questionnaire concerning their CRPS related complaints and symptoms, and 
disease course. Patients completed the questionnaire by themselves and during the visit 
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the investigator and patient solved incomplete answers together. A physical examination 
of the affected and contra-lateral unaffected extremity was also performed. 
     Patients were included as cases in the analysis if they were judged to have ever 
fulfilled the diagnostic criteria for CRPS as established by the International Association 
for the Study of Pain (IASP)3, using the combined information from the visit, electronic 
journal and specialist letters (if available). Patients who could not be visited but who 
had a specialist diagnosis of CRPS were included as a case in the primary analysis, but 
excluded in a secondary (sensitivity) analysis. The index date was chosen as the date on 
which CRPS was first mentioned in the medical records. 
Controls
Per case, up to four age (year of birth) and gender matched controls were selected from 
the IPCI database, with the requirement that each control had encountered a similar type 
of injury as its matching case within the two years prior to the date of CRPS diagnosis 
of the case. This meant that cases with CRPS following a fracture were matched to 
controls with a fracture, cases with CRPS following a soft tissue injury were matched to 
controls with a soft tissue injury, etc. If the CRPS had occurred in a case spontaneously 
(no initiating injury) the control was not required to have had an injury either. For each 
control the index date was established as the date of the injury plus the time between 
injury and CRPS onset in its matched case.
Use of antihypertensive drugs
Drug prescriptions were retrieved from the IPCI database. The available data comprised 
Anatomical Therapeutical Chemical (ATC) classification code, prescription start 
date, quantity, strength, indication and prescribed daily dose. The following groups 
of antihypertensives were included27: ACE inhibitors, angiotensin II (AT2) receptor 
antagonists, β-blockers, calcium channel blockers and diuretics (alone or in combination 
with other antihypertensives). AT2 receptor antagonists were analyzed separately from 
the ACE inhibitors since they do not affect SP and bradykinin degradation and therefore 
were not suspected of affecting CRPS occurrence. The duration of a prescription was 
calculated as the quantity of prescribed units (mostly tablets) divided by the daily intake 
of units. Episodes of use per drug were created by combining consecutive prescriptions 
and correcting for overlap. A person was classified as a current user of a certain drug if 
the duration of the most recent prescription plus seven days covered the index date. If 
the last prescription ended more than seven days prior to the index date, persons were 
classified as past users. In current users we assessed the duration of use as the number 
of days that the drug was used during the year prior to the index date. The prescribed 
daily dose was expressed as the number of dose equivalents of the defined daily dose 
(DDD) for the last prescription28. In order to evaluate the accuracy of the GP prescription 
data pharmacy delivery lists were requested for a subset of patients and compared to the 
prescription data.
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Covariables
The medical history prior to the onset of CRPS was extracted from the electronic 
medical records. Smoking and disorders related to antihypertensive drug use, including 
hypertension, hypercholesterolemia, cardiovascular diseases (for example angina 
pectoris and myocardial infarction) and diabetes mellitus (DM) type II were considered 
as potential confounders. Additionally, diseases that were found to be associated with 
CRPS onset in a previous study conducted within the IPCI database were taken into 
account, namely osteoporosis, migraine, asthma and menstrual cycle related disorders.29 
Current use of drugs that might be associated with either antihypertensive use or CRPS 
was also evaluated as potential confounder (NSAIDs, corticosteroids, statins, SSRIs, 
tricyclic antidepressants, anti-epileptics, and drugs for migraine (ATC: N02C)). 
Statistical analyses
Conditional logistic regression analyses were performed to study the association between 
current and past use of antihypertensive drugs use and CRPS onset, calculating crude and 
adjusted odds ratios (OR) with 95% confidence intervals (CI). Since two or even three 
antihypertensive drugs are frequently co-prescribed, antihypertensive drug monotherapy 
was analyzed separately, whereby (concomitant) users of other antihypertensives than 
the one of interest were classified into a separate category. Covariates were included in 
the model if they altered the OR for current use of ACE inhibitors by more than 10%. 
Sensitivity analyses were conducted to estimate the effect of outcome misclassification, 
including only the cases that were validated by a visit (using IASP criteria), thereby 
excluding the unvisited cases which were diagnosed by specialist. To investigate effect 
modification by gender stratified analyses were performed and interaction terms for 
gender and antihypertensive drug use were tested in the regression model.
Results
Two-hundred-and-fifty-nine cases were identified and reconfirmed by the GP in the source 
population of 204,281 persons: 191 (74%) with a specialist diagnosis and 68 (26%) with 
only a GP diagnosis. The procedure for final case inclusion in the main and sensitivity 
analyses is presented in figure 1. The final case set comprised cases that were validated 
upon a visit (n=102) supplemented with the specialist diagnosed cases from non visited 
patients (n=84). Thus, the total study population comprised 883 patients, including 186 
cases and 697 age, gender and injury matched controls (up to four per case). 
     Characteristics of the study population are displayed in table 1. The mean age on the 
index date in the study population was 51 years, 77% was female, and CRPS patients 
had more often migraine and osteoporosis in their medical history and they were more 
frequently current users of NSAID’s. 
     For 166 patients (19% of the total study population) complete pharmacy delivery lists 
were available for comparison with GP prescription records. The sensitivity for current 
use of an antihypertensive in the GP records was 82%, while the specificity was 99%. 
This was non-differential between cases and controls.
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Source population
N=204,281 
main analyses
cases validated upon a visit, supplemented with 
unvisited cases having a specialist diagnosis
Identified cases
Specialist 
diagnosis
only GP 
diagnosis
Invited for 
study participation
no reidentification
death
moved out
8
1
6
259
prevalent
other diagnosis
no iasp criteria
9
4
6
no response
refusal
6
19
no response
refusal
19
38
Participants
prevalent
other diagnosis
no IASP criteria
2
9
2
no reidentification
death
moved out
1
10
17
53
68
28
15
163
191
106
87Visited and 
fulfilling IASP criteria
85 unvisited cases
with a specialist diagnosis
no matching 
control for 1
102sensitivity analyses
only cases validated with 
information from visits (IASP criteria)
84 +
186
Figure 1. Inclusion of cases for main and sensitivity analyses. Re-identifiction means the process 
of decoding the patient number in the IPCI database. The first decoding step is performed by the 
IPCI gatekeeper, who subsequently contacts the GP. Only the GP can retrieve the patient names 
and addresses for contact purposes and all patient contact is mediated through the GP. Reasons 
for failure of re-identification are changes in software systems or retirement of the GP. In prevalent 
cases CRPS onset occurred before start of follow up time in the database. Since we were inter-
ested in drug use before CRPS onset these patients were excluded from the analyses.
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     Associations between antihypertensive drug use and the risk for CRPS are displayed 
in table 2. No significant associations were observed between CRPS and current use 
of β-blockers, AT2 antagonists, calcium channel blockers or diuretics. Current use of 
ACE inhibitors was associated with an increased risk of CRPS (OR: 1.9; 95%CI: 0.9-
4.1). This association became stronger upon adjustments for potential confounders 
(OR: 2.7, 95%CI: 1.1-6.8). The association further strengthened if monotherapy with 
ACE inhibitors was analyzed separately from combinations of ACE inhibitors and other 
antihypertensives (OR: 3.3, 95%CI: 1.1-9.8). A stratified analysis by gender displayed 
an even stronger effect of ACE inhibitor use in women (OR: 4.6, 95%CI: 1.6-13.2 in 
143 cases and 534 controls), while in men the association disappeared (OR: 0.5, 95%CI: 
0.1-4.9 in 43 cases and 163 controls). However, the multiplicative interaction term in the 
regression model was non-significant, argueing against significant effect modification. 
Hypertension was the primary indication for ACE inhibitor prescriptions in 9 of the cases 
(81.1%) and 17 of the controls (81.0%). 
Table 1. Characteristics of the study population.
Characteristics  CasesN=186
Controls
N=697 OR (95%CI)
             
Age Mean: 51 year, sd: 16 matched 
Gender (female) 677 (77%) matched 
            
  n % n %   
            
Smoking 36 36 (19.4) 127 127 (18.2) 1.1 (0.7-1.7)
              
Co-morbidity           
Hypertension 28 15.1% 119 17.1% 0.8   (0.5-1.3)
Hypercholesterolemia 16 8.6% 58 8.3% 1.1   (0.6-2.0)
Cardiovascular disorders 9 4.8% 25 3.6% 1.3   (0.6-3.0)
Diabetes Mellitus type II 6 3.2% 27 3.9% 0.8   (0.3-2.1)
Heart failure 2 1.1% 3 0.4% 3.2   (0.4-23.4)
Asthma 14 7.5% 32 4.6% 2.0   (0.9-3.3)
Migraine 13 7.0% 22 3.2% 2.4   (1.2-5.0)
Osteoporosis 13 7.0% 24 3.4% 2.4   (1.2-5.1)
Menstrual cycle related dis. 14 7.5% 33 4.7% 1.8   (0.9-3.6)
           
Co-medication (current)           
NSAIDs 16 8.6% 23 3.3% 2.8   (1.4-5.7)
Corticosteroids 0 0% 2 0% n.a.
Statins 7 3.8% 35 5.0% 0.8   (0.3-1.8)
SSRIs 5 2.7% 20 2.9% 1.0   (0.4-2.7)
TCAs 2 1.1% 5 0.7% 1.3   (0.2-7.5)
Anti epileptics 1 0.5% 4 0.6% n.a.
Anti migraine drugs 4 2.2% 4 0.6% 4.0   (1.0-16.0)
            
NSAID: non steroidal anti-inflammatory drugs, SSRI: selective serotonin reuptake 
Inhibitor, TCA: tricyclic antidepressant
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Table 2. Associations between the use of antihypertensive drugs and the risk for CRPS.
Antihypertensive CasesN=186
Controls
N=697
ORmatched
(95%CI)
ORadj1
(95%CI)
ORadjadj2
(95%CI)
n n
Ace-inhibitors
never
current
past
171
11
4
656
21
20
Ref
1.9 (0.9-4.1)
0.8 (0.3-2.3)
Ref
2.8 (1.1-6.8)
1.2 (0.3-4.2)
Ref
2.7 (1.1-6.8)
1.1 (0.3-4.1)
monotherapy†
never
current
past 
concomitant
137
7
1
41
532
7
8
150
Ref
3.3 (1.1-9.8)
n.a.
1.0 (0.7-1.6)
Ref
5.0 (1.5-16.9)
n.a
1.3 (0.8-2.1)
Ref
4.7 (1.4-16.3)
n.a.
1.2 (0.7-2.1) 
AT2 antagonists
never
current
past
183
2
1
679
13
5
Ref
0.6 (0.1-2.6)
n.a.
Ref
0.7 (0.2-3.4)
n.a.
Ref 
0.7 (0.1-3.4)
n.a.
monotherapy†
never
current
past 
concomitant
137
1
0
48
532
2
4
159
Ref
n.a.
n.a.
1.1 (0.8-1.6)
Ref
n.a.
n.a.
1.3 (0.8-2.2)
Ref
n.a.
n.a.
1.3 (0.8-2.2)
B-blockers 
never
current
past
160
8
18
598
47
52
Ref
0.7 (0.3-1.5)
1.3(0.7-2.3)
Ref
0.7 (0.3-1.6)
1.4 (0.7-2.5)
Ref
0.7 (0.3-1.7)
1.4 (0.8-2.7)
monotherapy†
never
current
past 
oncomitant
137
2
12
35
532
27
33
105
Ref
0.3 (0.1-1.3)
1.4 (0.7-2.8)
1.2 (0.8-1.9)
Ref
0.3 (0.1-1.4)
1.6 (0.8-3.4)
1.5 (0.8-2.6)
Ref
0.3 (0.1-1.4)
1.7 (0.8-3.5)
1.4 (0.8-2.5)
Ca antagonists
never
current
past
174
8
4
658
22
17
Ref
1.3 (0.5-3.0)
0.8 (0.3-2.6)
Ref
1.5 (0.6-3.8)
0.9 (0.3-2.8)
Ref
1.4 (0.6-3.8)
1.0 (0.3-3.1)
monotherapy†
never
current
past 
concomitant
137
3
3
43
532
6
5
154
Ref
1.3 (0.3-6.5)
2.0 (0.5-8.9)
1.1 (0.7-1.6)
Ref
1.6 (0.3-8.7)
2.1 (0.5-9.6)
1.3 (0.8-2.2)
Ref
1.8 (0.3-9.8)
2.4 (0.5-11.2)
1.2 (0.7-2.0)
Diuretics 
never
current
past
161
10
15
620
28
49
Ref
1.5 (0.7-3.2)
1.1 (0.6-2.0)
Ref
2.1 (0.9-5.0)
1.2 (0.6-2.3)
Ref
2.0 (0.8-4.8)
1.1 (0.6-2.1)
monotherapy†
never
current
past 
concomitant
137
2
9
38
532
6
27
132
Ref
1.4 (0.3-6.8)
1.0 (0.4-2.4)
1.1 (0.7-1.7)
Ref
1.6 (0.3-8.2)
1.1 (0.5-2.6)
1.4 (0.8-2.5)
Ref
1.6 (0.3-8.5)
0.9 (0.4-2.2)
1.5 (0.8-2.6)
† Concomitant users of other antihypertensives are classified into a separate group.
matched Matched on gender, year of birth, calendar time (2 year band), and type of injury. 
adj1 Adjusted for hypertension, hypercholesterolemia, DM, and cardiovascular disorders.
adj2 Additionally adjusted for the current use of NSAIDs and statins.
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     Long term use of ACE inhibitors, as well as a high dose, was associated with a stronger 
association with CRPS than short term use and a low dose (OR: 3.0, 95%CI: 1.1-8.1 and 
OR: 4.3, 95%CI: 1.4-13.7 respectively) (Table 3). The association between CRPS and 
current use of ACE inhibitors remained in a sensitivity analysis that was restricted to the 
cases that were confirmed CRPS upon expert visitation. 
ACE 
inhibitors
Main analysis Sensitivity analysis
Cases
N=186
Controls
N=697
ORadj
(95% CI)
Cases
N=102
Controls
N=381
ORadj
(95% CI)
    
  n n   n n   
Duration      
never 171 656 Ref 95 359 Ref
≤180 days 2 3 1.9 (0.3-23.9) 0 0 n.a
>180 days 9 18 3.0 (1.1-8.1) 6 11 4.6 (1.1-19.3)
past 4 20 1.1 (0.3-4.0) 1 11 0.5 (0.0-5.4)
Dose     
never 171 656 Ref 95 359 Ref
≤ 1DDD 4 12 1.6 (0.4-5.8) 2 7 1.7 (0.2-13.4)
> 1DDD 7 9 4.3 (1.4-13.7) 4 4 9.7 (1.7-54.2)
past 4 20 1.1 (0.3-4.0) 1 11 0.5 (0.0-5.6)
      
Main analysis: including cases verified upon a visit (N=102) + unvisited specialist diagnosed cases
(N=84), total N=186; Sensitivity analysis: including only cases verified upon a visit, total N=102
adj matched on gender, year of birth, calendar year (2 year band), and type of injury; adjusted for 
hypertension, hypercholesterolemia, cardiovascular diseases, diabetes mellitus, and current use 
of NSAIDs and statins.
Table 3. Associations between the duration and dosage of ACE inhibitor use and CRPS
In the main analysis and in a sensitivity analysis that excluded unvisited cases.
Discussion
In this nested population based case-control study we observed a dose and duration 
dependent association between use of ACE inhibitors and the risk of CRPS. Other 
classes of antihypertensive drugs were not associated with either a significant reduced 
or increased risk of CRPS. B-blockers tended to reduce the risk, but this should be 
investigated in a larger dataset to obtain sufficient power.
      The observed association between ACE inhibitors and CRPS was a-priori hypothesized 
due to its biological plausibility (figure 2). ACE is one of the most important kininases 
involved in the inactivation of SP23 and bradykinin22 and ACE inhibition therefore would 
increase the levels of these pro-inflammatory peptides. Both SP and bradykinin are 
well known mediators in inflammation and sensitization, two important mechanisms 
underlying CRPS, and both peptides have actually been demonstrated involved in CRPS 
pathology.9,30,31
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Figure 2. The intended effect of ACE inhibitors is to block the conversion of angiotensin I into an-
giotensin II in order to decrease blood pressure. However, as an unintended effect, ACE inhibitors 
prevent the degradation of substance P and bradykinin, causing accumulation of these peptides. In 
addition to this, ACE inhibitors upregulate the bradykinin (B2) receptor, thereby further potentiating 
bradykinin activity. Substance P and bradykinin are both important mediators in neuroinflammatory 
responses and sensitization and probably in the pathogenesis of CRPS.
     The role of ACE in CRPS and neurogenic inflammation has been investigated before 
from a genetic and experimental perspective yielding quite contradictory results. A 
Japanese study revealed an increased prevalence of the ACE polymorphism DD genotype 
in 16 CRPS patients compared to the general population (43% versus 20%).32 The DD 
genotype however is known to be associated with higher ACE levels and thereby with 
supposedly lower SP and bradykinin levels. Therefore, the DD genotype would be 
expected to correlate with a low risk of CRPS, instead of a high risk as was observed 
in the Japanese study. However, only a small study population (n=16) was included and 
the findings were not confirmed in a larger German study (48 sporadic and 12 familial 
patients).33  
ACE
Inhibitors
B2 receptor
bradykinin receptor
Bradykinin
accumulation
Substance P
conversion
inhibition
accumulation
upregulation
Plasma protein extravasation (PPE)
Neutrophil migration
Cellular immunity
Cytokine release
Peripheral/central sensitization
Angiotensin I
Angiotensin II
Vasodilatation
Sympathetic output ↓
Blood pressure ↓
Inflammation and sensitization
(unintended effect)
Antihypertensive effect
(intended effect)
degradation
inhibition
degradation
inhibition
decrease
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     An experimental study in healthy skin showed no facilitation of electrical C-fiber 
stimulation induced neurogenic inflammation by the ACE inhibitor captopril34, although 
this was expected because ACE inhibition would lead to SP and bradykinin accumulation. 
However, healthy skin is different from the inflamed tissue that is present in the early 
phase or pre-stadium of CRPS. ACE inhibitors do not facilitate neurogenic inflammation 
in healthy skin probably because there the levels of its substrates, SP and bradykinin, are 
low.34 On the contrary, inflamed skin holds increased levels of SP, released by primary 
afferents under the influence of cytokines35 and bradykinin. Normally SP and bradykinin 
should be degradated by ACE, but ACE inhibitors may block their catabolism, resulting 
in the further accumulation of these peptides. In this view, ACE inhibitors may not affect 
the initiation of the neuro-inflammatory response that underlies CRPS, but they can 
facilitate its progression once it has been triggered by other causes. Eventually this may 
cause an initially functional inflammatory response to develop towards a point that it 
becomes pathological, as in CRPS (figure 3).
     It has also been shown that under certain circumstances ACE inhibitors facilitate 
the degradation of CGRP36, another neuropeptide that has been found to be increased 
in CRPS patients.9 As ACE inhibitors may diminish CGRP levels, they could also have 
been found to protect against CRPS, the opposite to what we observed. However the 
interaction between ACE inhibitors and CGRP is indirect and occurs only when the main 
metabolizer of CGRP, an enzyme called neutral endopeptidase (NEP), is blocked.36 SP 
and bradykinin are direct substrates for ACE and our observation that ACE inhibitors 
increase (instead of decrease) the risk of CRPS suggests that SP or bradykinin or both are 
important mediators in CRPS. CGRP may be important in CRPS as well, but its actual 
relevance can not be derived from the present study, because the interaction between 
ACE and CGRP is more complex.      
SP and bradykinin low
(No effect of ACE-inhibitors)
healty skin inflammatory response / “pre-CRPS”
SP and bradykinin are increasing,
however, degradation by ACE 
limits exaggaration of the 
neuroinflammatiory process
clinical CRPS
Trigger
fracture, sprain,surgery, etc.
ACE inhibitor
diminished degradation of SP and bradykinin
Persistent increase of 
SP and bradykinin results in
florid neurogenic inflammation 
Figure 3. Ace inhibitors do not facilitate neurogenic inflammation in healthy skin (Kramer et. al. 
2005), but may enhance an existing neuroinflammatory response that has been initiated by a previ-
ous trigger by preventing the degradation of SP and bradykinin. In some cases this may cause a 
physiological inflammatory reaction (“pre-CRPS”) to develop towards a florid neurogenic inflamma-
tion, resulting in the clinical picture of CRPS. 
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     Strengths of our study include the unique population based setting and design, wherein 
controls had an injury similar to the cases. The availability of prescription records with 
accurate information on prescription dates allowed us to study the role of drugs in the onset 
of CRPS. However, the study also has some limitations. Misclassification of the CRPS 
diagnosis, a general problem in CRPS research, may have occurred also in our study, since 
the final verification of the diagnosis had to be performed retrospectively. Assuming that 
misclassification of the diagnosis was unrelated to the use of antihypertensive drugs this 
would only have resulted in an underestimation of the associations of interest. This was 
confirmed by a sensitivity analysis that was limited to the cases that were verified during 
a visit (more valid diagnosis) and showed an even stronger association between ACE 
inhibitor use and CRPS onset. Also, some non-differential misclassification of the exposure 
(current use of antihypertensives) was present, for example where antihypertensive drugs 
were prescribed by physicians other than the GP. Potential selection bias was reduced 
by including the specialist diagnosed cases who were not visited (including refusers 
and untraceable patients). In addition, antihypertensive drug use did not differ between 
participants and non-participants (derived from the prescription records in the database). 
Confounding was addressed as far as possible by the inclusion of various comorbidities 
and drugs in the model, but residual confounding cannot be ruled out.
     In conclusion, we found a positive dose and duration dependent association between 
the use of ACE inhibitors and the risk of CRPS. This points to the important role of SP 
or bradykinin or both in the pathogenesis of CRPS, as these inflammatory peptides are 
metabolized by ACE and increase during ACE inhibition. We hypothesize that ACE is a 
modulator of the neuro-inflammatory mechanisms that underlie CRPS.  
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Abstract
Introduction: Since the complex regional pain syndrome (CRPS) shows a clear 
female predominance we investigated the association between the cumulative as 
well as current exposure to estrogens, and CRPS.
Methods: A population based case-control study was conducted in the Integrated 
Primary Care Information (IPCI) project in the Netherlands. Cases were identified 
from electronic records (1996-2005) and included if they were confirmed during 
a visit (using International Association for the Study of Pain criteria), or had 
been diagnosed by a specialist. Controls were matched to cases on gender, age, 
calendar time and injury. Measures of cumulative endogenous estrogen exposure 
were obtained by questionnaire and included age of menarche and menopause, 
menstrual life, and cumulative months of pregnancy and breastfeeding. Current 
estrogen exposure at CRPS onset was retrieved from the electronic medical 
records and determined by current pregnancy or by the use of oral contraceptive 
drugs (OC) or hormonal replacement therapy (HRT). 
Results: Hundred-and-forty-three female cases (1,493 controls) were included 
in analyses on drug use and pregnancies, while cumulative endogenous estrogen 
exposure was studied in 53 cases (58 controls) for whom questionnaire data 
were available. There was no association between CRPS and either cumulative 
endogenous estrogen exposure, OC or HRT use. CRPS onset was increased 
during the first six months after pregnancy (OR: 5.6, 95%CI: 1.0-32.4), although 
based on small numbers.
Discussion: We did not find an association between CRPS onset and cumulative 
endogenous estrogen exposure or current OC or HRT use, but more powered 
studies are needed to exclude potential minor associations.
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Introduction
Rehabilitation from a physical trauma, such as a fracture or sprain, can be complicated 
by the complex regional pain syndrome (CRPS). CRPS is usually located in the distal 
part of the affected extremity and is marked by pain, vasomotor, sudomotor and motor/
trophic disturbances.1 Its pathogenesis is subject to speculation, but nervous system 
involvement has since long been acknowledged. However, more recently the interest 
in inflammatory disease mechanisms underlying CRPS has increased.2,3 Neurogenic 
inflammation is mediated by neuropeptides that are secreted by nociceptive nerve 
endings upon triggering by mechanical, chemical or physical injury.4 Neuropeptides, 
such as substance P (SP) and calcitonin gene related protein (CGRP), induce plasma 
protein extravasation5, recruitment of immune cells6 and release of pro-inflammatory 
cytokines, for example tumor necrosis factor α (TNFα), interleukin (IL)-1 and IL-
6.7,8 Moreover, reactive oxygen species (ROS) have been suggested to be involved in 
triggering or sustaining CRPS.9,10
     CRPS has a clear female predominance with a female/male ratio between three and 
four.11,12 The peak incidence occurring between the fifth and seventh decade suggests an 
increasing risk after the menopause, when endogenous estrogen levels drop. Furthermore, 
a previous study showed an association between CRPS and both menstrual cycle related 
disorders and osteoporosis.13 All these observations suggest that sex hormones, in 
particular estrogens, are of relevance in the pathogenesis of CRPS. 
     In women serum levels of 17β-estradiol (E2), the primary estrogen during pre-
menopausal life, are influenced by menarche, menstrual cycle, pregnancy and lactation, 
and menopause. Estrogen levels can also be affected by synthetic estrogens or estrogen 
mimicking drugs that are administrated, such as oral contraceptive drugs (OC) or as 
hormonal replacement therapy (HRT). The latter is frequently prescribed to women 
during the peri- or post-menopausal life in order to attenuate the negative effects 
accompanying decreasing E2 levels, such as vasomotor symptoms, mood changes and 
loss of bone mineral density. Beyond their role in sexual development and reproduction 
estrogens play an important role in the cardiovascular system14 and in bone metabolism.15 
Additionally, estrogens are widely involved in mechanisms of inflammation16 and may 
therefore interact with several presumed mediators in the pathogenesis of CRPS. For 
example, estrogens influence the metabolism of substance P and bradykinin17 and prevent 
the formation of reactive oxygen species during ischemia or inflammation.18 Moreover, 
NFκB, an important transcription factor in inflammation and probably also in CRPS19, 
is inhibited by interaction with estrogen receptors.20 Overall, these estrogen effects may 
attenuate the disease mechanisms of CRPS and we therefore hypothesized that high 
estrogen levels may prevent CRPS onset. 
     In the present study, we investigated whether exposure to estrogens affects the risk for 
CRPS onset. We performed a population based case-control study comparing measures 
of cumulative endogenous estrogen exposure during life, as well as current estrogen 
exposure at the moment of CRPS onset.
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Methods
Design and setting
The case-control study was nested within the integrated primary care information 
(IPCI) project, a general practitioners (GP) research database in the Netherlands. The 
database contains the electronic files of over one million patients and is representative 
of the Dutch population regarding age and gender.21,22 All inhabitants of the Netherlands 
are registered with a GP who receives and stores all health care information of their 
patients.23 Therefore, GPs can be considered to have complete medical information. GPs 
who participate in the IPCI project do not keep additional paper records. The electronic 
records store information on demographics, signs and symptoms (using the International 
Classification for Primary Care (ICPC)24 and narratives), diagnoses (using ICPC and 
narratives), clinical findings, specialist referrals, laboratory findings, hospitalizations, and 
drug prescriptions. Summaries from medical correspondence with specialists are entered 
in a free text format and hard copies of original letters can be provided upon request. The 
IPCI project complies with the European Union guidelines on the use of medical data for 
medical research and has been proven valid for (pharmaco-)epidemiological research.25 
The present study has been approved by the Scientific and Ethical Advisory Group of 
the Project (protocol number 04/70) and by the Medical Ethical Board of the Erasmus 
Medical Center (protocol number 2006-099). 
Source population
The source population comprised all persons with at least 1 year of valid history in the 
IPCI database during the study period (January 1996-June 2005) to ensure sufficient 
baseline information on all subjects. This meant that the practice had been contributing 
data for at least one year and that the patient had been registered with the GP for at least 
one year. Follow-up in the database started on the first of January 1996 or on the date that 
one year of valid history was available, whichever date was latest. Follow-up was ended 
upon transferring out of the practice, the date of last data supply by the GP, occurrence of 
CRPS, or at the end of the study period, whichever came first. Since GP co-operation was 
needed for additional data collection, the source population was restricted to practices 
that were still active in the IPCI database in 2006. 
Cases
CRPS cases were retrieved from the electronic records using a string search algorithm 
on narrative journal text, including Dutch synonyms for CRPS, abbreviations, and 
obvious spelling errors. Initial case validation occurred with a brief questionnaire to 
the GP to confirm or reject the CRPS diagnosis as mentioned in the records.11 Specialist 
correspondence was obtained if available. Subsequently, with mediation of the GP, 
confirmed cases were invited by mail for further study participation. Patients who 
provided informed consent were visited once by the primary investigator, a physician 
with clinical experience in diagnosing CRPS (MM). Prior to the visit participants had 
filled a questionnaire addressing CRPS complaints, disease course, treatment, medical 
history, sociodemographics, daily functioning and quality of life. During the visit the 
investigator and the patient briefly went over the questionnaire together to ascertain 
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completeness. Additionally, a physical examination of the affected limb and contralateral 
extremity was performed to assess signs of CRPS. 
     CRPS patients were included as cases in the study population if they could be confirmed 
by the investigator, applying the IASP criteria on the symptom and sign assessments 
during the visits, combined with information from the GP records and specialist letters. 
CRPS patients who could not be visited, because they were untraceable or refused 
participation, were included only if the CRPS diagnosis in the past had been confirmed 
by a medical specialist (instead of by GP only). The index date was chosen as the date on 
which the CRPS diagnosis was mentioned in the records for the first time. In this specific 
study only female patients were included.
Controls
Per case, an unrestricted number of age (year of birth) and gender matched controls was 
selected from the source population. To be included in the study controls were required 
to have experienced an injury identical to the one that precipitated the CRPS in their 
matching case, within a two year band of calendar time. This meant that cases with a 
fracture were matched to controls with a fracture, cases with a soft tissue injury were 
matched to controls with a soft tissue injury, etc. The index date in controls was chosen 
as the date of injury plus the delay time between injury and CRPS in the matching case. 
If a case had spontaneous CRPS (no precipitating injury), controls were not required to 
have had an injury either. A subset of the controls (1-3 per case) was invited to participate 
in assessments similar to the cases (self administered questionnaire and physical 
examination).  
Estrogen exposure
The role of estrogens was explored in various ways: 1. cumulative endogenous exposure 
2. current endogenous exposure and 3. current exogenous exposure. Information on these 
determinants was obtained either from questionnaires or from the medical records.
     Cumulative endogenous estrogen exposure until the index date was assessed using 
patient questionnaire data and included the following measures: age of menarche, age 
of menopause, menstrual life (in years), parity, cumulative months of pregnancy, and 
cumulative months of breast feeding. Menstrual life was determined as the age of 
menopause minus the age of menarche (post-menopausal women) or as the index date 
minus the age of menarche (pre-menopausal women). Cumulative months of pregnancy 
was calculated by summing the reported months of all pregnancies experienced during 
life, including full term, preterm and aborted pregnancies. Similarly, the cumulative 
months of breast feeding was calculated by summing the months of breast feeding for 
each child. Since all these measures were derived from the patients’ questionnaires, they 
could only be assessed in cases and controls that had participated to the additional data 
collection during visits. 
     Current endogenous estrogen exposure included pregnancy close to the index date. 
These pregnancies were identified in the IPCI database by a string and ICPC code search 
in free text and in the diagnosis table. Pregnancy start and duration were derived from the 
records. If this was not well recorded we assumed 280 days for full term deliveries, 245 
days for preterm deliveries, 105 days for late miscarriages, 60 days for early miscarriages, 
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and 70 days for intended abortions. The association between pregnancy and CRPS onset 
was studied in the three time windows: current pregnancy: CRPS onset (index date) 
during a pregnancy; recent pregnancy: CRPS onset within six months after delivery; 
past/no pregnancy: CRPS onset more than six months after delivery. 
     Current exogenous estrogen exposure at the index date included the use of oral 
contraceptive drugs (OC) (in pre-menopausal women), and use of hormonal replacement 
therapy (HRT) (in post-menopausal women). Information about the drug prescriptions 
was retrieved from the IPCI database. The prescription records comprised the 
Anatomical Therapeutical Chemical (ATC) classification code, prescription start date, 
quantity, strength, indication and prescribed daily dose. All estrogen containing OC were 
included (ATC codes G03AA and G03AB). For each 21 tablets a we took into account 
a 28 day exposure period, including a pill free week. HRT included all (oral, vaginal, 
transdermal) estrogen containing drugs intended for prevention or treatment of negative 
postmenopausal effects (G03C). For HRT we calculated the duration of a prescription 
as the quantity of prescribed units (mostly tablets) divided by the daily intake of units. 
Episodes of use were created by combining consecutive prescriptions and correcting for 
overlap. A person was classified as current user if the legend duration of the most recent 
prescription ended less than 30 days before the index date. Past users were subjects with 
the most recent prescription ending between 30 days and one year prior to the index date. 
Differentiation between pre- and post-menopausal status at the index date was done by 
imputing the reported average age of menopause in the visited patients into the unvisited 
patients. 
Covariables    
Determinants associated with either CRPS onset or with OC or HRT use were considered 
as potential confounders. Asthma, migraine, menstrual cycle related disorders 
(Dysmenorrhea, metro/menorragia, poly/oligomenorrhea) and osteoporosis were 
increased in CRPS patients during a previous study.13 In addition to these, smoking, 
hypertension, cardiovascular disorders, climacterial complaints, breast cancer, and 
cancer of the female reproductive organs were tested since they might be associated with 
OC or HRT use. All information regarding potential confounders was derived from the 
electronic journal texts. 
Statistical analyses
Standard comparative statistics were used to determine differences in means (paired 
t-test) and proportions (χ2-test). Odds ratios (OR) and 95% confidence intervals (CI) 
for associations between cumulative or current estrogen exposure and CRPS onset were 
calculated using conditional logistic regression. Measures of cumulative endogenous 
estrogen exposure were tested both as continuous variables and as categorical variables. 
Covariables were included in the final model if they were univariately associated with the 
exposure or the outcome, or if they altered the odds ratio by more than 10%. All analyses 
were conducted using the Statistical Package for Social Sciences (SPSS) version 12.0 
for windows.
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Results
The selection of the study population is displayed in figure 1. The response rate for 
participation concerning further data collection was 64% in CRPS cases and 28% in 
controls. Participants were not significantly different from non participants regarding age 
and medical history. The final study population comprised 143 female CRPS patients (81 
validated during a visit + 62 non visited patients with a specialist diagnosis) and 1,493 
matched controls (median 12 per case, range 2-53). This study population was used to 
conduct analyses regarding OC and HRT use and actual pregnancies at the moment of 
CRPS. Since measures of cumulative estrogen exposure could not be retrieved from the 
IPCI database, but had to be derived from patient questionnaires obtained during the 
visits, analyses regarding these determinants included only those individuals that had 
consented for participation in further data collection. For 53 of the participating cases at 
least one participating matched control was found. Therefore the analyses on cumulative 
estrogen exposure were conducted in 53 matched pairs (53 cases and 58 controls).
Figure 1. Selection of the study population. 1.This study population includes matched case-control 
pairs in the IPCI database. Cases (n=143) were validated during a visit by the investigator (n=81) or 
were confirmed by a specialist (n=62). Controls (n=1,493) were selected from the database, matched 
to the cases on age, gender and injury type. This study population was used in the analyses of deter-
minants that were derived from the records in the IPCI database, namely OC and HRT use and preg-
nancies during follow-up time in the database. 2.This subset of the study population includes only the 
matched case-control pairs whereby both the case and at least one control had participated to the 
additional data collection (visit and questionnaire). This subset was used in the analysis of determi-
nants that were derived from questionnaires, namely cumulative endogenous estrogen exposure.
Source population
from IPCI database
N=204,281 
Identified and GP reconfirmed
n=259
Invited for study participation
n=168
deanonymization problems: n=22
movement of patient: n=11
death of patient: n=1
Participated: n=107
Confirmed by investigator 
(IASP) criteria
n=81
prevalent: n=6
alternative diagnosis=17
no IASP criteria: n=3
no informed consent: n=61
men: n=57
women: n=202
n=143 n=1,493
62 unvisited cases with 
a specialist diagnosis
matched on age, gender and injury
n=62+
n=53 n=58
CRPS cases Controls
matched pairs that participated 
in the additional datacollection
2
1
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     Characteristics of the study population are displayed in table 1 and measures of 
cumulative endogenous estrogen exposure in table 2. Within the subset of visited 
participants (questionnaires available) the average age of menopause onset was 46.6 (sd: 
6.6) years for CRPS cases and 47.0 (sd: 6.9) for controls, which was statistically similar. 
The proportion of post-menopausal patients at the index date was similar between CRPS 
cases and controls. None of the measures of cumulative endogenous estrogen exposure 
was associated with CRPS onset, investigated either as continuous or as categorical 
variables.  
Table 1. Characteristics of the study population.
Characteristics CasesN=143
Controls
N=1,493
ORmatched
(95% CI)
Mean age at CRPS onset (sd) 51 (17) matched
Female 100% matched
n % n %
Smoking 29 20.3% 249 16.7% 1.3 (0.9-2.1)
Migraine 11   7.7% 54   3.6% 2.7 (1.3-5.2)
Asthma 9   6.3% 62   4.2% 1.8 (0.8-3.8)
Osteoporosis 10   7.0% 48   3.2% 2.5 (1.2-5.3)
Hypertension 25 17.5% 231 15.7% 1.1 (0.6-1.7)
Cardiovascular disorders 12   8.4% 116   7.8% 1.2 (0.6-2.3)
Venous thrombosis 2   1.4% 3   0.2% n.a.
Menstrual cycle related disorders 11   7.7% 88   5.9% 1.8 (0.9-3.7)
Climacterial symptoms 13   9.1% 95   6.4% 1.6 (0.9-3.2)
Breast cancer 1   0.7% 13   0.9% 0.7 (0.1-5.7)
Cancer female reproductive organs 0   0% 1   0.1% n.a.
matched Matched on gender, year of birth, calendar time (2 year band), and type of injury. 
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Endogenous estrogen exposure CasesN=53
Controls 
N=58
ORmatched
(95% CI)
            
Post-menopausal at index date 60% 59% 1.3 (0.3-4.8)
            
Mean age of menarche (sd)
Categories: 
<12yr
12-14yr
>=14yr
12.7 (2.4)
22%
40%
38%
13.2 (1.7)
14%
47%
40%
0.9 (0.7-1.1)
1.9 (0.6-5.8)
reference
1.2 (0.5-2.7)
            
Mean age of menopause (sd)†
Categories: 
<40yr
40-50yr
>=50yr
46.6 (6.6)
15% 
47%
37%
47.0 (6.9)
14%
45%
41%
1.0 (0.9-1.1)
0.9 (0.2-3.8)
reference
0.8 (0.3-2.3)
            
Mean cumulative years of menstrual life (sd) 
Categories:
<25yr
25-35yr
>=35yr
30.8 (9.4)
23%
40%
37%
30.1 (9.8)
24%
35%
41%
1.0 (1.0-1.1)
0.7 (0.1-3.0)
reference
0.7 (0.3-2.0)
            
Mean parity (sd)
Categories:                      
0
1-2
>2
1.8   (1.3)
23%
56%
21%
1.9   (1.2)
17%
57%
26%
0.9 (0.6-1.3)
1.8 (0.5-6.3)
reference
0.6 (0.2-1.6)
            
Mean cumulative months pregnancy (sd)
Categories:          
<12 months
12-24 months
>=24 months
17.6 (14.5)
30%
49%
21%
17.7 (12.4)
33%
38%
29%
(1.0-1.0)1.0 
0.8 (0.3-2.0)
reference
0.4 (0.1-1.2)
           
Mean cumulative months breast feeding (sd)
Categories: 
0 months
1-12 months
 >=12 months
5.3 (7.8)
45%
34%
21%
3.8   (5.4)
43%
45%
12%
1.0 (0.9-1.1)
1.5 (0.6-3.3)
reference
2.0 (0.4-8.1)
            
matched Matched on gender, year of birth, calendar time (2 year band), and type of injury. 
† Calculated in post menopausal women only (38 cases and 42 controls).
All data on determinants extracted from patient questionnaires, which were obtained only for a 
small subset of patients that was visited by the investigator.
Table 2. Cumulative endogenous estrogen exposure in CRPS case patients and controls.
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     When extrapolating the mean menopausal age from the questionnaires to the study 
population in the database, 44 cases (573 controls) were pre-menopausal at the index date 
and 99 cases (920 controls) were post-menopausal. In pre-menopausal patients neither 
current (OR: 1.0; 95%CI: 0.5-2.0) nor past (OR: 1.0; 95%CI: 0.3-3.2) use of OC was 
associated with CRPS onset (table 3). In post-menopausal women current HRT use was 
less prevalent in CRPS patients than in controls, but this was not statistically significant 
(OR: 0.5; 95%CI: 0.2-1.8) (table 3). 
     CRPS did not occur during pregnancy, therefore the association could not be calculated, 
but comparison with the controls suggests a protective effect. Two of the visited patients 
had reported in the questionnaire to have become pregnant after CRPS onset: one of 
them had experienced an improvement of CRPS during the pregnancy, while the other 
had noted no change whatsoever. The risk of CRPS was increased in the first six months 
after delivery (OR: 5.6 95%CI: 1.0-32.4), but the actual numbers were low (table 4).
Table 3. Estrogen therapy and the risk of CRPS.
OC use
(in pre-menopausal patients)
Cases
N=44
Controls
N=573
ORmatched
(95% CI)
ORadj1
(95% CI)
            
n % n %     
              
No use 24 54.5% 330 57.6% reference reference
Ever use (in prior year) 20 45.5% 243 42.4% 1.0 (0.5-1.9) 0.9 (0.5-1.8)
Current use 16 36.4% 189 33.0% 1.0 (0.5-2.0) 0.9 (0.4-1.8)
Past use 4 9.1% 54 9.4% 1.0 (0.3-3.2) 1.0 (0.3-3.2)
          
          
HRT use
(in post-menopausal patients)
Cases
N=99
Controls
N=920
ORmatched
(95% CI)
ORadj2
(95% CI)
            
n % n %     
              
No use 90 90.0% 827 89.9% reference reference
Ever use (in prior year) 9  9.1% 93 10.1% 0.9 (0.4-2.0) 0.9 (0.4-1.8)
Current use 3 3.0% 56 6.1% 0.5 (0.2-1.8) 0.5 (0.1-1.6)
Past use 6 6.1% 37 4.0% 1.6 (0.6-4.2) 1.4 (0.5-3.7)
          
matched Matched on gender, year of birth, calendar time (2 year band), and type of injury. 
adj1 Adjusted for migraine, osteoporosis, smoking and menstrual cycle related disorders.
adj2 Adjusted for migraine, osteoporosis and hypertension.
OC= oral contraceptive drugs, HRT=hormonal replacement therapy
137
Estrogens and the Risk of Complex Regional Pain Syndrome     3.3
Time since last pregnancy
(in pre-menopausal patients)
Cases
N=44
Controls
N=573
ORmatched
(95% CI)
          
n % n %   
            
>6 months or never pregnant 42 95.5% 561 97.9% reference
Current pregnancy 0 0% 8 1.4% n.a.
0-6 months since partus 2 4.5% 4 0.7% 5.6 (1.0-32.4)
            
matched Matched on gender, year of birth, calendar time (2 year band), and type of injury. 
Table 4. Pregnancy and the risk of CRPS
Discussion  
We studied the association between estrogen exposure and the risk of CRPS. Cumulative 
endogenous estrogen exposure was not associated with CRPS onset. In pre-menopausal 
patients OC use was not associated with CRPS, while in post-menopausal women we 
observed a non-significant protective effect during current HRT use. Although based on 
small numbers, the risk for CRPS seemed decreased during pregnancy and was increased 
during the first six months after delivery.
     Measures of cumulative and actual estrogen exposure have to our knowledge not 
been studied before in relation to CRPS, which makes it impossible to discuss our 
results in view of previous findings. However, estrogen exposure has been studied in 
relation to other in inflammatory disorders, for example in rheumatoid arthritis (RA) 
and multiple sclerosis (MS). In addition to the profound female predominance these 
disorders share clinical features with CRPS, such as inflammatory signs, pain and 
functional impairments. Moreover, the CRPS prevalence in a cohort of MS patients 
was high compared to estimated general population prevalences, suggesting a possible 
connection between CRPS and MS.26 
      Similar to our present findings for CRPS, studies in RA and MS patients commonly 
revealed no association with parity27-30 and menstrual life27,29, although breast feeding 
was protective for RA in one study.29 The association between OC use and both RA31 and 
MS30, 32, 33 is still controversial and due to large heterogeneity between study populations 
meta-analyses could not provide a final answer.31 Post-menopausal HRT use was only 
non- significantly protective for RA.34 In line with the observations in RA and MS studies, 
we did not observe a strong association between OC or HRT use and the onset of CRPS 
either, although due to power limitations we can not exclude a potential mild association. 
This is especially the case for HRT use, where the non-significant results point into the 
direction of a protective effect. Regarding OC use, the actual OR for current use is 0.9, 
which is suggestive of a non-association. It has been suggested before that OC affect 
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endogenous estrogen serum levels only to a minor extent and therefore can, if any, only 
play a limited role in the underlying mechanisms of immunological disorders.16
     During pregnancy the risk for both RA35,36 and MS30 is known to decrease, while post 
partum incidences are increased for both diseases. Hyperprolactinemia37 and relative 
hypocortisolism38 have been hypothesized to (partially) underlie this observation, since 
they both contribute to a pro-inflammatory immune status. Remarkably, we observed a 
similar pattern for CRPS, with a lower risk during pregnancy and a higher risk during the 
first months after, although it has to be noted that this was based on small numbers. 
     Estrogens interact with many modulators of the immune system, including immune 
cells, cytokines, growth factors, transcription factors and more.16 However, the precise 
role of estrogens is rather complex. Estrogens can induce predominantly anti- or pro-
inflammatory responses, dependent of the cell type, kind of trigger, timing, estrogen 
receptor type and other circumstances.16 Although the relevance of estrogens in 
immunologic diseases is reflected in the demographic patterns (female predominance, 
age distribution), it has been difficult to demonstrate clear associations between such 
diseases and estrogen exposure parameters. Because of the biologic complexity, high 
powered prospective studies within homogeneous populations are needed to uncover 
potential associations. For RA this has already been proven complicated31, and for a rare 
disease with a heterogeneous clinical presentation as CRPS it will be an even bigger 
challenge.  
     Apart from power issues, other limitations may apply to our study, such as 
misclassification of the outcome (CRPS diagnosis), the determinants (estrogen exposure), 
and confounding. Outcome misclassification may have been caused by the retrospective 
assessment of CRPS, which is usually diagnosed by its clinical presentation (IASP 
criteria). However, our case validation strategy was extensive and multiple sources 
for diagnostic information were used. Regarding exposure misclassification, the case/
control status is known to potentially influence recall of past events. However, we have 
no reason to believe that CRPS affects the recall on measures of estrogen exposure as 
how they were addressed in the questionnaires. Therefore, causing only non differential 
misclassification, recall problems will not likely have biased our results, although a 
potential minor association might have been diluted to such an extent that we have missed 
it. Recall was not an issue in the retrieval of OC and HRT use from the IPCI database, as 
this had been prospectively registered by the GP, who is the common prescriber for OC 
and HRT. Confounding may have been caused by factors that are associated with both 
CRPS and estrogen exposure. For the most common risk factors of CRPS, namely age, 
gender and injury, we corrected by through matching. Other potential confounders were 
included as co-variables. However, in the analyses for OC use and HRT we were not 
able to correct for measures of cumulative estrogen exposure, because these were only 
available for the small subset of visited patients. 
     To our knowledge we performed the first study addressing the association between 
estrogen exposure and CRPS. A strength of our study is that we were able to compare 
the findings in CRPS patients to a control group that was matched on injury, assuring 
an equal baseline CRPS risk for cases and controls. This detailed matching procedure 
was possible due to the large number of available controls in the IPCI database. Another 
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strong point is that part of the data on determinants (OC, HRT, pregnancy) had been 
prospectively registered by the GP, making information bias unlikely. Moreover, our 
study was performed in a population based setting, which means that the results are 
representative of CRPS patients in general, in contrast to hospital based studies that 
usually represent a subset of severe patients.
     In conclusion, we found no association between cumulative endogenous estrogen 
exposure and CRPS, and neither between OC or HRT use and CRPS. However, 
because of limited power, minor associations cannot be excluded and larger, preferably 
prospective studies are needed to draw more solid conclusions. Based on the small 
numbers, a decreased risk of CRPS during pregnancy and an increased risk immediately 
after pregnancy was observed, which is in line with patterns observed in RA and MS. 
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Abstract 
Introduction: collaborative efforts of physicians and basic scientists are often 
necessary in the investigation of complex disorders. Difficulties can arise, 
however, when large amounts of information need to reviewed. Advanced 
information retrieval can be beneficial in combining and reviewing data obtained 
from the various scientific fields. 
Methods: In this paper, a team of investigators with varying backgrounds has 
applied advanced information retrieval methods, in the form of text mining and 
entity relationship tools, to review the current literature, with the intention to 
generate new insights into the molecular mechanisms underlying a complex 
disorder. As an example of such a disorder the Complex Regional Pain Syndrome 
(CRPS) was chosen. CRPS is a painful and debilitating syndrome with a complex 
etiology that is still unraveled for a considerable part, resulting in suboptimal 
diagnosis and treatment.
Results: a text mining based approach combined with a simple network analysis 
identified Nuclear Factor kappa B (NFκB) as a possible central mediator in both 
the initiation and progression of CRPS.
Discussion: the result shows the added value of a multidisciplinary approach 
combined with information retrieval in hypothesis discovery in biomedical 
research. The new hypothesis, which was derived in silico, provides a framework 
for further mechanistic studies into the underlying molecular mechanisms of 
CRPS and requires evaluation in clinical and epidemiological studies. 
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Introduction
Early in the history of western medicine, the physician and the basic scientist were 
one and the same person. However, over the past century, clinical research developed 
as a separated branch from the basic sciences such as biology, molecular biology, 
biochemistry, and physiology. The main objective of clinical research is the collection 
and analysis of clinical data concerning symptoms of the disorders and responses to 
treatments. Based on these observations new theories about etiology and pathogenesis 
can be developed. However, detailed information regarding the molecular mechanisms 
underlying a certain disease process often remains elusive. One avenue into possible 
mechanisms of complex disorders is through the use of bioinformatics. Bioinformatics 
applies informatics techniques to organize bio-molecular data on a large scale.1 
     The combination of bioinformatics and biomedical approaches is expected to result 
in significant advantages in both understanding mechanisms of disorders and individual 
susceptibility, which in turn will open many possibilities in individualized medical health 
care.2 Infobiomed is a Network of Excellence funded by the European Union that aims at 
enforcing European biomedical informatics as an integrative discipline.3 One of the main 
objectives of Infobiomed is to enable pilot applications in several medical fields that 
demonstrate the benefits of a synergetic approach in biomedical informatics. An example 
of such a multidisciplinary project is the use of bioinformatics tools in the investigation 
of the relationship between clinical and molecular data. Of course, the current literature 
contains information from these different domains.  However, the amount of information 
has become so large that it is very difficult for a single individual to draw conclusions 
across the various disciplines. Literature based discovery support tools have been 
developed to bridge these interdisciplinary gaps, and novel scientific hypotheses have 
been generated and tested.4,5  This approach, wherein the clinician and the basic scientist 
collaborate, should be beneficial in the investigation of complex disorders, where clinical 
research alone is not sufficient to unravel the entire disorder process.  
     Case studies can be useful in exploring new ways to advance multidisciplinary 
biomedical research. The Complex Regional Pain Syndrome (CRPS) is an example 
of a complex disorder from which the etiology and pathogenesis remain unelucidated 
for a considerable part, despite intensive research in the medical field. For this reason 
CRPS was chosen as a case study on how text mining techniques could be used in 
multidisciplinary biomedical focused research. The results should not be regarded as 
answers to the long unsolved questions regarding CRPS, but rather as hypothetically new 
insights in the molecular mechanisms underlying the disorder. The main purpose of this 
exercise was to assess the benefit of a new approach on hypothesis discovery, based on 
the use of text mining tools by a multidisciplinary team of researchers.
      A brief introduction will be provided on the disorder CRPS in the next section, 
including a short description of the current theories about its pathogenesis.
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The Complex Regional Pain Syndrome
CRPS is a painful syndrome affecting one or more extremities of the body, marked by a 
wide variety of symptoms. The most prominent feature is pain, including spontaneous 
pain, allodynia, hyperpathia, and hyperalgesia. Additionally, the affected extremity can 
display changes in color and/or temperature (vasomotor disturbances), edema, alterations 
in transpiration, hair and nail growth (sudomotor disturbances), and muscular atrophy 
and/or dysfunction (motortrophic disturbances).6,7 It is usually described after a specific 
initiating event, in most cases a trauma or an operation, but sporadically it is observed 
after a stroke, myocardial infarction, infection or even without an obvious inciting event 
in a rarity of the cases.8 The course of the disorder varies from patient to patient, but 
often ends in diminished function of the affected limb which impacts the quality of life 
of the patient.  In rare cases, the disorder progresses to the point where amputation is 
necessary. 
     The pathogenesis of CRPS evolves from disturbances in both the peripheral nervous 
system (PNS) and the central nervous system (CNS) (figure 1). Regarding the initial 
phase of the disorder, recently the interest has increased towards the role of inflammatory 
responses. Inflammatory signs such as swelling, redness, warmth and pain are common 
features in the early stage of CRPS. Classic inflammation is marked by the presence of 
proinflammatory cytokines and in CRPS a local increase of the cytokines TNFα, IL-6 and 
tryptase (a product of mast cell degranulation) was observed in blister fluid derived from 
the affected extremity. 9,10 IL-1 and IL-6 were also found to be increased in spinal fluid.11 
Additional to classic inflammation, a process called neurogenic inflammation has been 
demonstrated in CRPS.12-16 Neurogenic inflammation resembles classic inflammation, 
but it is initiated by neuropeptides instead of lymphocytes and cytokines.17  Those 
neuropeptides include Substance P (SP), Calcitonin Gene Related Protein (CGRP), 
neuropeptide Y (NPY), Bradykinin (BK) and Vasoactive Intestinal Protein (VIP). 
Important modulators of neurogenic inflammation are Neutral Endopeptidase (NEP) and 
Angiotensin Converting Enzyme (ACE).18 
     Endothelial dysfunction, hypoxic changes, and free radical damage have also  been 
suggested as important processes in the pathogenesis of CRPS.19-23  Ischemia, together 
with inflammation, can result in the formation of free radicals, lactate acidosis and 
altered nitric oxide (NO) synthesis.  The NO metabolism in its turn has an effect on 
the microcirculation and thus can influence peripheral oxygen supply.24 An impaired 
microcirculation might underlie a cold extremity that is observed in some cases of 
CRPS. 
     In time, the peripheral alterations give rise to disturbances at the level of the CNS, and 
the clinical picture of CRPS evolves more towards that of a neuropathic pain syndrome. 
The mechanisms behind the development of neuropathic pain have been investigated 
extensively in animal models.25,26 The pathogenesis of neuropathic pain is marked by 
a phenomenon called neural plasticity, which is described by Woolf and Salter as the 
capacity of central and peripheral neurons to change their function, chemical profile, 
and their structure in reaction to activation of peripheral afferent nerve endings.27 This 
conducts towards a state of hyperexcitability of the peripheral C- and A-fiber transducers, 
and of the neurons in the dorsal root ganglia (DRG) of the CNS, referred to as peripheral 
and central sensitization respectively. Sensitization results in a painful response to 
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a normally not painful stimulus, leading to features as allodynia and hyperalgesia. A 
prominent factor in the evolvement of sensitization is the interaction between glutamate 
and the N-methyl-D-aspartate (NMDA) receptor, from which functional status Mg2+ is 
a modulator27. Following central sensitization, alterations at the supraspinal level might 
evolve, resulting in an altered sensory mapping in the cerebral cortex. This pays an 
additional contribution to the sensational disturbances in chronic CRPS.28
     Dysregulation of the sympathetic nerve system was classically supposed a main 
feature of CRPS. This was based on the observation that pain relief could be obtained 
by performing a sympathectomy, although only in a subset of CRPS patients. Vasomotor 
disturbances (warm or cold limb)29 and sympathetically maintained pain (SMP)30-33 are 
features that have been ascribed to sympathetic dysregulation. The painful responses may 
result from the expression of α-adrenoreceptors on sensory fibers.33 Due to sympathetic 
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Classic Inflammation
primary afferent
SP (NK-1R)
PPE
CGRP (CGRP-R)
Vasodilatation
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Figure 1. The four pathogenic mechanisms in CRPS and their interactions. SP=substance P, 
CGRPS=Calcitonin Gene Related Protein, VIP=Vasoactive Intestinal Protein, NPY=Neuropeptide Y, 
NPY-Y1-R=Neuropeptide Y-Y1 receptor, NEP=Neutral Endopeptidase, ACE=Angiotensin Convert-
ing Enzyme, SMP=Sympathetically Maintained Pain, NO=nitric oxide, iNOS=inducible nitric oxidase, 
ONOO=peroxynitrite, NMDA-R=N-methyl-D-Aspartate receptor, NK1-R=Neurokinin-1 receptor, 
CNS=central nerve system,  PNS=peripheral nerve system.
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sprouting new communication pathways are formed between sympathetic terminals 
and sensory neurons34. Additionally, the α-adrenoreceptors might have developed a 
hypersensitivity for normal stimulation by cathecholamines.29 
     The authors have decided in this paper to focus mainly on the peripheral processes in the 
initial phase of CRPS. The first reason for this is that it is very feasible that the neuropathic 
pain component of CRPS does not form the initial pathogenesis of the disorder, but that 
it is preceded and sustained by the presence of the peripheral inflammatory and hypoxic 
reactions in the affected extremity.34 The second reason is that, until now, biomolecular 
research on CRPS in humans and animals concerned mostly the peripheral inflammatory 
aspect of the disorder.  Sensitization and neuronal plasticity have been studied broadly in 
models for neuropathic pain in general. However, they have never been demonstrated in 
models for CRPS in particular, although is it highly reasonable to assume that they occur 
in CRPS in a similar manner.
Methods
The Infobiomed Network of Excellence is organized into various work packages 
with different aims. The aim of the so called “pilot applications” is to analyse the 
impact of biomedical informatics in specific fields (Pharmainformatics, Genomics 
and Microbiology, Genomics and Chronic Inflammation, and Genomics and Cancer). 
The team of researchers behind the study outlined in this paper was part of the pilot 
application Pharmainformatics, which aims at assessing the mutual impact of BMI and 
pharmaceutical research. Research in this area focuses on establishing the information 
continuum pathology – pathway – target – ligand.  
     The pathogenesis of CRPS was one of the subjects that were chosen for a case 
study.  The purpose was to investigate how to gain further insight into pathogenesis 
behind a complex disease and to identify possible pathways, targets and ligands for 
improving pharmacological therapy, using a multidisciplinary approach. The team of 
researchers had varying backgrounds mirroring the biomedical informatics research 
area (one physician with domain expertise on CRPS that was asked to participate in the 
work package only for this specific case study; one bioinformatician; one specialist in 
text mining). No formal leader was chosen for the group. All researches provided input 
based on their background and a plan of action took form by mutual agreement. The 
physician provided biological and medical concepts that are possibly linked to CRPS, the 
bioinformatician provided the appropriate software tool to be used in the study, and the 
text mining expert provided knowledge on how to best perform the extensive literature 
analysis. The analysis took place in September 2004, at the premises of AstraZeneca in 
Molndal, Sweden. 
     The selection of the CRPS related concepts was based on current (but not always 
objectified) opinions about the pathogenesis and treatment of CRPS and on different 
pathogenic mechanisms described in a selection of articles concerning the pathogenesis 
of CRPS.32,35-38 The focus was on chemical and biochemical identities and mainly, but not 
completely, on the peripheral components of the disorder. The collection of concepts and 
their synonyms can be found in Table 1.
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     The text mining/entity relationship tool PathwayAssisTM (Version 2.5) was used to 
visualize the connections between the CRPS concepts in a network and to search for 
new concepts taking part within these relations. PathwayAssist is a software application 
developed for navigation and analysis of biological pathways, gene regulation networks 
and protein interaction maps. It has been used before in studies to identify genes that are 
involved in autism39 and in regulation of human primordial follicle development.40 The 
application has been described in more detail by Nikitin and colleagues.41 PathwayAssist 
finds connections between concepts, henceforth referred to as ‘nodes’, by searching 
through a database of interactions derived from literature, using the natural language 
processing (NLP) based software MedScan. MedScan performs a grammatical and 
semantic analysis of the complete Medline database of life sciences and biomedical 
bibliographic information. The MedScan software has been described  by Novichkova 
et al.42 and more recently by Daraselia et al.43 A brief overview of the technology is 
presented below.
When parsing a Medline document, a semantic interpreter of the NLP component 
transforms the syntactic structure into a semantic structure. The syntactic structure and 
main constituents (surrounded by square brackets) of a sentence can be exemplified 
using the general sentence Protein X inhibits protein Y, which has the syntactic structure 
of [[Protein X
[N]][NP] [inhibits[V] Protein Y[N]][VP]][S]. The phrasal category is shown 
immediately following each constituent (NP designates noun phrase, N designates noun, 
V designates verb, VP designates verbal phrase, S designates sentence). The syntactic 
structure will be transformed to a semantic frame of inhibition that has an ‘agent’ protein 
X and a ‘patient’ protein Y. The output of the semantic parse is the input for an ontological 
analysis that was developed by Daraselia et al.43 In this an ‘entity’ is represented either as 
a protein, a cellular object, a cellular process, or a small molecule and ‘controls’ describe 
functional relationships between these entities. Relations between entities are stored in 
a relational database. These relations can be displayed and explored through a graphical 
interface. 
     The list of concepts provided by the physician was regarded as current knowledge 
about CRPS (table 1) and was used as input for PathwayAssist. PathwayAssist views 
these concepts as nodes. The option “find only direct interactions between selected 
nodes” was used to search the underlying interaction database for direct connections 
between the CRPS concepts. Based on these connections, the system builds a network. 
This procedure would only detect direct relationships between two nodes; mechanisms 
that require a new intermediate node (a node not present in the original list of nodes 
that was provided as input) would not be detected. Such intermediate nodes, however, 
might represent knowledge that the scientists entering the concepts were not aware of at 
the time of input (such as factors acting as enhancers for a critical step in a pathway, or 
co-factors needed for a transcription factor to bind to DNA). Therefore, an option was 
used that incorporates a new node in the network if that node is the intermediate node 
that allows the creation of a triplet connecting two input nodes. When a new node is 
added to the network, all links to and from that node to all other nodes in the network 
are displayed. 
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Results 
The resulting network based on the imported CRPS concepts is shown in Figure 2. 
In addition to the original concepts that were provided as input nodes, six new nodes 
have been added by the algorithm (nodes that were not in the original list of concepts 
known to be associated with CRPS). Of these six new nodes, the node NFκB was the one 
connecting to most of the original CRPS concepts and was pivotal in the final network. 
NFκB appeared as new node because it was part of a triple connection between mannitol 
and TNFα with the actual sentence being ‘High glucose or mannitol also enhanced 
TNFalpha-stimulated NF-kappaB activity’: TNFα stimulates NFκB, and mannitol acts as 
an enhancer of this process. The sentence describing this particular relationship between 
mannitol, TNFα, and NFκB had been parsed from the article by Hattori et al.44 
     The transcription factor NFκB is known as a mediator in many different physiological 
processes.45,46 It is also related to 7% of all the nodes that exist in PathwayAssist, which 
mirrors its versatility. However, even though NFκB has a very high connectivity in 
PathwayAssist and is involved in many physiological processes, the calculated p-value 
Node type Node name
Complex Neuronal acetylcholine receptor
Functional Class NMDA receptor (N-methyl-D-aspartate receptor)
Protein CALCA  (calcitonin/calcitonin-related polypeptide, alpha), IL1A 
(interleukin 1 alpha), IL6 (interleukin 6), NGFB (nerve growth factor, 
beta polypeptide), NGFG (nerve growth factor, gamma subunit), NPY 
(neuropeptide Y), PTGS1 (prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and cyclooxygenase)), TAC1 (tachykinin, 
precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, 
neuromedin L, neurokinin), TACR1 (tachykinin receptor 1),  TNF 
(tumor necrosis factor), BDKRB2 (bradykinin receptor B2), PTGS2 
(prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase)), NTRK1 (neurotrophic tyrosine kinase, receptor, 
type 1), TRPV1 (transient receptor potential cation channel, subfamily 
V, member 1), Ngfa (nerve growth factor, alpha), BDK (Bradykinin), VIP 
(vasoactive intestinal peptide)
Small Molecule glutamate, DMSO (Dimethyl sulfoxide), PGE2 (Prostaglandin E2), 
magnesium, noradrenaline, capsaicin, glucocorticoid, mannitol, 
pentoxifylline, naproxen, bisphosphonate, verapamil, morphine, 
ketamine, amitriptyline, clonidine, carbamazepine, nortriptyline, lidocaine, 
GABA (gamma-aminobutyric acid), ketanserin, infliximab, gabapentin, 
amantadine, lioresal, benzodiazepine, Baclofen, N-acetyl-cystein
Table 1. Concepts used when building the CRPS network in PathwayAssist (description in paren-
thesis).
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Figure 2. Resulting network of CRPS concepts from PathwayAssist. The PathwayAssist network 
shows that NFκB is connected with many concepts that are related to CRPS. Red circles denote 
proteins, red hexagons denote protein complexes, green circles denote small molecules, orange 
circles denote enzymes, and orange hexagons denote protein functional classes. Concepts for which 
PathwayAssist could not find a link to any other of the concepts in the network are shown in the up-
per left.
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using a one-tailed Chi-square test with Yates’s correction was highly statistically 
significant (p-value less than 0.0001). This demonstrates the significance of NFκB in the 
CRPS network in comparison to the whole PathwayAssist database of interactions.
     To investigate the possibility that NFκB appeared in the network simply because it is 
a highly connected node in the database, the in PathwayAssist equally highly connected 
node “protein tumor protein p53” was manually included into the network and tested for 
its connectivity with the CRPS concepts. The p-value was found to be equally significant 
as for NFκB (p-value less than 0.0001). The reason for TP53 not appearing in the 
expanded CRPS network is related to on the algorithm that was chosen to find new nodes. 
In order for a new node to be incorporated into the network by PathwayAssist it has to 
be part of a triplet that connects two input nodes. This was the case for NFκB but not for 
TP53. There are also other algorithms available in PathwayAssist for incorporating new 
nodes in a network. These include an algorithm to find the shortest paths between the 
nodes in the network, an algorithm to find common targets, an algorithm to find common 
regulators, and also an option to expand the network by finding all nodes in the database 
that are connected to the nodes in the network. The shortest paths algorithm yielded 
20 new nodes, the common target algorithm 46 new nodes and the common regulators 
algorithm yielded 38 new nodes. The option of finding all nodes connected to the nodes 
in the CRPS network (the expanded network algorithm) yielded 3872 nodes and it was 
considered to be practically infeasible to analyze all these nodes separately for their 
connectivity in the CRPS network. Neither NFκB nor TP53 were found by using any of 
the other algorithms except for the expand network algorithm. Thus, it might be possible 
that NFκB emerged in the CRPS network simply because it is a highly connected node 
in the whole PathwayAssist database. However, NFκB was still connected to more nodes 
in the CRPS network than the reference node TP53. Therefore it was still regarded as a 
candidate for a key role in the pathogenesis of CRPS
     As far as the authors of this paper know, NFκB has never before been mentioned 
together with CRPS. For this reason NFκB was considered interesting enough to be 
explored further by manual research of literature, using advanced PubMed queries 
concerning the relation between NFκB and the CRPS concepts. Based on the results of 
this literature research, and on discussions about this topic within the Pharmainformatics 
group of the Infobiomed network of excellence, theories for the involvement of NFκB 
in the described pathogenic mechanisms in CRPS were developed.  A summary of these 
theories is described table 2 and further explained below.
Role of NFκB in CRPS related mechanisms
NFκB involvement in neurogenic and classic inflammation
NFκB has been demonstrated to be an essential transcription factor in the mediation of 
the effects of neuropeptides that are also involved in CRPS: 1. SP induced expression of 
IL-6 and TNFα (cytokines that are locally increased in CRPS) is regulated by NFκB47,48; 
2. glutamate, released in the dorsal horn together with SP induces neuronal apoptosis 
through NFκB induction49; 3. expression of CGRP (an important neuropeptide in CRPS) 
is induced by an NFκB mediated pathway, initiated by IL-1β stimulation11; 4. bradykinin 
activates NFκB and cyclooxygenase-2 via more than one pathway50,51; 5. VIP inhibits 
155
Applied Information Retrieval: New Hypotheses on Complex Regional Pain Syndrome     4.1
Table 2. Key concepts and their relations to CRPS and NFκB.
Key concept Relation to CRPS Relation to NFκB
       
Substance P Locally elevated upon electrical C-fiber stimulation 
Induces NFκB mediated release of IL-6 and 
TNFα 
 
       
CGRP Systemically and locally  elevated Suppresses NFκB activity in thymic cells  
       
Bradykinin Systemically elevated Activates NFκB  
       
VIP Systemically elevated Locally decreased 
Inhibits NFκB mediated chemokine production 
by macrophages. Prevents NFκB binding to 
promoter site for NO
 
       
Neuropeptide Y Systemically elevated NPY-Y1-R expression is regulated by NFκB  
       
NEP Speculated to be decreased No relation with NFκB described  
       
ACE Speculated to be decreasedPolymorphism in CRPS patients Reduces NFκB activity
 
       
TNFα Locally increased Induced by NFκB,  Activates NFκB  
       
IL-1β Locally increased Stimulates NFκB mediated apoptosis in sympathetic neurons 
 
       
IL-6 Locally increased Induced by NFκB  
       
Tryptase Locally increased Induced by NFκB  
       
Free radicals Signs of free radical damage Second messenger in NFκB activity  
       
Nitric oxide Elevated after monocyte stimulation 
NO reduces NFκB activity, but ONOO induces 
NFκB 
 
       
Protons (acidosis) Lactate increased in skin Influences NFκB activity    
       
α-receptor Up-regulated in analgesic skin Pro-inflammatory responses mediated through NFκB 
 
       
Sympathetic neuron Speculated to be damaged in CRPS NFκB  mediates Il-1β induced apoptosis 
 
       
NMDA receptor Role in development of central sensitization 
NFκB  is involved in the up-regulation of some 
types of NMDA receptors 
 
       
CGRP=calcitonin gene related protein, VIP=vasoactive intestinal protein, NEP=neutral 
endopeptidase, ACE=angiotensin converting enzyme, TNF=tumor necrosis factor, IL=interleukine, 
NMDA=N-methyl-D-aspartate,  NO=nitric oxide, NPY-R=neuropeptide Y receptor.
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NFκB mediated chemokine production by macrophages52 and it also prevents NFκB 
from binding to the promotor site for nitric oxide synthethase iNOS, thereby affecting 
the microcirculation in CRPS53; 6. for the NPY receptor, potential NFκB binding sites 
have been found in the promoter regions, suggesting a role for NFκB in the expressional 
regulation of this receptor54; 7. the important inflammatory modulator ACE reduces 
NFκB activity.55 The overall effect appears to be that NFκB activity is upregulated by 
the neuropeptides involved in CRPS, resulting in a pro-inflammatory response mediated 
through NFκB.
NFκB involvement in hypoxic changes 
NFκB activity is inhibited by NO.44,56,57 However, peroxynitrite (ONOO), which is formed 
from NO after reaction with radical oxygen intermittents, sustains NFκB activity.44 NFκB 
also is involved in the expression of inducible nitric oxide synthethase (iNOS) induced 
by pro-inflammatory cytokines TNFα and IL1-β , which are locally elevated in CRPS.9,58 
Additionally, NFκB activity is involved in and affected by free radical formation49,59,60 
and acidosis.21,61,62 
NFкB and neuropathic pain
Several animal models demonstrate the role of NFκB in pain induction and pain 
maintenance in the CNS. For example, NFκB is involved in the upregulation of some 
types of NMDA receptors which are important mediators in the development of central 
sensitization.63 Additionally, NFκB in the CNS mediates IL-1 induced COX-2 up-
regulation and prodynorphin expression.64,65 The derived compound dynorphin is an 
endogenous opiate that causes hyperalgesia and allodynia in mice. In line with this, 
intrathecal (in the central spinal fluid) or neuronal injected NFκB inhibitors attenuate 
proinflammatory cytokine mediated pain in rats.66,67
NFκB involvement in sympathetic dysregulation
Pro-inflammatory responses induced by the catecholamines derived from the sympathetic 
nervous system, which might be dysregulated in CRPS, are mediated by NFκB.68-70 
Additionally, NFκB up-regulates directly the expression of the β-adrenoreceptor on 
immune cells.71 Moreover, the expression of the α-receptor might be regulated by NFκB 
in an indirect way which involves Il-1β mediated apoptosis of sympathetic neurons, 
leading to up-regulation and/or hypersensitivity of the peripheral α-receptors expressed 
on blood vessels, immune cells, and nociceptive primary afferents.72
Discussion 
This paper describes how a multidisciplinary team of investigators applied advanced 
information retrieval methods, in the form of a text mining/entity relationship tool, with 
the purpose of discovering new hypotheses concerning the pathogenesis of a complex 
disorder, exemplified here by CRPS. The exercise should be regarded as a “journey” to 
discover what benefit could emerge from this kind of collaboration between bioinformatics 
experts and clinical experts. The purpose was neither to assess the specificity of the used 
methodology, nor to discover complete underlying biochemical pathways.
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     The text mining/entity relationship tool PathwayAssist provided a new concept, 
named NFκB, which is related to a majority of the concepts described to be involved in 
CRPS. After manual literature search, NFκB appeared to be a link between the various, 
previously described pathogenic mechanisms and appeared to serve as a mediating 
component in their connections. 
Validity of the method
The MedScan system has been manually validated by the developers through random 
extraction and analysis of direct physical protein-protein interactions from MEDLINE.43 
From the interactions extracted by MedScan, 91% was correct (precision). Most errors 
were attributed to the extracted functional interference between proteins rather than 
physical interaction. Coverage (recall), however, was low: 21%. This is primarily due 
to the low coverage rate of the NLP component (34%). The concept network on CRPS 
(figure 2) was validated manually by the authors of this paper by checking all relations 
leading to or from NFκB. Out of 38 relations, 34 were correct and 4 incorrect.  
     Naturally, it would be helpful if some sort of independent relevance score could be 
provided for new hypotheses generated by the method used in this report. In this view, 
a p-value was calculated for the new node NFκB in the network using a one-tailed Chi-
square test with Yates’s correction, comparing its node connectivity in the PathwayAssist 
database to its node connectivity in the CRPS concepts network. In addition, the protein 
TP53 was chosen as a reference case because of the equally high connectivity in the 
PathwayAssist database compared to NFκB. Unfortunately, TP53 was found to be 
equally significant in the CRPS network as NFκB. However, NFκB was connected to 
more concepts in the original CRPS network than TP53. 
     An automatic network analysis approach, where a variety of nodes (for example all 
highly connected proteins in the PathwayAssist database, all nodes generated by the 
expanded network algorithm, or simply all nodes in the PathwayAssist database) would 
be tested for positive association to a subnetwork of predefined disease-specific nodes, 
would be valuable for both hypotheses generation and testing. Unfortunately, there is no 
such algorithm available in the PathwayAssist version used by the authors of this paper. 
Furthermore, the necessary data required for carrying out these types of tests outside the 
framework of the tool (specific connectivity information for each node in the database, i.e. 
which other nodes it is connected to) are not provided by PathwayAssist. The assessment 
of the connectivity to the CRPS network for NFκB and TP53 was performed manually, 
an activity that is very time consuming and not defendable for a larger number of nodes. 
Despite the limitations regarding the assessment of the specificity of the results, a new 
node found by one of the network gap analysis algorithms provided by PathwayAssist, 
which was significantly related to the CRPS network, was considered important enough 
for further investigation.  
     One should bear in mind that results from text mining exercises as described in 
this paper are far from the solution to the medical problem or the complete answer to 
outstanding questions. The current tools in the biomedical domain are not capable of 
delivering clear and already assessed hypotheses. However, in this case, the results of a 
simple knowledge gap analysis provided a new idea that, after further manual exploration 
in literature, appeared very plausible and worthwhile investigating in biological 
experiments and epidemiological studies. 
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     The generalizability of this method of hypothesis discovery needs to be assessed by 
repeating the exercise for other complex medical conditions. However, it would be an 
exhaustive and extremely time consuming task to repeat the exercise for a large group of 
complex disorders. This is a well-known problem in the evaluation of text mining tools 
in general.73 
Testing the new hypothesis
New biological data are needed to verify the in silico derived hypothesis concerning 
the involvement of NFκB in the pathogenesis of CRPS. These data could be generated 
through animal models, clinical studies, and epidemiological studies. A rat model for 
CRPS has been developed by Coderre and colleagues.74 They named it the chronic post 
ischemia pain (CPIP) model, since CRPS like symptoms are provoked by ischemia and 
reperfusion of the hindpaw by binding it temporarily with a tourniquet. This model may 
prove useful to investigate the role of NFκB in the early development of CRPS, for 
example by measuring the transcription of NFκB in the affected tissue. Additionally, 
in this model the effect of administration of NFκB inhibitors could be studied. In the 
past, NFκB knockout and transgenic animal models have been extensively used to study 
the NFκB pathway.75 An increased inflammatory response coupled with an increased 
susceptibility to opportunistic infections has been recorded76,77, and a decrease of the 
electroacupuncture-induced analgesic effects has also been shown.78 A failure to induce 
CRPS like symptoms in NFκB knock mice would support the hypothesis of a NFκB as 
a crucial factor in CRPS.
     Clinical and epidemiological studies to test the hypothesis could involve the 
investigation of determinants of altered NFκB activity and the comparison in this view 
between CRPS cases and healthy controls. For example it could be tested whether other 
NFκB related disorders (asthma, autoimmune disorders or atherosclerosis) co-occur 
with CRPS. Viral infections are known to upregulate NFκB activity. Thus the time 
relation between CRPS and the occurrence of a viral infection may also be worthwhile 
investigating. Finally, one could search for features from a genetic origin. The increased 
prevalence of an ACE polymorphism in CRPS patients was found in a small study.79 
Since ACE is also an inhibitor of NFκB activity, further investigations regarding this 
polymorphism might be of interest. Certain drugs affect (perhaps unintentionally) 
the NFκB pathway and could influence the development of CRPS (see also section 
Targeting the NFκB pathway). Currently, according to the recently developed Dutch 
evidence based Guideline Complex Regional Pain Syndrome type 180, nine drugs have 
been proven beneficial in the prevention or treatment of CRPS, including ketamine81, 
gabapentine82, DMSO crème83, N-acetylcysteine83, corticosteroids84, bisfosfonates85, 
calcium antagonists86, ketanserine87, and vitamin C.88 Interestingly, 126 small molecules 
are listed as NFκB inhibitors in PathwayAssist, and 5 of these overlap with the list of 
drugs proven beneficial for preventing or treating CRPS (ketamine89, DMSO cream90, 
N-acetylcysteine91, corticosteroids92, and calcium antagonists93).
     A Dutch cohort of CRPS patients was identified in the Integrated Primary Care Database 
(IPCI), a database that makes electronic patient records used in routine care available to 
investigators.94  This cohort has been used before in research on CRPS95 and will be used 
for further testing of these hypotheses within the framework of Infobiomed. 
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Clinical relevance
NFκB is a transcription factor that is known to be involved in many processes, but its 
function is best described in inflammation.45 In the recent past NFκB has been discovered 
as an important mediator in diseases due to chronic and exaggerated inflammatory 
responses, including sepsis, asthma, rheumatic disorders, inflammatory bowel disease, 
and psoriasis. However, in the current available literature NFκB has never before 
been mentioned in association with CRPS. Therefore, this relation is an interesting 
new result derived from the text mining exercise. Especially remarkable is that, in the 
generated network, NFκB is not only linked with the inflammatory concepts related in 
CRPS, but also to the non-inflammatory concepts in CRPS, such as neuropeptides and 
catecholamines. 
     Realizing the possible central role for the NFκB pathway in the mechanisms underlying 
CRPS (or in the stress response caused by CRPS), unanswered questions concerning the 
disorder can be reviewed from a new point of view. For instance, when placing NFκB 
in the centre of the pathogenic process, the wide variety of precipitating events could 
be explained by the observation that all pathogenic mechanisms in CRPS are related 
to each other. This relation suggests that an event that specifically triggers one of the 
four mechanisms induces the entire complex pathogenic process (figure 3A-D). For each 
mechanism separately the potential triggers are limited, but for the four mechanisms 
together the possibilities are numerous. With the addition of NFκB, the biochemical 
picture underlying CRPS becomes one in which several processes can initiate the disorder 
and in which NFκB can play a key role in its propagation. 
     Assuming the central unifying role of NFκB in the pathogenesis of CRPS, independent 
whether NFκB is the final molecule in the pathway or not, new targets for drug therapy 
could be provided. Current therapy in CRPS is aimed at targeting separate mechanisms. 
However, targeting one mechanism in CRPS is not enough, as made apparent by the 
limited success rate for the majority of treatments. Based on the new hypothesis, targeting 
the NFκB pathway may provide a way to target all the underlying mechanisms at once. 
Thereby, progression of the disorder may be more effective, since it will be prevented 
at more than one level. Independent from the inciting event or principle disturbed 
mechanism, NFκB pathway inhibitors might remove the ‘engine’ that keeps the process 
running.
     Targeting NFκB as a therapy in sepsis, inflammatory diseases and neuronal diseases 
is proposed by several authors.46,49,96,97 It is suggested to be very promising for a wide 
variety of patients, but due to the involvement of NFκB in a wide variety of physiological 
processes, there are safety implications. New drugs that target one of the components of 
the NFκB pathway are currently under development. One of these drugs, bortezomib, 
was already launched in the United States in 2003 for the treatment of multiple myeloma. 
Other drugs are in various stages of development (table 3). The NFκB pathway inhibitors 
are designed for the use in treatment of a variety of disorders, including inflammatory 
diseases, autoimmune diseases, atopic disorders, arteriosclerosis and malignancies. None 
of the drugs currently under development is mentioned for treatment of CRPS. When 
these drugs have proven to be safe, the therapeutic effect of NFκB pathway inhibitors 
could be studied in CRPS patients.
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Conclusion
Computer-assisted literature analysis to support the generation of novel and testable 
hypotheses has previously been proven useful.4,5 This study builds upon this research, 
and extends it by bringing together researchers and clinicians with a wide variety of 
backgrounds. An experimental exercise was performed in which a text-mining/entity 
relationship tool has been applied to systematically synthesize the knowledge in existing 
literature about a complex disorder, exemplified by CRPS. Within the created literature 
network, a simple knowledge gap analysis was performed, using node connectivity. This 
approach was essential in formulating the hypothesis that NFκB might be a key player 
molecule in the pathogenesis of CRPS. This example of multidisciplinary research 
illustrates how the collaborative efforts of investigators from different fields of expertise 
can demonstrate new directions for future biological and epidemiological research on a 
complex disease. 
Development status No. of drugs
Discovery Research 22
Clinical (unspecified) 1
Phase I clinical trials 4
Phase II clinical trials 4
Phase III clinical trials 0
Pre-registered 0
Registered 0
Launched 1 (bortezomib)
Research tools 1
Suspended 0
Withdrawn 0
No development reported 4
Discontinued 4
Table 3. Current development status of NFκB pathway inhibitors. (Investigational Drugs DataBase, 
Nov 15 2005 (107), advanced search by activity field on Nuclear factor kappa B inhibitor).
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Abstract
Introduction: NFκB is involved in several pathogenic mechanisms that are 
believed to underlie the complex regional pain syndrome (CRPS), including 
ischemia/reperfusion (IR) injury, inflammation and sensitization. Chronic post-
ischemia pain (CPIP) has been developed as an animal model that mimics the 
symptoms of CRPS-I. The possible involvement of NFκB in CRPS-I was studied 
in CPIP rats. 
Methods: Under sodium pentobarbital anesthesia a tourniquet was placed around 
the rat left ankle joint to produce 3 hrs ischemia, followed by rapid reperfusion. 
Tissue from muscle and spinal cord was obtained at 2 hrs, 48 hrs and 7 days 
after IR injury. NFκB was measured in nuclear extracts using ELISA. At 48 
hrs post-reperfusion, rats were tested for mechanical (von Frey filaments) and 
cold allodynia (acetone drop test) before and after systemic (10, 30 or 100 mg/
kg), intrathecal or intraplantar (both 250 μg per rat) administration of the NFκB 
inhibitor pyrrolidine dithiocarbamate (PDTC). 
Results: At 2 and 48 hrs after IR injury, NFκB was elevated in muscle and spinal 
cord of CPIP rats compared to sham rats. At 7 days NFκB levels were normalized 
in muscle, but were still elevated in spinal cord tissue. Systemic PDTC treatment 
relieved mechanical and cold allodynia in a dose-dependent manner, lasting for 
at least three hrs. Also intrathecal, but not intraplantar, administration relieved 
mechanical allodynia. 
Discussion: The results suggest that muscle and spinal NFκB plays a role in the 
pathogenesis of CRPS. Since current treatments for CRPS are often ineffective, 
NFκB might make an interesting new target for therapy in CRPS patients. 
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Introduction
Complex regional pain syndrome (CRPS) is considered to evolve from several 
pathological mechanisms, including oxidative stress1,2, classic3-6 and neurogenic3,4 
inflammation, and autonomic and sensory nerve system alterations.7,8 A previous described 
automated analysis of literature has revealed that the transcription factor nuclear factor 
kappa B (NFκB) is involved in all these disease mechanisms.9 For example, affected 
limbs of human CRPS patients show signs of chronic ischemia1,10, which can induce 
NFκB activation, mediated by the formation of reactive oxygen species (ROS) and 
peroxinitrite.11,12 Inflammatory mediators, including tumor necrosis factor alpha (TNFα), 
interleukin-1 (IL-1) and IL-6 have been demonstrated in blister or spinal cord fluid of 
CRPS patients5,13, and can activate or are activated themselves by NFκB.14-16 Moreover, 
NFκB interacts with neuropeptides that have been found abnormally expressed during 
CRPS4,17, such as calcitonin gene related protein (CGRP)18 and substance P (SP).19 
Finally, animal studies have revealed that NFκB is involved in nociceptive sensitization 
through up-regulation of glutamate receptors in dorsal root ganglion cells20, and through 
interactions with cytokines.21  
     NFκB resides in the cytosol of many different cell types, and can be activated by many 
triggers, including ultraviolet radiation, free radicals, cytokines and products of bacterial 
and viral infections.22 Upon activation, inhibitory kappa B (IκB) protein is cleaved from 
the NFκB complex, which subsequently forms dimers that are capable of passing through 
the nuclear membrane. In the nucleus, NFκB promotes the transcription of a wide variety 
of genes. NFκB has been attracting considerable scientific attention over the past years 
as a key factor in inflammation, apoptosis, and neuronal-glial interactions.23 Excessive 
NFκB activity has been attributed to the pathogenesis of several chronic inflammatory 
disorders and oncological diseases.24 Since 2005, the NFκB pathway inhibitor bortezomib 
(Veldane®) has been applied successfully in the therapy of multiple myeloma and other 
malignancies.25 
     Pyrolidine dithiocarbamate (PDTC) is a chemical with metal chelating and antioxidant 
properties, which inhibits NFκB activity by blocking the phosphorylation of IκB.26,27 
Systemically administrated PDTC and other dithiocarbamates have been shown to be 
protective and therapeutic in animal models for ischemia and reperfusion (IR) injury28, 
acute inflammation29 and neuropathic pain.30 The aim of the present study was to investigate 
the potential involvement of NFκB in the pathogenesis of CRPS. NFκB levels and the 
effect of NFκB inhibition by PDTC were studied in rats with chronic post-ischemia 
pain (CPIP). These rats develop CRPS-like symptoms, such as edema, hyperemia and 
allodynia, after IR injury of the hind paw, without evident nerve damage.31 
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Methods
Study design
NFκB levels were measured in muscle and spinal cord tissue of CPIP animals and 
compared to sham animals at 2 hrs (CPIP: N = 15, sham: N = 9), 48 hrs (CPIP: N = 15, 
sham: N = 9 - 10) and 7 days (CPIP: N = 6, Sham: N = 7) after IR injury. 
     The effect of NFκB inhibition by systemic PDTC administration on allodynia was 
studied in CPIP rats using four treatment groups (saline and 10, 30, and 100 mg/kg of 
PDTC; 10 rats per group) and in sham rats using two treatment groups (saline and 100 
mg/kg of PDTC; 10 rats per group). PDTC/saline was administered intraperitoneally 
(i.p.) 48 hrs after IR injury. Animals were tested for mechanical and cold allodynia in the 
ipsilateral hind paw just before treatment, and at 30, 60, 90, 120 and 180 minutes after 
treatment. 
     Additionally, to investigate the site of PDTC effects, intrathecal or intraplantar 
administrations (250 μg per rat) were performed in two additional groups of animals 
(N = 10 per group) and compared to saline treatment using both administration routes 
(N = 10 per group). Intrathecal injections (20 μl volume) were performed by L6 lumbar 
puncture under brief anesthesia with isofluorane, whereby intrathecal delivery was 
confirmed by observing an injection induced tail-flick.32 Intraplantar injections (50 μl 
volume) were performed in the ipsilateral foot of awake animals. Mechanical allodynia 
was measured in both the ipsi- and the contralateral hindpaw at 30 and 60 minutes after 
PDTC administration.
     All treatment and testing procedures were performed in a blinded manner by a single 
experimenter per test. PDTC was obtained from Sigma Aldrich and was freshly dissolved 
daily in saline.
Animals
Male Long Evans rats (275-300 g, Charles River, Quebec) arrived at least 5 days before 
the start of the experiments. They were kept under a 12 hrs/12 hrs light-dark cycle (lights 
on at 7:00 h), with free access to food and water. All experiments were performed during 
the light cycle. Methods were approved by the Animal Care Committee at the McGill 
University, and conformed to the ethical guidelines of the Canadian Council on Animal 
Care. 
Chronic post-ischemia pain (CPIP)
CPIP was induced by ischemia and reperfusion (IR) injury of the left hind paw as described 
by Coderre and colleagues.31 Briefly, animals were anesthetized over a three hour period 
with a bolus (55 mg/kg, i.p.) and chronic i.p. infusion of sodium pentobarbital for 2 hrs 
(27.5 mg/kg/h). After induction of anesthesia, a Nitrile 70 Durometer O-ring (O-rings 
West, Seattle, WA) with 7/32” internal diameter was placed around the rat’s left ankle 
joint. After three hrs the O-ring was cut, allowing reperfusion of the hind limb. Sham 
animals underwent anesthesia similar to the CPIP animals, but an O-ring was not placed 
around the ankle.
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Tissue sampling and preparation
Animals were euthanized by decapitation under anesthesia with isofluorane. Immediately, 
muscle samples of the superficial plantar layer (one each from the Flexor Hallucis Brevis, 
Flexor Digiti Minimi Brevis and Flexor Digitorium Brevis, each weighting between 
29 and 50 mg) and spinal cord samples at L5-L6 (each weighting 12 to 20 mg) were 
obtained and quickly frozen in isopentane, kept on dry ice, and stored at -80°C until 
processing. Samples were thawed at 4°C and homogenized either mechanically (muscle) 
or by sonification (spinal cord) in 12.0 μl/mg tissue of RIPA buffer containing 50 mM 
Tris-HCl, 150 mM NaCl, 1mM EDTA, 1% Igepal (Sigma, St.Louis, MO), 1% Sodium 
deoxycholate and 0.1% SDS (Ph 7.4), to which was added a 1% protease inhibitor cocktail 
(Sigma, St.Louis, MO). Tissue homogenates were centrifuged at 3,000 g for 10 min, and 
the supernatant was collected and processed for nuclear fraction extraction following the 
recommended procedure of a commercially produced extraction kit (Chemicon Nuclear 
Extraction Kit, Millipore Corp., Billerica, MA). Briefly, after spinning at 250 g for 5 
min, samples were diluted 1/5 (vol/vol) in cytoplasmic lysis buffer and incubated at 
4°C for 20 min. The homogenates were mechanically sheared by repeatedly drawing 
and ejecting each sample through a series of 25 ga, 26 ga and finally 27 ga needles and 
centrifuged at 8,000 g for 20 min at 4°C. Subsequently, the pellets were resuspended in 
nuclear extraction buffer, mechanically disrupted with a 27 ga needle, incubated for 60 
min, and then centrifuged at 16,000 g for 6 min at 4°C, in order to obtain the supernatant 
that contained the nuclear fraction. Nuclear fractions were concentrated by centrifugal 
filtration at 14,000 g for 20 min using cellulose filters with a 30 kDa cut-off (Microcon 
YM-30, Millipore Corp., Billerica, MA). Nuclear fractions remaining after filtration 
were collected and diluted in buffer to a final volume of 100 μl for muscle and 50 μl for 
spinal samples. Total sample protein content was determined by the Bradford method.33 
Nuclear extracts were stored at -80°C until further analysis.
Measurement of NFκB by ELISA
NFκB measurements were performed using a commercially supplied NFκB transcription 
factor binding assay (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s 
suggested protocol. Briefly, duplicate 10 μl samples of nuclear extract were first 
incubated overnight at 4°C in wells pre-coated with a dsDNA sequence corresponding 
to the NFκB consensus motif. After five washes, the samples were incubated overnight 
at 4°C with a rabbit polyclonal antibody to the p50 subunit of NFκB at a final dilution 
of 1:100 (sc-7178, Santa Cruz Biotechnology, Santa Cruz, CA). Subsequently samples 
were incubated for 60 min with an HRP-conjugated goat anti-rabbit secondary antibody 
(Cayman Chemical, Ann Arbor, MI), followed by colorimetric detection (measured as 
absorbance at 450 nm; Versamax, Molecular Devices, Sunnyvale, CA). After background 
subtraction, absorbance measures were referred to a standard curve obtained from a series 
of duplicate wells containing measured amounts of human recombinant p50 (Cayman 
Chemical, AnnArbor, MI) and then converted to an estimate of the quantity of p50/
well, which was normalized by dividing the p50 estimate by the total amount of protein 
measured in the sample.
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Mechanical and cold allodynia
Mechanical allodynia was assessed by measuring the 50% withdrawal response to 
stimulation with von Frey filaments, according to a modified method as described by 
Chaplan and colleagues.34 Briefly, rats were placed in Plexiglas® cages with a wire grid 
bottom. Filaments (Stoelting, Illinois, USA) were applied to the plantar surface of the 
hind paw for approximately five seconds in either ascending or descending strength, 
to determine the filament closest to the threshold of response. CPIP rats that had not 
developed mechanical allodynia at 48 hrs post IR injury (‘non-responders’, 50% 
threshold > 10 g) were excluded from the further measurements of mechanical allodynia 
after PDTC treatment.
Cold allodynia was assessed using a modification of the acetone drop method as described 
by Choi and colleagues.35 A drop of acetone was placed on the plantar surface of the 
foot and the response was measured as the amount of seconds of nociceptive behavior 
observed during the first min after acetone application. Again, non-responders for cold 
allodynia at 48 hrs post IR injury (pain behavior for one second or less) were excluded 
from the further measurements of cold allodynia after PDTC treatment.
Mechanical and cold allodynia were tested in the same animals, whereby mechanical 
allodynia was always tested first. When both sides were tested, the contralateral side was 
tested before the ipsilateral side.
Statistics
     All statistical analyses were performed using the statistical package for social sciences 
(SPSS) version 12.0. Significance was established at p < 0.05. Data were plotted as the 
mean +/- standard error of the mean (SEM).
     NFκB in tissue from the ipsi and contralateral side of CPIP rats was compared to sham 
rats using a Mann-Whitney U test. Ipsi- versus contralateral differences within rats were 
compared using a Wilcoxon signed rank test.  
     Baseline mechanical and cold allodynia test results were compared with one-way 
ANOVA. Post-treatment differences between groups were analyzed using repeated 
measures ANOVA with a Greenhous-Geisser correction for sphericity. In post hoc 
analyses, each treatment group was compared to the saline control group applying a 
Bonferoni correction. In CPIP rats only, decreases in cold allodynia relative (percentage) 
to pre-treatment values were calculated and compared to the saline control group. For 
mechanical allodynia, a delta area under the curve (ΔAUC) relative to pre-treatment 
values was calculated over the period of observation and compared with the saline group 
using one-way ANOVA followed by a post hoc LSD test. Pre- and post-treatment values 
within one treatment group were compared using a Wilcoxon signed rank test. 
Results
NFκB in muscle and spinal cord
The results of NFκB measurements in muscle and spinal cord are depicted in figure 1. 
Because in sham rats NFκB levels at both sides were similar (p = 0.162 for muscle and 
p = 0.694 for spinal cord), the right and left side measures of sham rats were combined 
in the comparison to CPIP rats. At both 2 and 48 hrs after IR injury, NFκB was increased 
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Figure 1. A. NFkB levels in muscle from the ipsilateral (ipsi) and contralateral (contra) hind paw of 
CPIP rats compared to shams at 2 hrs, 48 hrs and 7 days post-reperfusion, measured by ELISA. 
CPIP ipsilateral at 2 and 48 hrs: N = 15, at 7 days: N = 6. CPIP contralateral at 2 and 48 hrs: N = 
15, at 7 days: N = 6. Sham at 2 and 48 hrs: N = 18, at 7 days N = 14. *p < 0.05, **p < 0.005, Mann-
Whitney U test compared to shams. B. NFkB levels in spinal cord from the ipsilateral (ipsi) and con-
tralateral (contra) side of CPIP rats compared to shams at 2 hrs, 48 hrs and 7 days post reperfusion, 
measured by ELISA. CPIP ipsilateral at 2 and 48 hrs: N = 15, at 7 days: N = 6. CPIP contralateral at 
2 and 48 hrs: N =15, at 7 days: N = 6. Sham at 2 and 48 hrs: N = 18, at 7 days N=14. *p < 0.05, **p 
< 0.005, Mann-Whitney U test compared to shams.
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compared to sham rats in muscle (p = 0.004 at 2 hrs, p = 0.020 at 48 hrs) as well as spinal 
cord (p = 0.027 at 2 hrs and p = 0.001 at 48 hrs) from the ipsilateral side of CPIP rats. At 
7 days after IR injury, NFκB levels in muscle did not differ between CPIP and sham rats. 
However, in spinal cord the ipsilateral NFκB levels from CPIP rats were still elevated (p 
= 0.001). Remarkably, also on the contralateral side of CPIP rats NFκB was increased 
compared to shams in muscle and spinal cord tissue, although this was not statistically 
significant. Moreover, within CPIP rats there was no significant difference between ipsi- 
and contralateral sides. 
Systemic PDTC treatment
Paw-withdrawal thresholds of the ipsilateral hind paw at baseline did not differ between 
CPIP and sham rats (13.2 +/- 3.6 g and 13.4 +/- 3.0 g respectively, p = 0.823). At 48 hrs 
after IR injury, CPIP rats developed a decrease in paw-withdrawal threshold (mean 50% 
von Frey threshold of 6.83 +/- 3.64 g) compared to shams (mean 50% von Frey threshold 
of 11.88 +/- 3.42 g) (p < 0.0001). Within the CPIP group, 32 rats (80%) displayed a 50% 
von Frey threshold < 10.0 and were regarded as responders for mechanical allodynia.
     Acetone responses at baseline were similar between CPIP and sham rats (1.075 +/- 
1.8 s and 1.10 +/- 1.6 s respectively, p = 0.957). Compared to shams (2.05 +/- 3.1 s), 
acetone responses were increased in CPIP rats at 48 hrs after IR injury (3.78 +/- 4.3 s), 
although the difference was not significant (p = 0.113). In the CPIP group, 26 rats (65%) 
displayed pain behavior for more than one second, and were considered as responders 
for cold allodynia.
     The effect of systemic PDTC treatment at 48 hrs after IR injury on mechanical 
allodynia is displayed in figure 2A. A significant main effect of time was observed 
(F(4,121) = 14.3, p < 0.001), as well as a significant main effect of treatment (F(3,28) 
= 8.1, p < 0.001), but there was no significant time × treatment interaction (F(13,121) 
= 1.29, p = 0.229). In post hoc analyses, CPIP rats that had received the highest dosage 
of PDTC (100 mg/kg) showed a decrease in mechanical hypersensitivity compared to 
the saline group (p = 0.02) and the group that received the lowest dose of PDTC (10 
mg/kg, p = 0.02). The ΔAUC showed an effect of treatment for the highest (100 mg/
kg, p = 0.002) and middle (30 mg/kg, p = 0.021) doses of PDTC, compared to saline 
controls. In the sham rats, no significant effect of time was observed, but there was a 
significant main effect of treatment (F(1,17) = 7.3, p = 0.015) and a significant time 
× treatment interaction (F(6,102) = 3.1, p = 0.008). Also within sham rats, the ΔAUC 
differed between the PDTC and the saline treated group (p = 0.028).
     Regarding the absolute values for cold allodynia, a significant main effect of time 
was observed (F(5,104) = 5.7, p < 0.001), but the main effect of treatment (F(3,22) = 
2.6, p = 0.079) and the time × treatment interaction (F(14,104) = 1.7, p = 0.057) just 
failed to reach significance. In sham rats, there was no significant main effect of time 
(F(3,50) = 1.8, p=0.164) or treatment (F(1,17) = 0.8, p=0.377) nor was there a significant 
time × treatment interaction (F(3,50) = 1.2, p = 0.318). For CPIP rats only, the relative 
(percentage) decrease in cold allodynia after systemic PDTC treatment is depicted in 
figure 2B. A significant main effect of treatment was observed (F(3,22) = 4.0, p = 0.020), 
and post hoc analyses demonstrated a decrease in cold allodynia in rats that had received 
the highest dose of PDTC compared to saline treatment (p = 0.035) and the lowest PDTC 
dose (p = 0.045).
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Figure 2.A. Mechanical paw-withdrawal threshold in CPIP and sham rats after systemic PDTC treat-
ment at 48 hrs post-reperfusion, compared to saline treatment. CPIP saline: N = 7; CPIP PDTC 10 
mg/kg: N = 9; CPIP PDTC 30 mg/kg: N = 9; CPIP PDTC 100 mg/kg: N = 7; Sham saline: N = 10; 
Sham CPIP: N = 10. * p < 0.05, repeated measurements ANOVA followed by a post-hoc Bonferoni 
test compared to the saline control group. # p<0.05 ## p<0.005, one-way ANOVA followed by a post-
hoc LSD test compared to the saline control group. B. Relative changes in aceton responses in the 
ipsilateral hind paw of CPIP rats after systemic saline or PDTC treatment at 48 hrs post-reperfusion, 
compared to aceton responses before treatment. CPIP saline: N = 9; CPIP PDTC 10 mg/kg: N = 
6; CPIP PDTC 30 mg/kg: N = 4; CPIP PDTC 100 mg/kg: N = 7. *p < 0.05, repeated measurements 
ANOVA followed by a post-hoc Bonferoni test compared to the saline control group.
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Intrathecal and intraplantar PDTC treatment
At baseline, there was no difference in mechanical sensitivity between the right and left 
hind paw (13.5+/-2.15 g and 13.3+/-2.20 g, p = 0.689), while after IR injury, 26 out of 40 
rats (65%) had developed mechanical allodynia. 
     The effects of intrathecal and intraplantar PDTC treatment are depicted in Fig 3. For 
intrathecal treatment, there was a significant main effect of time (F(2,27) = 21.6, p < 
0.001), but there was no significant main effect of treatment (F(1.14) = 2.6, p = 0.132) or 
time × treatment interaction (F(2,27) = 2.6, p = 0.094). However, in the PDTC treatment 
group the mean 50% VF threshold was increased at both 30 min (p = 0.017) and 60 min 
(p = 0.012) post-treatment, compared to the pre-treatment threshold. No pre versus post 
differences were observed in the saline treatment group (p = 0.687). The ΔAUC was 
significantly larger for the PDTC group compared to the saline group (p = 0.034). 
     For intraplantar PDTC treatment, a significant main effect of time was observed 
(F(2,14) = 45.9, p<0.001), but there was no significant main effect of treatment (F(1,8) 
= 0.0, p=0.980) or time × treatment interaction (F(2,14) = 1.9, p=0.195). The mean 
50% von Frey thresholds did not differ significantly between before and after treatment. 
Additionally, the ΔAUC was not significantly different.
Discussion
We investigated the involvement of NFκB in chronic post-ischemia pain (CPIP), an 
animal model of CRPS-I. NFκB was increased in muscle and spinal cord from CPIP rats 
compared to shams at both 2 and 48 hrs after IR injury. At 7 days after IR injury, NFκB 
levels were equal to shams in muscle tissue, but still elevated in the spinal cord. Systemic 
PDTC administration at 48 hrs after IR injury relieved mechanical and cold allodynia 
in a dose-dependent manner. Mechanical allodynia was also relieved upon intrathecal 
treatment, but not upon intraplantar treatment.
     Considering previous studies, a role of NFκB in CPIP was a plausible expectation. 
First, several studies in different tissue types have demonstrated increased NFκB activity 
early after hypoxia, for example in myocardial tissue, brain, hepatic tissue, and skeletal 
muscle.26,27,36,37 In all of these studies, the extent of the damage caused by IR injury could 
be attenuated by administration of an NFκB inhibitor. Second, CPIP rats display signs of 
inflammation.31 IR injury is known to provoke a well documented cascade of inflammatory 
events38, and NFκB is an important mediator in such inflammatory responses. Third, CPIP 
rats develop neuropathic pain-like symptoms, including mechanical and cold allodynia. 
Previously, increased NFκB activity has been demonstrated in animal neuropathic pain 
models, while these symptoms can be relieved by an NFκB inhibitor.21,39,40
     The hypothetical involvement of NFκB in CPIP is confirmed by our present 
observations. NFκB elevation in muscle tissue is consistent with a previous report 
of muscular NFκB activation upon ischemia by arterial clamping.26 On the contrary, 
increases in spinal NFκB levels following peripheral IR injury is to our knowledge a 
new finding, although spinal NFκB activation has been reported following peripheral 
nerve section41 and nerve inflammation.42,43 These peripheral triggers can induce an 
intra-spinal cytokine release, a process that may be mediated by NFκB.21,40 However, 
neuropathic pain-like symptoms and spinal NFκB activation in CPIP rats are subsequent 
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Figure 3. A. Mechanical paw-withdrawal thresholds in CPIP rats after intrathecal treatment with 
PDTC 48 hrs post-reperfusion. Saline ipsilateral (ipsi): N = 8; PDTC ipsilateral: N = 8; Saline con-
tralateral (contra): N = 8; PDTC contralateral: N=8.  t p < 0.05, Wilcoxon signed rank test comparing 
each post-treatment value with its pre-treatment value. # p<0.05, One-way ANOVA compared to 
the saline control group. B. Mechanical paw-withdrawal thresholds in CPIP rats after intraplantar 
treatment with PDTC 48 hrs post-reperfusion. Saline ipsilateral (ipsi): N = 5; PDTC ipsilateral: N = 5; 
Saline contralateral (contra): N = 5; PDTC contralateral: N = 5.
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to IR injury instead of traumatic nerve injury or direct immunological stimulation.31 
Presumably, IR injury can induce pathological responses in the central nervous system 
(CNS) similar to those induced by mechanical or inflammatory nerve damage, either 
through direct activation of nociceptors by reactive oxygen species (ROS) or by ROS-
induced inflammatory reactions. The observation in CPIP rats of prolonged spinal NFκB 
activity (until at least 7 days after IR injury), when peripheral levels were normalized, 
suggests that eventually the CNS pathology becomes independent of its initial peripheral 
trigger. This is consistent with previous observations showing that CPIP rats display 
ongoing mechanical allodynia at 7 days after IR injury, while plasma extravasation in the 
affected hind paw had been normalized within 24 hrs.31
     NFκB activity is also increased in the contralateral muscle tissue of CPIP rats, although 
not as profound as on the ipsilateral side, and within CPIP rats a significant difference 
between the ipsi- and contralateral sides not observed. A possible explanation may be 
the spread of free radicals and subsequently activated inflammatory mediators from the 
side of IR injury to the opposite side by blood circulation. In support of this, contralateral 
allodynia has been found in the CPIP rats in the past31, although not consistently in all 
studies.44 It may be that contralateral allodynia depends on spinal sensitization which 
may be mediated by NFκB that is increased in the contralateral spinal cord dorsal horn. 
     The anti-allodynic effect of systemic PDTC administration was clear and dose-
dependent. Results from intrathecal administration were less pronounced, and no effect 
was obtained by intraplantar treatment. Presumably, at 48 hrs after IR injury mechanical 
allodynia is mainly caused by the enhanced central, and not the peripheral NFkB activity. 
PDTC passes the blood brain barrier and systemic doses will likely produce CNS effects, 
whereas low concentration intraplantar injections should not. However, it is also possible 
that we were unable to determine the effective dose for local treatment. 
     Few animal models exist that mimic the clinical pattern of CRPS-I. The CPIP model 
resembles human CRPS-I in several aspects. CPIP rats display features that represent 
both inflammatory and neuropathic pain-like symptoms of human CRPS. Moreover, 
CPIP rats express sympathetically maintained pain45, a phenomenon that in the past has 
been considered almost pathognomic for CRPS, although currently it is acknowledged 
to be present in only a subset of CRPS patients. Similar to CRPS-I patients, CPIP rats 
receive poor pain relief from classical anti-inflammatory and anti-neuropathic pain 
treatments44. Inhibitors of NFκB have been suggested as interesting new therapeutics 
for (chronic) inflammatory disorders, such as asthma46, rheumatoid diseases47 and 
inflammatory bowel disorders.48 CRPS may very well be another candidate disorder for 
such treatment, since NFkB is likely involved in both peripheral (ischemia, inflammation) 
and central (sensitization) underlying disease mechanisms. However, because of serious 
immunological consequences there may be safety issues associated with targeting NFkB 
in human patients24, and the current therapeutic indications are restricted to oncology. 
On the other hand, some non-specific modulators of NFkB activity have already been 
demonstrated beneficial in attenuating CRPS in animal models, as well as in human 
trials, including N-acetylcysteine31,49 and corticosteroids.44,50,51 Currently, these drugs are 
not applied generally for CRPS treatment, but these new mechanistic insights warrant 
further clinical studies to establish their clinical benefits.
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     In conclusion, we have demonstrated increased NFkB activity in both muscle and 
spinal cord, as well as a therapeutic effect of NFkB inhibition on allodynia, in CPIP rats. 
We believe that these results encourage further exploration of the role of NFkB in the 
pathogenesis of inflammatory pain disorders, like CRPS-I. Safety issues warranted, these 
studies might provide new treatment opportunities for CRPS-I.
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Introduction
The complex regional pain syndrome (CRPS) was first described near the end of the 19th 
century and has carried a long lasting image of obscurity. An inflammatory origin had 
already been suggested by Sudeck1, but it was only recently that (neuro-) inflammatory 
mediators in CRPS were actually demonstrated.2-4 Mechanisms of neuroplasticity are 
assumed to underlie the sensory and functional impairments, but they remain largely to 
be elucidated.5,6 Sympathetic hyperactivity has been considered pathognomic for CRPS 
in the past, but nowadays its contribution to the pathogenesis is subject of debate7,8, as 
is the contribution of stress and psychological factors.9-11 The aim of the present thesis 
was to increase the insight into the incidence, general characteristics, determinants and 
etiology of CRPS. 
     The introductory chapter provided a review of literature reflecting the current 
knowledge on CRPS. Subsequently, the second chapter presented three descriptive 
studies regarding the incidence, disease outcome, and treatment and referral patterns 
of CRPS in the Netherlands. The third chapter included three studies on determinants 
associated with CRPS, namely medical history, antihypertensive drug use, and estrogen 
exposure. All research described in the second and third chapter was performed within 
the Trauma Related Neuronal Dysfunction (TREND) consortium, a Dutch knowledge 
consortium that integrates research on CRPS.12 The fourth chapter described a search 
for new mechanistic hypotheses. The initial step was performed within the Infobiomed 
consortium, a European Union funded network that aims at enforcing biomedical 
informatics as integrative discipline.13 Basically, this study was set up to see whether 
benefit could emerge from an advanced information retrieval approach towards a clinical 
problem. A new mechanistic hypothesis was generated, involving the role of NFκB in 
CRPS, and further explored in a CRPS animal model during a collaborative project 
with the McGill University in Montréal (Canada). The main findings, methodological 
considerations and suggestions for future studies will be discussed in this final chapter.
 
Main findings
CRPS Incidence in the Netherlands
After Sandroni et al.14 we have performed in IPCI only the second published population 
based CRPS incidence study and have reported an incidence rate (IR) of 26.2 per 
100,000 person years (PY)15 for the study period from 1996 until 2005. According to our 
findings, CRPS is more common than for example multiple sclerosis (5.5 per 100,000 PY 
in United Kingdom)16 or systemic lupus erythematodes (3.0 per 100,000 PY in Quebec, 
Canada).17 It implies that in the Netherlands there are approximately 4,000 new CRPS 
patients each year. 
     In the IPCI database we identified incident CRPS cases by using a search algorithm 
on the narratives of the electronic patient records. Subsequently we asked the GPs to 
confirm or reject the diagnosis in a short questionnaire. Before us, in Olmsted County 
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(USA) Sandroni et al. used the computerized diagnostic indexes (1989-1999) of the 
electronic medical file system of that area and identified initially 389 new CRPS cases 
over 1,336,088 person years. An IR calculation based on these numbers would have 
yielded an IR of 29.1 per 100,000 PY in Olmsted County, which would have been in line 
with the IR of 26 that we found in the IPCI database. However, in their article Sandroni 
et al. presented an IR that was based on only the cases that, by review of the medical 
records, fulfilled the diagnostic criteria from International Association for the Study 
of Pain (IASP). Because of non fullfillment, 81% of the initially identified cases was 
exluded and the final IR reported by Sandroni et al. was only 5.5 per 100,000 PY. The 
difference in case validation (IASP criteria in the Sandroni study versus GP confirmation 
in our study) apparently may, at least partially, explain why we found a much higher 
IR of 26 per 100,000 PY. However, the conveniency of medical record review for 
application of the IASP criteria has been questioned and the suggestion that 81% of the 
physician established CRPS diagnoses was incorrect seems irrealistically high18. The 
concise and unstandardized registration of clinical features in medical records might 
have leaded to an (overly) strict exlusion of cases in the Sandroni study, and thereby to 
an underestimation of the IR. 
    Initially we based our IR calculation on the GP confirmed CRPS diagnoses, 
without taking the fulfillment of diagnostic criteria into account. We realised the risk 
of overdiagnosis, but we restrained from futher validation by clinical featurs, because 
we considered the electronic medical journal not reliable for this. However, in a later 
stadium of our studies we visited (a subset) of the CRPS patients and retrospectively we 
collected information on their past and present clinical features in a standardized manner. 
Applying the IASP criteria on this information, combined with the medical records and 
requested specialist letters, we rejected 24% of the original indentified cases as false 
positives (compared to 81% in the Sandroni study). With the new numbers we performed 
a second IR calculation and found 20 new CRPS cases per 100,000 PY (instead of 26), 
which is still much more than previously reported. While our original IR  may have been 
affected by overestimation, this overestimation has been minimalised in our revised IR, 
due to the extensive case validation procedure. Underestimation will now be more of 
relevance, since during the case identification procedure we used a free text search that 
was broad, but presumably not all including and not all CRPS cases might have been 
acknowlegded as such by the GP.  
Descriptions of disease outcome, referrals and treatment
The disease outcome, prognostic factors, referral patterns and applied treatment strategies 
for CRPS have been scarcely described. As a consequence, prognostic information and 
uniform treatment can hardly be provided to patients. Generally, CRPS is regarded as a 
long lasting disorder that causes severe discomfort and impairments, perhaps even for 
life. Participants of reported studies are often affected for many years.19-22 However, this 
somewhat pessimistic scenario has been contradicted by others, who suggest that the 
patients in these studies represent only a subgroup of severe cases, that are recuited in 
specialized tertiary care centers.14,23 
     Outcome measures for disease recovery in CRPS are not well defined and this 
complicates research concerning the prognosis. When is a CRPS patient recovered? As 
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CRPS is mainly defined by its clinical presentation one could argue that resolution of its 
symptoms and signs should be the standard. Oerlemans et al. therefore have developed a 
multicomponent impairment level sumscore (ISS) in which clinical features are not only 
assessed (as in the diagnostic criteria) but also quantified and combined into one score.24 
A low ISS suggests good recovery. However, these impairments do not necessarily reflect 
the activity of the underlying disease mechanisms, since it has been demonstrated that 
patients who improved according to the ISS still had increased inflammatory mediators 
in their blister fluids.25 Presumably, a distinction could be made between the clinical 
features that indicate active ongoing CRPS (perhaps the inflammatory signs) and clinical 
features that should be regarded as remaining impairments while the actual CRPS has 
resolved (perhaps the motor disturbances). Such a distinction remains yet to be defined.
     We have found in our GP based CRPS patient cohort that persistent complaints 
are present in more than 80% of the patients at an average of 5.7 years (range: 2-11) 
since CRPS onset (defined as the date of the precipitating injury). In over 60% one 
or more disturbances were also objectified during physical examination. According to 
self reports only 30% considered themselves completely recovered, while most patients 
(54%) reported the CRPS to have been stabilised. In a minority (16%) the CRPS was still 
progressive. The impact on work was high: more than half of the patients had permanently 
changed (28%) or even aborted (31%) their former working activities. 
     A medical specialist consultation (usually an anesthesiologist or rehabilitation 
physician) was needed in most cases (80%), and the majority had received physical 
therapy (89%) or pharmacotherapy (93%). Only 18% received nerve blocks, with 
variable success according to the patients. 
     All the above mentioned findings contradict the previous suggestions that CRPS 
is generally mild and spontaneously resolving.14 Despite the absence of direct 
evidence  it is generally assumed that early intervention favours the disease course 
and outcome. According to the Dutch treatment guideline26 free radical scavengers, 
such as dimethylsulfoxide crème and N-acetylcysteine, form the recommended first 
pharmacologic treatment step for CRPS, combined with physiotherapy. However, only 
half of the patients in our study had received this treatment within the first three months 
after the onset of CRPS (precipitating injury). Perhaps the treatment delay can be limited 
by encouraging GPs, to whom 64% of the CRPS cases presents first, to initiate basic 
treatment in an early stadium, while waiting for the results of futher consulation of a 
CRPS specialist.
Risk Factors and Leads to Etiology  
Over the past decade the disease mechanisms underlying CRPS have become increasingly 
clarified, although we are still far from complete understanding. The results from 
fundamental and preclinical studies, as well as the heterogeneous clinical presentation 
of CRPS all point at a multifactorial disease origin. The five main contributing disease 
mechanisms (as reviewd in the introductory chapter) include disturbances of the autonomic 
(sympathetic) and somatic nervous system,  (neurogenic) inflammation, ischemia, and 
psychological aspects. Until today, only limited epidemiological studies have contributed 
to the better understanding of CRPS. However, apart from revealing clinically relevant 
risk factors, the study of determinants of CRPS could aid in confirming the mechanistic 
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theories that were derived from experimental and  (pre-) clinical studies. The other way 
around, determinants may provide new leads for further mechanistic studies. 
     Since we had a special interest in the neuroimmune aspects of CRPS we focused 
in our case-control studies on potential determinants of CRPS that are related to a 
neuroinflammatory pathogenesis. We performed two studies that both strengthened the 
idea that neurogenic inflammation is of importance in CRPS onset. In the first study we 
found that CRPS patients have more often than controls a medical history of asthma and 
migraine, both disorders that involve mast cells and neuroinflammatory peptides, such 
as substance P (SP) and calcitonin gene related protein (CGRP). In the second study, 
we found a strong association between CRPS onset and the use of drugs that inhibit the 
activity of the angiotensin converting enzyme (ACE). ACE is a known metabolizer of 
SP and bradykinin (involved in inflammation and periphere nociceptor sensitization) and 
thereby a potential modulator of neuroinflammatory responses. SP, CGRP, bradykinin 
and mast cells have all been demonstrated to be abnormally expressed or activated in 
CRPS patients27-30 and many clinical features of CRPS are consistent with the effects 
of neuropeptides.31 Moreover, symptom relieve in CRPS patients can be achieved by 
compounds that interfere with the release or activity of SP32,33 and CRPS patients respond 
stronger in experimentally induced neurogenic inflammation.34,35 Our results affirm the 
previous findings from experimental and (pre-) clinical studies by showing that in an 
epidemiological perspective there is indeed a connection between the risk of CRPS and 
the presence of exaggerated neuroinflammatory processes.      
     Estrogens are also known to affect inflammatory responses. The high incidence 
of CRPS in women compared to men and the increasing incidence during the post-
menopausal years of life have both raised the interest toward a potential role of 
estrogens in the immunologic mechanisms that underlie CRPS. However, in our case-
control study we demonstrated no association between cumulative endogenous estrogen 
exposure and the risk of CRPS. Moreover, CRPS onset in pre-menopausal women was 
not affected by the use of oral contraceptive drugs. Oral contraceptives influence the 
actual endogenous estrogen levels only very moderately, and may therefore hardly 
affect eventual inflammatory responses. On the contrary, hormonal replacement therapy 
(HRT) in post-menopausal women affects endogenous estrogen levels to a much larger 
extent. We observed a probable protective effect of HRT use on the risk of CRPS, but the 
results were not significant due to low power in study. Additionally, a protective effect of 
preganancy (high estrogen levels) was suggested by our results, as well as an increased 
risk of CRPS shortly after delivery (drop of estrogen levels), although again this was 
based on very small numbers. Unfortunately the power issues withholds us from drawing 
sound conclusions, but the actual observations do warrant the further exploration of the 
role of estrogens in the pathogenesis of CRPS. 
The role of NFκB
In the past two decades the nuclear transcription factor κB (NFκB) has gained major 
scientific attention as a mediator in inflammatory responses and in cell survival 
mechanisms. NFκB resides inactive in the cytoplasm of many cell types and becomes 
activated when its inhibitory protein (IκB) is cleaved off by phosphorylation through 
the enzyme IKK. A wide variety of stimuli can induce NFκB activity, including 
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bacterial and viral products (via Toll like receptor activation), cytokines, growth factors, 
neurotransmitters, neuropeptides, reactive oxygen species (ROS), physical stress, and 
various chemical stimuli.36 Upon activation, NFκB forms dimers that translocate to the 
cell nucleus, where it regulates the expression of over 150 target genes.36 NFκB has been 
attributed a role in the disease mechanisms underlying acute and chronic inflammatory 
responses, cancer and neurodegenerative disorders.37
     In order to find previously unacknowledged potential mediators in CRPS we used 
an automated information retrieval tool (PathwayAssist™) to overview all abstracts in 
Medline. We discovered a high connectivity between NFκB and the assumed disease 
mechanisms of CRPS, including inflammation, ischemia/reperfusion injury and 
sensitization. This leaded to the idea that NFκB may be a common mediator in the 
multifactor origin of CRPS. We explored this hypothesis further by using an animal model 
for CRPS type I, known as the chronic post ischemia pain (CPIP) model. Involvement of 
NFκB in this model was demonstrated in two ways. First, NFκB levels were increased 
in muscle and spinal cord at the affected side of CPIP rats compared to controls. Second, 
systemic administration of an NFκB inhibitor (pyrrolidine dithiocarbamate) relieved 
mechanical and cold allodynia in a dose-dependent way.       
     The potential unifying role of NFκB in the pathogenesis of CRPS may provide, once 
further explored, new pharmacotherapeutic opportunities. Beneficial results have already 
been observed from treatment with non-specific NFκB inhibitors such as N-acetylcysteine 
and vitamine C. Targeting NFκB specifically has been suggested as a promising strategy 
for autoimmune diseases, neurodegenerative disorders and cancer. Perhaps CRPS would 
be another candidate for such treatment. However, targeting the NFκB pathway may 
also prove a complex and dangerous effort.37 NFκB mediated responses are regulated in 
a complex network of positive and negative feedback mechanisms. Interference might 
disturb the physiological balance between cell stimulation (inflammation) and cell death 
(apoptosis), which can lead to immunosupression as a dangerous adverse effect. 
 
Methodological considerations
Setting
All the epidemiologic population based studies that are described in the second and 
third chapter of this thesis have been performed within the Integrated Primary Care 
Information (IPCI) project, a Dutch general practice database that is maintained by 
the Medical Informatics department of the Erasmus Medical Center. The database is 
representative of the general population of The Netherlands regarding age and gender 
distribution.38 Since in the Dutch health care system the GP acts as a gatekeeper and 
information receiver for secondary care39, the GP journals can be considered to store the 
necessary medical information of the patients. To maximize completeness of the data 
GPs participating in the IPCI project do not keep additional paper records, except for 
specialist letters, that are available for the investigators on request. The data have proven 
valid for (pharmaco)-epidemiological studies.40 
     The large source population in the database provided the opportunity to identify a 
relative large subset of CRPS patients, as well as controls with detailed matching on 
injury. A unique feature of the IPCI project is that, with mediation of the GP, patients 
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can be contacted and visited, which allowed for diagnostic validation and additional 
data collection. The population based setting makes the results representative for CRPS 
patients in general.
 
Study population: cases and controls
All CRPS patients and controls were derived from the source population in the IPCI 
database. The final study population varied per study as is depicted in figure 1.
     In any study on CRPS, validation of the cases is an issue of major concern. The 
absence of a reasonably sensitive and specific biomarker leaves the clinical presentation 
as a single basis for diagnosis. The interpretation of the findings during anamnesis and 
physical examination41,42, the choice for a specific set of criteria43, and the time of clinical 
evaluation all affect the final case definition.44 
     For patients identified in the IPCI database diagnostic validation was of particular 
concern since it had to be done in retrospect. However, by using multiple sources for 
the gathering of clinical information, including the electronic GP journals, requested 
specialist letters, and patient reports when a visit was possible, we were able to apply the 
IASP diagnostic criteria for CRPS relatively accurate. Moreover, at the time of CRPS 
onset, the diagnosis was confirmed by a medical specialist in almost 80% of the cases. We 
excluded all cases for whom the history of symptoms appeared questionable during the 
visit, especially when a potential alternative diagnosis was not sufficiently investigated. 
     Controls were matched to cases on age (year of birth) and gender. Moreover, controls 
were required to have experienced an identical injury as their matching case within a two 
year band of calendar time. This meant that each case with a fracture was compared to 
controls with a fracture; each case with a soft tissue injury to controls with a soft tissue 
injury, etc. Since CRPS generally occurs after an injury, matching on this risk factor is 
important in order to properly study other determinants of interest. A detailed injury 
matching was possible due to the large number of patients in the GP database. We believe 
that matching on injury has been a unique and strong feature of our studies.
Observational studies: selection, bias and confounding 
Using a population based GP source population we intended to generate knowledge 
that is representative of all CRPS patients. However, by visiting only a subset of cases 
confirmed by the GP for additional data collection, some selection has been introduced. 
This was inevitable since 17% could not be traced for invitation and another 32% refused 
participation. Despite our clear statements in the invitation letter that participation was 
relevant regardless CRPS severity we suspect that well recovered patients were less eager 
to cooperate than patients with ongoing complaints. In this sense there may be some 
selection of severe cases present in our study population, although presumably this is 
much less than in a hospital based setting. We believe this selection is however confined, 
as participants and non participants were not significantly different on characteristics as 
age, gender and medical history. 
     In association studies bias can be introduced by misclassification of the determinants 
or the outcome (or both). In our studies information on the determinants of interest 
(prior to CRPS history, medication use) was retrieved from the electronic GP journals. 
As the data registration by GPs originally serves a care and not a scientific purpose 
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Figure 1. Flow chart for the inclusion of the study populations for different studies described in 
chapters 2 and 3 of this thesis. 
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some misclassification will be of relevance. However, since the registration occurred 
in a prospective manner by the GP before the onset of CRPS (both patient and GP 
were unaware of the patients’ susceptibility to CRPS) this misclassification is probably 
random and should therefore lead only to an underestimation of the true associations. 
Misclassification of antihypertensive drug use according to the GP prescription records 
was investigated by comparison with pharmacy dispensing lists that were available 
for 19% of the patients in the study population. This revealed a sensitivity of 81% and 
a specificity of 99%, indifferent between cases and controls. Misclassification of the 
outcome (CRPS diagnosis) was limited by the extensive case validation procedure. 
Moreover sensitivity analyses were always conducted, wherein only cases confirmed 
during a visit were included (most valid diagnosis).
     Confounding occurs when a variable is associated with the determinant of interest as 
well as the outcome, while not being part of the causal pathway. It leads to an incorrect 
estimate of the association under study. The most well known risk factors for CRPS are 
age, gender and physical trauma, all of which we dealt with by matching. Relevance 
of other potential confounders, such as prespecified diseases and concomitant use drug 
use, was tested by including them in the multivariate conditional logistic regression 
model and observing the change in the odds ratio’s. Effect modification was studied 
by performing subgroup analyses on gender and on warm and cold type CRPS, and by 
including interaction terms in the regression model.    
  
Automated information retrieval
The large and rapidly expanding amount of biological information stored in scientific 
databases demands for advanced methodologies of analysis and interpretation. The 
extensive data quantity  that is generated in the genomics and proteomics area needs 
to be integrated with clinical and epidemiological knowledge. Bioinformatics tools are 
designed to aid in these complex efforts and are increasingly applied, for example in 
autoimmunity research (immunoinformatics)45 and drug development (toxicogenomics).46 
PathwayAssist™ is such a (commercially available) bioinformatics tool, developed for 
navigation and analysis of biological pathways, gene regulation networks, and protein 
interaction maps.47 It has been applied in many different manners with the purpose to 
increase the insight in the underlying molecular mechanisms of normal physiological 
responses and several diseases.48 
     We used PathwayAssistTM and its incorporated text mining module MedScan to 
retrieve information on the interactions between prespecified CRPS concepts (mediators, 
receptors, drugs), from all abstracts available in Medline. The emerging visualized network 
enabled us to see connections that previously had been overlooked due to information 
overload. Having better overview, we recognized the central position of NFκB, a 
transcription factor that had never been connected with CRPS before. Our methodology, 
using text mining and automated information retrieval to obtain new hypotheses on a 
clinical problem, was experimental. As we found a new direction for further research, 
we might conclude that in our particular case the approach was successful. However, 
we did not demonstrate generalizability of this methodology in the sense that automated 
information retrieval will always aid in the development of new ideas for clinical or 
biomedical research. Repeated efforts performed with other poorly understood diseases 
are recommended to demonstrate the general benefit.
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CPIP model 
Several animal models have been applied to study the disease mechanisms of CRPS. 
Some of these are general models for neuropathic pain, such as the sciatic nerve section32 
model and the chronic constriction injury model.49 CRPS symptoms in these models 
follow upon actual nerve injury and therefore they are more representative for CRPS type 
II, as in human this is defined by the presence of a nerve lesion. Animal models whereby 
symptoms were induced without direct nerve injury, similar to human CRPS type 1, 
included straight forward tibia fracture and casting50, local infusion with a free radical 
donor51, intra-arterial infusion of SP52, and local ischemia/reperfusion (IR) injury.53 
     The IR injury model, known as the chronic post ischaemia pain (CPIP) model, 
had several advantages above the others, which made it preferable for our study on 
NFκB involvement in CRPS: 1. since there is no nerve injury it reflects CRPS type I; 
2. both inflammatory and sensory aspects of human CRPS are reflected in the model; 
3. pathology is induced by physical injury (instead of chemical infusion), resembling 
a physical trauma in human CRPS; 4. significant allodynia is present in approximately 
70% of the animals as early as 48 hours after IR injury. This high response rate limits 
the number of animals needed to be included, while the rapid onset of allodynia confines 
the duration of experiments. 5. CPIP animals respond poorly to treatment with standard 
analgesics, similar to human CRPS.54 
However, being an animal model, extrapolation of the results to human should occur 
with appropriate reserve.
Conclusions from the thesis
We provided population based descriptions of the incidence, disease outcome and 
treatment of CRPS in the Netherlands. Our results suggest that CRPS occurs more 
frequently than previously thought and that its disease outcome is less favorable than 
assumed, since the far majority still has complaints after two or more years of disease 
duration. This somewhat unfortunate reality emphasizes the relevance of further efforts 
to improve the understandings of CRPS. Hopefully this will result in better prevention 
and treatment opportunities that offer eventually a more optimistic perspective.
     Our case-control comparisons revealed substantial new indications that neurogenic 
inflammation is of relevance in CRPS, while recent experimental studies and clinical 
observations point in the same direction.31 Mediators of neurogenic inflammation may be 
interesting targets for pharmacotherapy, since it is a plausible idea that early confinement 
of the neuroinflammatory responses prevents further damage. However the exact 
interaction between peripheral (neuro-) inflammatory mechanisms and central nervous 
system alterations remains unclarified. Advanced information retrieval methods led to 
the speculation that NFκB might play a role in this, being a mediator in both (neuro-) 
inflammatory and neuropathological disease mechanisms. The results from an animal 
(CPIP) study confirmed the actual involvement of NFκB in the pathogenesis of CRPS. 
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Proposed further research
An issue of major concern in all human CRPS research remains the ongoing vagueness 
in CRPS definition and the differentiation of potential subtypes. The distinction between 
type I and type II has become debatable, since sub-clinical nerve injury may commonly 
be present after fractures or other injuries. Also discrimination between the warm 
and cold type may not always accurately reflect the underlying disease mechanisms 
as inflammation and autonomic dysregulation. However, as long as the diagnosis and 
classification of patients is suboptimal, study populations will remain heterogeneous, 
which makes it difficult to find determinants, treatment effects or biomarkers. Therefore, 
a strong need exists for prospective studies wherein symptoms and signs are assessed in 
a large cohort of post-trauma patients. Cluster analysis techniques could aid in pattern 
recognition, which would eventually derive CRPS subtypes and also discriminate 
between CRPS and physiological trauma responses. Ideally, the clinical spectrum of 
CRPS could be linked to a (composition of) biomarker(s). 
     Because of retrospective symptom/sign assessments the study design of the present 
thesis was inconvenient for improving clinical definition and phenotype classification. 
However, this would be possible if a prospective setup could be embedded within the 
IPCI project. IPCI is unique above most other GP databases, as it allows patient contact 
mediated by the GP. If the GP could alert the investigator each time CRPS is diagnosed 
or suspected, patients could be visited for clinical assessments early after disease onset 
(preferably within three months). Repeated symptom/sign evaluations from that moment 
onwards would provide accurate disease course descriptions, which are lacking until 
today. Technical improvements are expected to allow expanding of the IPCI database 
with new participating GPs and the perspective is to have one million patients in active 
follow-up by 2009. Based on our estimated incidence rate this would imply 260 new 
cases in IPCI each year. Considering a participation rate of 60% (as in the present thesis), 
theoretically a four year follow-up period would yield over 500 early assessed cases from 
a population based setting. However, the complex logistic issues bound to such a setup 
are not to be underestimated and require careful consideration in advance.
     Once CRPS is better defined and classified, the further study of risk factors and 
determinants should be resumed. Eventually, this may improve anticipation of CRPS 
onset in high risk patients, as well as the understanding of underlying mechanisms of 
disease. A specific genetic profile could be such a determinant, for example one that 
predisposes for neurogenic inflammation or rapid sensitization. Also trauma related 
factors (trauma type, immobilization) and specific patients’ characteristics (age, gender, 
medical history, drug use, life style, etc) may be relevant. A GP database as IPCI is highly 
convenient for such studies because much information on determinants of interest is 
usually recorded by the GP. Patient visits make additional data collection possible, for 
example through questionnaires or by obtaining body materials (blood, sputum, urine, 
skin, etc.). Also from patients who were visited in regard of the present thesis venous 
blood has been obtained and stored. Further analysis of these samples could include 
genome-wide association assays, determination of infection history, and assessment of 
autoimmunity markers.
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     Although the contribution of (neurogenic) inflammation to CRPS remains to be clarified 
further, results until this far warrant clinical attempts to attenuate exaggeration of this 
disease mechanism. For example, corticosteroids have occasionally been shown effective 
in the treatment of CRPS55 and well performed randomized blinded clinical trials could 
prove its true benefit. Corticosteroids are notorious for their adverse effects, but this has 
not restrained physicians from applying them in other inflammatory disorders. Another 
promising pharmacotherapy option in this view is provided by free radical scavengers, 
as ROS are common triggers as well as products of neurogenic inflammation. Apart 
from confirming the positive results from previous trials, the relevance of timing (i.e. 
administration early in the disease course) could be studied, as well as the costs and 
benefits of standardized high dose vitamin C prescription after fractures. Finally, drugs 
that prevent sensitization are of interest, such as inhibitors of SP (may also be effective 
against a neurogenic inflammation) and NK-1 or NMDA receptor antagonists.
     On a more fundamental level, the exact interaction between the several disease 
mechanisms involved in CRPS demands further exploration. NFκB might be a linking 
factor, but although its involvement is supported by observations in the CPIP model, the 
actual connection between NFκB activity and the expression of other mediators in CRPS 
has not yet been demonstrated. As NFκB potentially promotes the transcription of over 
150 genes, it would be useful to understand which of these are particularly promoted in 
CRPS, and at which point in the disease process. Additionally, mechanistic questions can 
be raised regarding the interference with the NFκB pathway for therapeutic purposes. 
This can be done on different levels and the optimal target should be determined: it 
may be NFκB itself, but also one of its effector products such as substance P or TNFα. 
Moreover, the safety of such treatment is an issue of concern.      
     More than a century has past since Sudeck published the first article on “die 
akute untzündliche Knochenartrophie”. Since then many physicians and scientists 
have attempted to unravel the complex etiology and slowly we progress to a better 
understanding of CRPS, but we need to keep on searching.  
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Summary
The complex regional pain syndrome (CRPS) is a painful and potentially disabling 
complication of a physical injury, for example a fracture or contussion. It usually occurs 
in the distal end of the affected extremity and is marked by a variety of symptoms, 
including pain and sensory abnormalities, vasomotor and sudomotor disturbances, and 
motor/trophic impairments. Although the general insights in CRPS have increased over 
the past decade, there is still limited understanding of the actual etiology, pathogenesis, 
risk factors, and prognosis.
     The aim of this thesis is briefly introduced in chapter 1.1 as to gather more insight 
in CRPS as a clinical entity and into its pathogenesis and etiology. In chapter 1.2 we 
provide a review of the current knowledge regarding the underlying disease mechanisms, 
including disturbances in the autonomic (sympathetic) and the somatic nervous system, 
neurogenic inflammation, hypoxia, and psychological factors. Mediators involved in all 
these separate mechanisms are likely to interact and thereby to contribute all together to 
the complex, multifactor pathogenesis of CRPS. Additionally, we summarize currently 
known risk factors and emphasize the need for further epidemiologic studies to reveal 
determinants of CRPS.
     Chapter 2 comprises three descriptive studies on CRPS in the Netherlands. All studies 
were conducted in a cohort of CRPS patients who were identified in a general practice 
database, the Integrated Primary Care Information (IPCI) project. In chapter 2.1 we 
describe a population based incidence rate (IR) calculation for CRPS, revealing an IR 
of 26 per 100.000 person years. The mean age at CRPS onset was 52 years and the 
peak incidence occurred between the fifth and seventh decade. Women were affected 3.4 
times more often than men. The most common precipitating event was a facture, (44%), 
followed by a sprain (18%) and surgery (12%). In a minority (10%) of patients CRPS 
had developed spontaneously.   
     In chapter 2.2 we studied the outcome of CRPS. We assessed symptoms and signs 
in 102 patients at on average 5.8 years (range: 2.1-10.8) after CRPS onset. More than 
80% of the patients still reported CRPS symptoms (subjective) that could be objectified 
(signs) in over 60%. This was significantly more than in reference patients with a similar 
precipitating injury but no CRPS. Symptom and sign prevalences were not associated 
with time since onset. In addition to clinical features, we studied other parameters of 
CRPS outcome: 64% of the patients still fulfilled the IASP diagnostic for CRPS; 27% 
received ongoing treatment. Based on self reports, 30% of the patients was recovered, 
in 54% CRPS was stabilized, and 16% suffered from progressive severe disease. Of 
the patients that had a job at the moment of CRPS onset, 31% had become completely 
incapable to work, while 28% worked with adjustments. Finally, with the purpose to 
distinct patients further by disease outcome, we performed a K-means cluster analyses on 
sign and symptom prevalences. Of the three emerging clusters, one clearly represented 
the poorest outcome subgroup. Poor outcome was associated with an affected upper 
extremity, an atypical precipitating injury (no fracture), and cold CRPS.  
     Chapter 2.3 addresses the referral and treatment patterns for CRPS in the Netherlands 
from 1996 until 2005. CRPS patients received a large diversity of treatments from many 
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different physicians. Scavengers and common analgesics were applied early in the 
disease course, while vasodilative drugs and anti-neuropatics were prescribed later on. 
More that 90% of the patients received additional non-pharmacological treatments, such 
as physiotherapy. A minority (18%) received invasive pain blocks. Most (63%) patients 
consulted the GP before referral to a medical specialist. Dutch guidelines for CRPS 
treatment were released in 2006 (after the study period) and recommend free radical 
scavenger prescription as general first treatment step for all patients, combined with 
analgesics and physiotherapy. This therapy is harmless and since an early start may favor 
the prognosis of CRPS, we would encourage GPs and other physicians to commence the 
therapy in an early stadium, while waiting further evaluation by a CRPS specialist. 
     Chapter 3 includes three case-control studies, which were also performed in IPCI, 
regarding potential determinants of CRPS. In these studies the controls were matched 
to the cases on type of injury, additional to age and gender. First, in chapter 3.1, we 
evaluated the medical history of CRPS patients by reviewig the complete electronic 
GP records. CRPS patients more often had a prior to CRPS history of migraine (OR: 
2.43, 95%CI: 1.18-5.02) and asthma (OR: 3.0, 95%CI: 1.3-6.9). Neuro-inflammatory 
mediators, for example substance P (SP), are involved in both disorders, which may 
connect them to CRPS. Additionally, a history of osteoporosis (OR: 2.44, 95%CI: 1.17-
5.14), menstrual cycle related disorders (OR: 2.60, 95%CI: 1.16-5.83) and neuropathies 
(OR: 5.7, 95%CI: 1.8-18.7) was more common in CRPS patients, suggesting that these 
are risk factors. In contrast to previous suggestions, psychological factors were not 
associated with CRPS. 
     Since some antihypertensive drugs interact with mediators or disease mechanisms 
in CRPS (neuropeptides, adrenergic receptors, vasoconstriction), we studied their 
association with CRPS onset in chapter 3.2. Current use of ACE inhibitors was associated 
with CRPS onset (OR: 2.7, 95%CI: 1.1-6.8) and the risk increased even further with a 
longer duration of use and with a higher dose. Calcium channel blockers, angiotensin 
II receptor antagonists, β-blockers, and diuretics did not affect the risk of CRPS onset. 
Since ACE is involved in the metabolism of SP and bradykinin we hypothesize that ACE 
inhibitor induced accumulation of these peptides facilitates the neurogenic inflammation 
underlying CRPS.
     The pronounced female predominance of CRPS, as well as the increasing incidence 
in women at post-menopausal age, leaded us to investigate the relation between CRPS 
and estrogen exposure in chapter 3.3. Cumulative estrogen exposure was assessed as 
the ages of menarche and menopause, menstrual life, parity, and cumulative time of 
pregnancy and breast feeding. None of these measures were significantly associated with 
CRPS. Actual estrogen exposure, defined by the current use of oral contraceptive drugs 
or hormonal replacement therapy (HRT), did not significantly affect the risk for CRPS 
either, although HRT use showed a non significant protective effect (OR: 0.5, 95%CI: 0.1-
1.6) During the first six months post partum (fast decreasing estrogen levels) CRPS onset 
was increased (OR:5.6, 95%CI: 1.0-32.4). However, power limitations demand cautious 
interpretation of the results. The overall results are in line with those for other painful 
inflammatory disorders with a similar gender distribution pattern, such as rheumatoid 
arthritis and multiple sclerosis.
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     Chapter 4 describes the development and testing of a new hypothesis on the molecular 
pathogenesis of CRPS. First, elaborated on in chapter 4.1, we used the text mining 
based information retrieval tool PathwayAssistTM to visualize a Medline based network 
of interactions between known concepts of relevance in CRPS (proteins, small molecules, 
drug, etc). This network provided the overview that was needed to recognize the central 
position of the nuclear transcription factor κB (NFκB) amongst acknowledged other 
mediators in CRPS. NFκB has been attributed an important role in inflammatory disorders, 
for example in rheumatologic diseases and asthma. Although it has never been connected 
to CRPS before, its involvement in the disorder is theoretically very plausible.  
     This hypothesis was tested in an animal model for CRPS, which is decribed in 
chapter 4.2. In the chronic post ischemia pain (CPIP) model CRPS-like symptoms are 
induced in rats by ischemia and reperfusion (IR) injury of the left hind paw. At 2 and 
48 hours post IR injury, we observed increased NFκB activity (using ELISA) in the 
muscle and spinal cord of the affected sides of CPIP rats compared to shams. At day 7 
post IR injury NFκB activity in muscle was equal between CPIP rats and shams, while 
in the spinal cord of CPIP rats the NFκB levels sustained increased. Additionally, the 
mechanical and cold allodynia that developes following IR injury could be reversed in a 
dose dependent manner by the systemic administration of an NFκB inhibitor (pyrrolidine 
dithiocarbamate). The results suggest a contribution of NFκB to allodynia in CPIP rats, 
and perhaps to human CRPS. 
     Finally, in chapter 5 the main results and methodological aspects are discussed. 
Suggestions for further research are provided.
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Samenvatting (in Dutch)
Het  complex regionaal pijn syndroom (CRPS) is een pijnlijke en soms invaliderende 
complicatie van een lichamelijk letsel, bijvoorbeeld een fractuur of contussie. Het komt 
meestal voor distaal in de aangedane extremiteit en kan leiden tot veel verschillende 
symptomen, waaronder pijn en sensorische afwijkingen, maar ook vasomotore, 
sudomotore en motor/trofische stoornissen. Hoewel er in het afgelopen decenium steeds 
meer over CRPS bekend is geworden, bestaat nog steeds veel onduidelijkheid omtrent 
de etiologie, pathogenese, risicofactoren en de prognose. 
     Het doel van dit proefschrift wordt kort geïntroduceerd in hoofstuk 1.1, waar het wordt 
omschreven als het verkrijgen van meer inzicht in het algemene voorkomen van CRPS 
en in de onderliggende pathogenese en etiologie. In hoofdstuk 1.2 wordt een overzicht 
gegeven van wat momenteel bekend is over de onderliggende ziektemechanismen. 
Hierbij komen pathologie van het autonome en somatische zenuwstelsel, neurogene 
inflammatie, hypoxie en de rol van psychologische factoren aan de orde. Veelvuldige 
interactie tussen de verschillende betrokken mediatoren is waarschijnlijk en dit leidt 
tot een complexe en multifactoriële etiologie. Ook de tot nu toe bekende risicofactoren 
voor CRPS worden besproken en het belang van toekomstig epidemiologisch onderzoek 
wordt benadrukt. 
     Hoofdstuk 2 omvat drie beschrijvende studies over CRPS in Nederland. Deze 
studies werden verricht in een cohort van CRPS patiënten die waren geïdentificeerd in 
een huisartsendatabase, het ‘Integrated Primary Care Information’ (IPCI) project. In 
hoofdstuk 2.1 beschrijven we een incidentie berekening voor CRPS, die uitkomt op een 
schatting van 26 nieuwe patiënten per 100.000 persoonsjaren. De gemiddelde leeftijd 
waarop patiënten CRPS kregen was 52 jaar en de incidentie was het hoogt in de leeftijd 
van 50 tot 70 jaar. Vrouwen kregen 3.4 keer vaker CRPS dan mannen. Een fractuur was 
het meest voorkomende voorafgaande letsel (44%), gevolgd door een contussie (18%) 
en een operatie (12%). In een minderheid (10%) had CRPS zich spontaan ontwikkeld. 
     Hoofdstuk 2.2 behandelt het herstel van CRPS. De subjectieve en objectieve 
symptomen werden onderzocht in 102 patiënten met een gemiddelde tijdsduur van 5.8 
jaar (spreiding 2.1-10.8) sinds het ontstaan van CRPS. Meer dan 80% rapporteerde nog 
steeds CRPS klachten, die in meer dan 60% ook konden worden geobjectiveerd. Dit was 
significant meer dan in controle patiënten die hetzelfde letsel hadden gehad, maar geen 
CRPS. Binnen de groep van CRPS patiënten waren de klachten niet afhankelijk van de 
ziekteduur. Naast het klinisch beeld werden ook een aantal andere operationalisaties van 
herstel bekeken: 64% van patiënten voldeed nog steeds aan de IASP criteria voor CRPS; 
27% kreeg nog steeds enige vorm van therapie. Zelf raporteerde 30% van de patiënten 
een goed herstel, 54% beschouwde de aandoening als gestabiliseerd en 16% ondervond 
nog steeds achteruitgang. Van degenen die voorafgaand aan de CRPS een baan hadden, 
had 31% deze blijvend moeten opgeven vanwege CRPS, terwijl 28% alleen aangepast 
werk kon verrichten. Om verder onderscheid te maken ten aanzien van herstel werd 
een cluster analyse verricht op basis van de aanwezigheid van subjectieve en objectieve 
symptomen. Van de drie verkregen clusters omvatte één duidelijk slechter herstelde 
patiënten ten opzichte van de andere twee. Slecht herstel was geassocieerd met CRPS 
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aan de bovenste extremiteit, een atypisch voorafgaand letsel (geen fractuur) en de koude 
vorm van CRPS.
     Hoofdstuk 2.3 gaat over de verwijs- en behandelpatronen van CRPS in Nederland tussen 
1996 en 2005. CRPS patiënten in Nederland kregen veel verschillende behandelingen 
die werden voorgeschreven door een variëteit aan behandelaars. Scavengers, of wel 
‘vrije radicaal wegvangers’ en algemene pijnstillers werden vooral voorgeschreven 
vroeg in het ziektebeloop, terwijl vaatverwijdende medicatie en co-analgetica pas later 
werden gestart. Meer dan 90% van de patiënten onderging tevens niet farmacologische 
behandelingsvormen, zoals fysiotherapie. Een minderheid (18%) onderging pijn 
blokkades. De meeste patiënten (63%) bezochten eerst de huisarts voordat ze voor de 
CRPS een medisch specialist bezochten. In 2006 (na de studie periode) is in Nederland 
een behandelingsrichtlijn voor CRPS verschenen, waarin een algemene eerste stap wordt 
geadviseerd voor alle patiënten. Deze stap omvat, naast fysiotherapie en pijnstilling, het 
voorschrijven van een scavenger met als doel de beschadiging, die wordt veroorzaakt 
door vrije radicalen, te ondervangen. Omdat deze vorm van therapie relatief onschuldig 
is en een vroege start wellicht het ziektebeloop ten goede komt, zouden huisartsen, maar 
ook specialisten, deze behandeling in een vroeg stadium moeten beginnen, terwijl het 
oordeel van een geconsulteerd CRPS specialist verder wordt afgewacht.
     In hoofdstuk 3 worden drie case-control studies besproken waarin werd gekeken 
naar mogelijke determinanten van CRPS, allen verricht in IPCI. In deze studies werden 
de controles gematched met de cases voor de aard van het voorafgaande letsel, alsook 
voor de leeftijd en het geslacht. In hoofdstuk 3.1 werd gekeken naar de medische 
voorgeschiedenis, waarbij gebruik werd gemaakt van het complete electronische dossier 
van de huisarts. CRPS patiënten hadden vaker dan controle personen migraine (OR: 
2.43, 95%CI: 1.18-5.02) en astma (OR: 3.0, 95%CI: 1.3-6.9) in de voorgeschiedenis. 
Neuro-inflammatoire eiwitten, bijvoorbeeld substance P (SP), spelen een rol in beide 
aandoeningen, wat hen mogelijk in verband brengt met CRPS. Ook osteoporose (OR: 
2.44, 95%CI: 1.17-5.14), menstruele cyclus gerelateerde klachten (OR: 2.60, 95%CI: 
1.16-5.83) en neuropathieën (OR: 5.7, 95%CI: 1.8-18.7) kwamen frequenter voor bij 
CRPS patiënten en zouden daarom als risicofactoren kunnen worden beschouwd. In 
tegenstelling tot wat in het verleden is gesuggereerd, bleek het risico op CRPS niet 
geassocieerd met psychologische factoren in de voorgeschiedenis.
     Sommige antihypertensiva hebben een effect op mediatoren en mechanismen die een 
rol kunnen spelen in CRPS (neuropeptiden, adrenoreceptoren, vasoconstrictie). Daarom 
werd in hoofdstuk 3.2 de associatie tussen het gebruik van antihypertensiva en CRPS 
onderzocht. Het gebruik van ACE-remmers was geassocieerd met een verhoogd risico 
op CRPS (OR: 2.7, 95%CI: 1.1-6.8). Dit effect nam toe bij langdurig gebruik en bij 
hoge dosering. Andere antihypertensiva, waaronder calcium antagonisten, β-blockers, 
angiotensine-II receptor antagonisten en diuretica, waren niet geassocieerd met CRPS. 
ACE is van belang voor het metabolisme van de neuroinflammatoire eiwitten SP en 
bradykinine. Via accumulatie van deze eiwitten kunnen ACE-remmers mogelijk de 
neuroinflammatore processen in CRPS patiënten faciliteren. 
     Omdat CRPS een duidelijk vrouwelijke predominantie kent, alsmede een verhoogde 
incidentie op post-menopausale leeftijd, werd in hoofdstuk 3.3 de relatie tussen CRPS 
en oestrogenen onderzocht. De cumulatieve expositie aan endogene oestrogenen werd 
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benaderd op basis van de leeftijd van menarche en menopauze, de menstruele levensduur, 
de pariteit en het totaal aantal maanden zwangerschap en borstvoeding. Geen van deze 
maten bleek echter geassocieerd met het risico op CRPS. Expositie aan oestrogenen 
ten tijde van de start van CRPS werd onderzocht door te kijken naar het gebruik van 
orale anticonceptiva (in pre-menopausale vrouwen) of van hormonale suppletie therapie 
(in post-menopausale vrouwen). Ook hierbij werden geen significante associaties met 
CRPS gevonden, hoewel een niet-significant beschermend effect werd gezien tijdens 
het gebruik van hormonale suppletie therapie (OR:0.5, 95% betrouwbaarheids interval 
0.1-1.6). In de eerste zes maanden post partum (snelle daling oestrogeen spiegels) was 
het risico op CRPS verhoogd (OR:5.6, 95%CI: 1.0-32.4). Door de lage aantallen moeten 
resultaten van deze studie terughoudend worden geïnterpreteerd. Echter, de bevindingen 
zijn grotendeels in overeenstemming met die voor andere pijnlijke inflammatoire 
aandoeningen die eveneens een vrouwelijke predominantie kennen, zoals rheumatoïde 
artritis en multipele sclerose.
     Hoofdstuk 4 beschrijft de ontwikkeling en het verdere onderzoek van nieuwe ideeën 
over de moleculaire achtergrond van CRPS. In hoofdstuk 4.1 bespreken we hoe een 
‘text mining’ applicatie werd toegepast (PathwayAssistTM) om de interacties tussen 
CRPS concepten (eiwitten, kleinere moleculen, medicijnen) te visualeren in een netwerk, 
waarbij Medline als onderliggende informatie bron werd gebruikt. Het overzicht in het 
netwerk maakte het mogelijk de centrale positie van de nucleaire transcriptie factor 
κB (NFκB) te herkennen tussen de al bekende bij CRPS betrokken mediatoren. NFκB 
wordt al langer verondersteld een belangrijke rol te spelen in inflammatoire ziekten, 
bijvoorbeeld rheumatische aandoeningen en astma. Een verband met CRPS was nog niet 
eerder gesuggereerd, maar is theoretisch aannemelijk, gezien de veelvuldige interactie 
met andere mediatoren.
     Deze hypothese werd onderzocht in een dier model voor CRPS, zoals beschreven 
in hoofdstuk 4.2. In het ‘chronic post ischemia pain’ (CPIP) model ontwikkelen ratten 
CRPS-achtige verschijnselen na een periode van ischemie en reperfusie (IR) in de linker 
achterpoot. Zowel 2 uur als 48 uur na de IR periode werd een verhoogde NFκB activiteit 
(ELISA) gevonden in spier en ruggemerg weefsel aan de aangedane zijde van de CPIP 
ratten, in vergelijking tot controle ratten. Op dag 7 na de IR periode was de NFκB 
activiteit het spierweefsel gelijk voor CPIP en controle ratten, maar nog steeds verhoogd 
in het ruggemerg van CPIP ratten. De door de IR periode veroorzaakte mechanishe en 
koude allodynie in CPIP ratten verbeterde dosisafhankelijk na toediening van een NFκB 
remmer (pyrrolidine dithiocarbamaat). De resultaten wijzen op een rol van NFκB in het 
CPIP model en daarmee mogelijk ook in CRPS bij mensen.
     Tenslotte worden in hoofdstuk 5 de hoofdresultaten en methodologische aspecten 
besproken. Tevens worden enige suggesties gedaan voor toekomstig onderzoek. 
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n.a.  not applicable
ACE  Angiotensin Converting Enzyme
AMPA  Apha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA  Analysis of Variances
ATC code Anatomical Therapeutical Chemical code
AT2  Angiotensin-II
CGRP  Calcitonin Gene Related Peptide
CI  Confidence Interval
CNS  Central Nervous System
CPIP  Chronic Post Ischemia Pain
CRPS  Complex Regional Pain Syndrome
DDD  Defined Daily Dose
DM   Diabetes Mellitus
DMSO  Dimethylsulfoxide
ELISA  Enzyme Linked Immuno Sorbent Assay
ET-1  Endotheline-1
GP  General Practitioner
HLA  Human Leukocyte Antigen
HRT  Hormonal Replacement Therapy
IASP  International Association for the Study of Pain
IL  Interleukin
IPCI  Integrated Primary Care Information
IR  Incidence Rate
IR injury  Ischemia and Reperfusion injury
MS  Multiple Sclerosis
NEP  Neutral Endopeptidase
NFκB  Nuclear Factor κB
NK-1  Neurokinin 1
NMDA  N-Methyl-D-Aspartate
NO  Nitric Oxide
NPY  Neuropeptide Y
NSAID  Non Steroidal Anti-inflammatory Drug
OC  Oral Contraceptive drugs
OR  Odds Ratio
PDTC  Pyrrolidine Dithiocarbamate
PNS  Peripheral Nervous System
PY  Person Years
RA  Rheumatoid Arthritis
ROS  Reactive Oxygens Species
SMP  Sympathetically Maintained Pain
SMR  Standardazid Morbidity Ratio
SP  Substance P
SSRI  Selective Seretonin Reuptake Inhibitor
TCA  Tricyclic Antidepressant
TENS  Transcutaneous Electronic Neurostimulation
TNF  Tumor Necrosis Factor
TP53  Tumor Protein 53
VIP  Vasoactive Intestinal Protein
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